WO2002034754A2 - Benzoxazinone derivatives, their preparation and use - Google Patents

Benzoxazinone derivatives, their preparation and use Download PDF

Info

Publication number
WO2002034754A2
WO2002034754A2 PCT/EP2001/012344 EP0112344W WO0234754A2 WO 2002034754 A2 WO2002034754 A2 WO 2002034754A2 EP 0112344 W EP0112344 W EP 0112344W WO 0234754 A2 WO0234754 A2 WO 0234754A2
Authority
WO
WIPO (PCT)
Prior art keywords
methyl
benzo
oxazin
piperidinyl
ethyl
Prior art date
Application number
PCT/EP2001/012344
Other languages
French (fr)
Other versions
WO2002034754A3 (en
Inventor
Christopher Norbert Johnson
Harshad Kantilal Rami
Geoffrey Stemp
Kevin Thewlis
Mervyn Thompson
Antonio Kuok Keong Vong
Original Assignee
Smithkline Beecham P.L.C.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0026224A external-priority patent/GB0026224D0/en
Priority claimed from GB0111858A external-priority patent/GB0111858D0/en
Priority to JP2002537744A priority Critical patent/JP4242643B2/en
Priority to KR10-2003-7005789A priority patent/KR20030051747A/en
Priority to HU0301458A priority patent/HUP0301458A2/en
Priority to US10/415,119 priority patent/US6939871B2/en
Priority to DE60127434T priority patent/DE60127434T2/en
Priority to AU2002224791A priority patent/AU2002224791A1/en
Application filed by Smithkline Beecham P.L.C. filed Critical Smithkline Beecham P.L.C.
Priority to EP01988720A priority patent/EP1330460B1/en
Priority to MXPA03003820A priority patent/MXPA03003820A/en
Priority to CA002426706A priority patent/CA2426706A1/en
Priority to IL15552001A priority patent/IL155520A0/en
Priority to BR0114881-8A priority patent/BR0114881A/en
Publication of WO2002034754A2 publication Critical patent/WO2002034754A2/en
Publication of WO2002034754A3 publication Critical patent/WO2002034754A3/en
Priority to NO20031838A priority patent/NO20031838L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Definitions

  • the present invention relates to novel compounds, processes for their preparation, pharmaceutical compositions containing the same and their use as medicaments. More particularly this invention relates to novel benzoxazinone derivatives and their utility in the treatment and/or prophylaxis of CNS and other disorders.
  • WO 97/45419 discloses a series of benzoxazinone compounds as dopamine D4 receptor antagonists which are claimed to be useful in the treatment of psychosis and schizophrenia.
  • EP 0900 792 Al discloses a series of piperazine and piperidine derivatives as 5-HT; receptor agonists which are claimed to be useful for treating CNS disorders.
  • a novel series of benzoxazinone compounds has now been found that possess high affinity for 5-HT ⁇ _ type receptors and / or potent serotonin reuptake inhibition activity.
  • the present invention therefore provides, in a first aspect, a compound of formula (I) or a pharmaceutically acceptable salt thereof:
  • Ar is phenyl, naphthyl, a monocychc heteroaromatic group or a bicyclic heteroaromatic group, said Ar group being optionally substituted by 1 - 4 substituents, which may be the same or different, and which are selected from the group consisting of:
  • R' is hydrogen, C] .galkyl, C3_galkenyl, C3_galkynyl or arylCj .galkyl;
  • R- is halogen, C i -galkyl, cyano, CF3, C ⁇ .galkanoyl, Cj-galkoxy or hydroxy;
  • Alkyl groups which may be employed, whether alone or part of another group, include methyl, ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl and any branched isomers thereof such as isopropyl, t-butyl, sec-butyl, and the like.
  • . galkyl respectively refer to alkyl groups having from one to four and from one to six carbon atoms, in all isomeric forms.
  • Cj ⁇ alkyl would include: methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl and tert-butyl.
  • Cj .galkyl would include, in addition, pentyl, neopentyl, sec-pentyl, n-pentyl, isopentyl, tert-pentyl and hexyl.
  • halogen is used herein to describe, unless otherwise stated, a group selected from fluorine, chlorine, bromine and iodine.
  • aryl whether alone or as part of another group, is intended, unless otherwise stated, to denote an aromatic carbocyclic or heterocyclic group such as phenyl, pyrimidine, pyrazine or naphthyl, optionally substituted by one or more halogen, C ⁇ -galkyl, CF3, cyano, hydroxy, C[-galkanoyl, or Cj-galkoxy.
  • naphthyl whether alone or as part of another group, is intended, unless otherwise stated, to denote both 1 -naphthyl and 2-naphthyl groups.
  • the term "monocychc heteroaromatic group” is used to describe stable 5 or 6 membered heteroaromatic rings containing 1 to 4 heteroatoms selected from oxygen, nitrogen and sulfur. Suitable examples of such groups include thienyl, furanyl, pyrrolyl, triazolyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, oxadiazolyl, isothiazolyl, isoxazolyl, thiadiazolyl, pyridyl, pyrimidyl, triazinyl, pyridazyl and pyrazinyl.
  • bicyclic heteroaromatic group is used to describe stable 6,5 and 6,6 heteroaromatic rings containing 1 to 4 heteroatoms selected from oxygen, nitrogen and sulfur.
  • Suitable examples of such groups include indolyl, quinolinyl, isoquinolinyl, benzofuranyl, benzothienyl, benzimidazolyl, indazolyl, 4-, 5-, 6- or 7-azaindolyl, benzothiazolyl, benzoxazolyl, benzisoxazolyl, benzisothiazolyl, quinazolinyl, quinoxalinyl, cinnolinyl and naphthyridinyl.
  • Cj .galkoxy refers to a straight chain or branched chain alkoxy (or " alkyloxy") group having from one to six carbon atoms, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, tert-butoxy, pentoxy, neopentoxy, sec-pentoxy, n-pentoxy, isopentoxy, tert-pentoxy and hexoxy.
  • C ⁇ .galkylthio refers to a straight chain or branched chain alkylthio group having from one to six carbon atoms, such as methylthio, ethylthio, propylthio, isopropylthio, butylthio, isobutylthio, sec-butylthio, tert-butylthio, pentylthio, neopentylthio, sec-pentylthio, n-pentylthio, isopentylthio, tert-pentylthio and hexylthio.
  • arylC].galkoxy refers to an aryl group which is linked by a C ⁇ _ galkoxy group. Examples include phenylmethoxy, phenylethoxy, naphthymethoxy, naphthylethoxy, phenylpropoxy, naphthylpropoxy, phenylbutoxy and naphthylpentoxy.
  • C 3 . 7 cycloalkylC ⁇ . galkoxy refers to a cycloalkyl group consisting of from 3 to 7 carbon atoms (for example cyclopropane, cyclobutane, cyclopentane, cyclohexane and cycloheptane) attached to an C [ .galkoxy group.
  • Ci .galkanoyl refers to an alkanoyl group having from 1 to 6 carbon atoms, such as methanoyl (or “ formyl” ), ethanoyl (or “ acetyl”), propanoyl, butanoyl, pentanoyl and hexanoyl.
  • aroyl refers to a group having the formula “aryl-CO” wherein “ aryl” is as defined above.
  • C3_gazacyloalkane ring refers to a cycloalkane ring containing from 3 to 6 carbon atoms, wherein one or more of the carbon atoms may be replaced by a nitrogen atom. Examples include aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl and azepanyl.
  • C3_galkynyl refers to an unsaturated hydrocarbon group containing one or more triple C-C bonds, having from three to six carbon atoms, in all isomeric forms, such as propynyl, butanediylidyne, butenylidyne, butylidyne, pentenynyl, and pentylidyne.
  • Ar is phenyl, naphthyl, indolyl, quinolinyl, quinazolinyl, indazolyl, isoquinolinyl, cinnolinyl or benzofuranyl, said groups being optionally substituted as defined above.
  • Ar* is preferably a monocyclic heteroaromatic group (particularly isoxazolyl), optionally substituted as defined above.
  • Z is a single bond.
  • preferred examples of the resulting bicyclic system include 2,3-dihydrobenzo[b]furanyl, 3,4-dihydro-2H-benzo[b]pyranyl, 2,2-dimethyl- 2,3-dihydrobenzo[b]furanyl, 2,2-dimethyl-3,4-dihydro-2H-benzo[b]pyranyl, or 5-oxo- 5,6,7,8-tetrahydronaphthyl, the said groups being optionally further substituted as defined above.
  • Preferred optional substituents for Ar are halogen (particularly fluoro or chloro), C j -galkyl (particularly methyl, ethyl and propyl), cyano, CF3, Ci -galkoxy (particularly methoxy, ethoxy or isopropoxy), Cj-galkanoyl or a group Ar ⁇ -Z as defined above.
  • Ar groups including optional substituents, are 4-indolyl, 4-indolyl(2-CN), 5-quinolinyl, 5-quinolinyl(2-Me), 8-quinolinyl, 1-isoquinolinyl, naphthyl, phenyl(2-CN), phenyl(2,3-dichloro), phenyl(3-Br), phenyl(3-Me), phenyl(3- CF3), phenyl(2-propyl), phenyl(2-CN, 4-F), phenyl(2-(5-isoxazolyl), phenyl(3-ethyl-4- Cl), 2,2-dimethyl-2,3-dihydrobenzo[b]furan-7-yl, (5-F)-2,2-dimethyl-2,3- dihydrobenzo[b]furan-7-yl, (6-F)-3,4-dihydro-2H-benzo[b]pyranyl, (2,
  • Ar groups including optional substituents, are 5- quinolinyl(2-Me), 5-quinolinyl(2-Me, 7-C1), 5-quinolinyl(2-Me, 7-F) and 5- quinazolinyl(2-Me).
  • R ⁇ is C ] -galkyl
  • a preferred group is methyl.
  • R ⁇ is hydrogen or methyl.
  • preferred substituents include halogen (particularly fluoro or chloro), C ⁇ -galkyl (particularly methyl or ethyl), cyano, Ci-galkanoyl or CF3.
  • n 2
  • n 2
  • q 1
  • r is 0, 1 or 2.
  • R ⁇ is halogen, particularly fluoro.
  • Y is oxygen or is a single bond.
  • Y is oxygen
  • p is 0 or 1.
  • p is 1, so that X and the benzoxazinone group are linked by a CH 2 group.
  • Preferred compounds of this invention are examples El - El 67 (as described below) and pharmaceutically acceptable salts thereof. Particularly preferred compounds according to this invention are:
  • the compounds of formula (I) can form acid addition salts thereof. It will be appreciated that for use in medicine the salts of the compounds of formula (I) should be pharmaceutically acceptable. Suitable pharmaceutically acceptable salts will be apparent to those skilled in the art and include those described in d. Pharm. Sci., 1977, 66, 1-19, such as acid addition salts formed with inorganic acids e.g. hydrochloric, hydrobromic, sulfuric, nitric or phosphoric acid; and organic acids e.g. succinic, maleic, acetic, fumaric, citric, tartaric, benzoic, p-toluenesulfonic, methanesulfonic or naphthalenesulfonic acid.
  • inorganic acids e.g. hydrochloric, hydrobromic, sulfuric, nitric or phosphoric acid
  • organic acids e.g. succinic, maleic, acetic, fumaric, citric, tartaric, benzoic, p
  • Certain of the compounds of formula (I) may form acid addition salts with one or more equivalents of the acid.
  • the present invention includes within its scope all possible stoichiometric and non-stoichiometric forms.
  • the compounds of formula (I) may be prepared in crystalline or non-crystalline form, and, if crystalline, may optionally be hydrated or solvated.
  • This invention includes within its scope stoichiometric hydrates or solvates as well as compounds containing variable amounts of water and/or solvent.
  • Certain compounds of formula (I) are capable of existing in stereoisomeric forms (e.g. geometric or (" cis-trans") isomers, diastereomers and enantiomers) and the invention extends to each of these stereoisomeric forms and to mixtures thereof including racemates.
  • the different stereoisomeric forms may be separated one from the other by the usual methods, or any given isomer may be obtained by stereospecific or asymmetric synthesis.
  • the invention also extends to any tautomeric forms and mixtures thereof.
  • R is a C3_galkenyl group
  • the compounds may also exist as geometric isomers around the double bond.
  • the present invention includes within its scope all such isomers, including mixtures.
  • this invention provides a process for the preparation of a compound of formula (I) or a pharmaceutically acceptable salt thereof, which process comprises:
  • suitable leaving groups include halogen (particularly chloro or bromo), methylsulfonyloxy and 4-toluenesulfonyloxy (tosylate).
  • halogen particularly chloro or bromo
  • methylsulfonyloxy and 4-toluenesulfonyloxy (tosylate).
  • the reactions of compounds of formula (II) and (III) are typically carried out in the presence of a base, such as diisopropylethylamine or sodium bicarbonate, in a suitable solvent such as isopropanol or dimethylformamide.
  • Compounds of formula (I) can be converted into further compounds of formula (I) using standard techniques. For example, and by way of illustration rather than limitation, for compounds of formula (I) wherein R is hydrogen it may be possible to introduce a Ci .galkyl group by conventional alkylation using 1 molar equivalent of a C].galkylhalide and 1 molar equivalent of a suitable base in an inert solvent. Further, compounds of formula (I) may be converted to further compounds of formula (I) by interconversion of either of substituents R?- or those on group Ar.
  • Protective groups in organic synthesis can be used.
  • primary amines can be protected as phthalimide, benzyl, t-butyloxycarbonyl, benzyloxycarbonyl or trityl derivatives.
  • Carboxylic acid groups can be protected as esters.
  • Aldehyde or ketone groups can be protected as acetals, ketals, thioacetals or thioketals. Deprotection of such groups is achieved using conventional procedures well known in the art.
  • protecting groups such as t-butyloxycarbonyl may be removed using an acid such as hydrochloric or trifluroroacetic acid in a suitable solvent such as dichloromethane, diethylether, isopropanol or mixtures thereof.
  • compositions may be prepared conventionally by reaction with the appropriate acid or acid derivative.
  • 5-HT1 receptors can be determined by the radioligand binding assay as described in
  • the intrinsic activity of the compounds of this invention can be determined according to the [35s]GTP ⁇ S functional assay which is also described in
  • 5-HTi rj receptors 5-HTi rj receptors. It has been found, using the [35s]GTP ⁇ S functional assay, that certain compounds of formula (I) appear to be antagonists at 5-HT] type receptors whilst others appear to be inverse agonists, agonists or partial agonists.
  • the efficacy of the compounds of this invention to inhibit the re-uptake of serotonin can be measured in a 5-HT uptake assay by measurement of uptake of [ 3 H]- 5-HT into rat cortical synaptosomes as described in Thomas, D.R.; Nelson, D.R.; and Johnson, A.M. Psychopharmacology 93: 193-200 (1987). All compounds tested according to this uptake assay were found to have potency at the uptake site of pKi > 6.0, with many showing a considerably higher potency (having pKi values > 8.0).
  • Certain compounds of formula (I) demonstrate both affinity for the 5-HTJ A receptor (or affinity for 5-HT j , 5-HTJ B and 5-HTI J receptors) and potency at the uptake site in the higher ranges indicated above.
  • Compounds of formula (I) and their pharmaceutically acceptable salts are of use in the treatment or prophylaxis of certain CNS disorders such as depression, which term is used herein to include bipolar depression, unipolar depression, single or recurrent major depressive episodes with or without psychotic features, catatonic features, melancholic features, atypical features or postpartum onset, seasonal affective disorder, dysthymic disorders with early or late onset and with or without atypical features, neurotic depression and social phobia, depression accompanying dementia for example of the Alzheimer's type, vascular dementia with depressed mood, schizoaffective disorder or the depressed type, and depressive disorders resulting from general medical conditions including, but not limited to, myocardial infarction, diabetes, miscarriage or abortion, etc.
  • CNS disorders which may be treated or prevented include anxiety disorders, including generalised anxiety, schizophrenia, panic disorder, agoraphobia, social phobia, obsessive compulsive disorder and post-traumatic stress disorder, pain (particularly neuropathic pain), memory disorders, including dementia, amnesic disorders and age-associated memory impairment, disorders of eating behaviours, including anorexia nervosa and bulimia nervosa, sexual dysfunction, sleep disorders (including disturbances of circadian rhythm, dyssomnia, insomnia, sleep apnea and narcolepsy), withdrawal from abuse of drugs such as of cocaine, ethanol, nicotine, benzodiazepines, alcohol, caffeine, phencyclidine (phencyclidine-like compounds), opiates (e.g.
  • cannabis heroin, morphine
  • sedative ipnotic e.g. dextroamphetamine, methylamphetamine
  • amphetamine-related drugs e.g. dextroamphetamine, methylamphetamine
  • motor disorders such as Parkinson's disease, dementia in Parkinson's disease, neuroleptic-induced Parkinsonism and tardive dyskinesias, as well as other psychiatric disorders.
  • Compounds of formula (I) may also have utility in the treatment of certain gastrointestinal disorders such as irritable bowel syndrome, Crohn's disease, ulcerative colitis, non-steroidal anti-inflammatory drug induced damage.
  • the invention also provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, for use as a therapeutic substance, in particular in the treatment or prophylaxis of the above disorders.
  • the invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof for use as a therapeutic substance in the treatment or prophylaxis of depression.
  • Compounds of the invention may be administered in combination with other active substances such as 5HT3 antagonists, NK-1 antagonists, serotonin agonists, selective serotonin reuptake inhibitors (SSRI), noradrenaline re-uptake inhibitors (SNRI), tricyclic antidepressants and/or dopaminergic antidepressants.
  • active substances such as 5HT3 antagonists, NK-1 antagonists, serotonin agonists, selective serotonin reuptake inhibitors (SSRI), noradrenaline re-uptake inhibitors (SNRI), tricyclic antidepressants and/or dopaminergic antidepressants.
  • Suitable 5HT3 antagonists which may be used in combination of the compounds of the inventions include for example ondansetron, granisetron, metoclopramide.
  • Suitable serotonin agonists which may be used in combination with the compounds of the invention include sumatriptan, rauwolscine, yohimbine, metoclopramide.
  • Suitable SSRIs which may be used in combination with the compounds of the invention include fluoxetine, citalopram, femoxetine, fluvoxamine, paroxetine, indalpine, sertraline, zimeldine.
  • Suitable SNRIs which may be used in combination with the compounds of the invention include venlafaxine and reboxetine.
  • Suitable tricyclic antidepressants which may be used in combination with a compound of the invention include imipramine, amitriptiline, chlomipramine and nortriptiline.
  • Suitable dopaminergic antidepressants which may be used in combination with a compound of the invention include bupropion and amineptine.
  • the compounds of the combination or composition may be administered simultaneously (either in the same or different pharmaceutical formulations), separately or sequentially.
  • the invention further provides a method of treatment or prophylaxis of the above disorders in mammals including humans, which comprises administering to the sufferer a therapeutically safe and effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.
  • the invention provides for the use of a compound of formula (1) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in the treatment or prophylaxis of the above disorders.
  • a pharmaceutical composition which comprises a compound of formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.
  • the present invention provides a process for preparing a pharmaceutical composition, the process comprising mixing a compound of formula (I) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or excipient.
  • a pharmaceutical composition of the invention which may be prepared by admixture, suitably at ambient temperature and atmospheric pressure, is usually adapted for oral, parenteral or rectal administration and, as such, may be in the form of tablets, capsules, oral liquid preparations, powders, granules, lozenges, reconstitutable powders, injectable or infusible solutions or suspensions or suppositories. Orally administrable compositions are generally preferred.
  • Tablets and capsules for oral administration may be in unit dose form, and may contain conventional excipients, such as binding agents (e.g. pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose);, fillers (e.g. lactose, microcrystalline cellulose or calcium hydrogen phosphate);, tabletting lubricants lubricants (e.g. magnesium stearate, talc or silica);, disintegrants (e.g. potato starch or sodium starch glycollate); and acceptable wetting agents (e.g. sodium lauryl sulphate).
  • binding agents e.g. pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose
  • fillers e.g. lactose, microcrystalline cellulose or calcium hydrogen phosphate
  • tabletting lubricants lubricants e.g. magnesium stearate, talc or silica
  • disintegrants e.g.
  • Oral liquid preparations may be in the form of, for example, aqueous or oily suspension, solutions, emulsions, syrups or elixirs, or may be in the form of a dry product for reconstitution with water or other suitable vehicle before use.
  • Such liquid preparations may contain conventional additives such as suspending agents (e.g. sorbitol syrup, cellulose derivatives or hydrogenated edible fats), emulsifying agents (e.g. lecithin or acacia), non-aqueous vehicles (which may include edible oils e.g. almond oil, oily esters, ethyl alcohol or fractionated vegetable oils), preservatives (e.g.
  • Preparations for oral administration may be suitably formulated to give controlled release of the active compound.
  • fluid unit dosage forms are prepared utilising a compound of the invention or pharmaceutically acceptable salt thereof and a sterile vehicle.
  • Formulations for injection may be presented in unit dosage form e.g. in ampoules or in multi-dose, utilising a compound of the invention or pharmaceutically acceptable salt thereof and a sterile vehicle, optionally with an added preservative.
  • the compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilising and/or dispersing agents.
  • the active ingredient may be in powder form for constitution with a suitable vehicle, e.g. sterile pyrogen-free water, before use.
  • the compound depending on the vehicle and concentration used, can be either suspended or dissolved in the vehicle.
  • the compound can be dissolved for injection and filter sterilised before filling into a suitable vial or ampoule and sealing.
  • adjuvants such as a local anaesthetic, preservatives and buffering agents are dissolved in the vehicle.
  • the composition can be frozen after filling into the vial and the water removed under vacuum.
  • Parenteral suspensions are prepared in substantially the same manner, except that the compound is suspended in the vehicle instead of being dissolved, and sterilisation cannot be accomplished by filtration.
  • the compound can be sterilised by exposure to ethylene oxide before suspension in a sterile vehicle.
  • a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound.
  • Lotions may be formulated with an aqueous or oily base and will in general also contain one or more emulsifying agents, stabilising agents, dispersing agents, suspending agents, thickening agents, or colouring agents.
  • Drops may be formulated with an aqueous or non-aqueous base also comprising one or more dispersing agents, stabilising agents, solubilising agents or suspending agents. They may also contain a preservative.
  • the compounds of the invention may also be formulated in rectal compositions such as suppositories or retention enemas, e.g. containing conventional suppository bases such as cocoa butter or other glycerides.
  • the compounds of the invention may also be formulated as depot preparations. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection.
  • the compounds of the invention may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.
  • the compounds of the invention may be formulated as solutions for administration via a suitable metered or unitary dose device or alternatively as a powder mix with a suitable carrier for administration using a suitable delivery device.
  • compounds of formula (I) may be formulated for oral, buccal, parenteral, topical (including ophthalmic and nasal), depot or rectal administration or in a form suitable for administration by inhalation or insufflation (either through the mouth or nose).
  • the compounds of the invention may be formulated for topical administration in the form of ointments, creams, gels, lotions, pessaries, aerosols or drops (e.g. eye, ear or nose drops).
  • Ointments and creams may, for example, be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agents.
  • Ointments for administration to the eye may be manufactured in a sterile manner using sterilised components.
  • the composition may contain from 0.1% to 99% by weight, preferably from 10 to 60% by weight, of the active material, depending on the method of administration.
  • the dose of the compound used in the treatment of the aforementioned disorders will vary in the usual way with the seriousness of the disorders, the weight of the sufferer, and other similar factors.
  • suitable unit doses may be 0.05 to 1000 mg, more suitably 1.0 to 200 mg, and such unit doses may be administered more than once a day, for example two or three times a day. Such therapy may extend for a number of weeks or months.
  • Crotonaldehyde (17.5 mL, 0.21 mol) was added dropwise to a refluxing solution of 2- chloro-5-methoxyaniline hydrochloride (10.36 g, 53.4 mmol) in 5 N hydrochloric acid
  • Crotonaldehyde (28 mL, 0.33 mol) was added dropwise to a refluxing solution of 3,5- difluoroaniline (10.75 g, 0.083 mol) in 5 N hydrochloric acid (450 mL) and reflux was continued for a further 0.5 h. Reaction mixture was cooled, diluted with water (200 mL) and washed with ether (200 mL). The aqueous layer was basified (pH 14) with 50%) NaOH (aq) and extracted into MDC (3 x 200 mL).
  • Triethylamine (2.4mL, 17.3mmol) was added to a suspension of 7,8-difluoro-4H- benzo[l ,4]oxazine-3-one-6-carboxylic acid (3.6g, lSJmmol) in anhydrous T ⁇ F
  • Manganese dioxide (2.3g, 26.3mmol) was added to a mixture of 7,8-difmoro-6- hydroxymethyl-4H-benzo[ 1,4] oxazin-3 -one (1.13g, 5.25mmol), dichloromethane (70mL) and T ⁇ F (50mL). The mixture was stirred for 6 hours and then filtered through celite. The filtrate was evaporated in vacuo to give the title compound (1.02g, 80%) as a pale yellow solid.
  • Tables 1 - 6 were prepared in a similar manner to Example 1 or Example 3.
  • the resulting oil was purified by chromatography on silica eluting with 50% ethyl acetate - hexane followed by 0 - 25% methanol - ethyl acetate gradient elution, to give the title compound (0.04 g, 26%) as an oil.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

The present invention relates to novel compounds of formula (I) or a pharmaceutically acceptable salt thereof, wherein Ar is phenyl, naphthyl, a monocyclic heteroaromatic group or a bicyclic heteroaromatic group, said Ar group being optionally substituted by 1-4 substituents, which may be the same or different, and which are selected from the group consisting of: halogen, hydroxy, cyano, nitro, trifluoromethyl, trifluoromethoxy, C1-6alkyl, trifluoromethanesulfonyloxy, pentafluoroethyl, C1-6alkoxy, arylC1-6alkoxy, C1-6alkylthio, C1-6alkoxyC1-6alkyl, C3-7cycloalkylC1-6alkoxy, C1-6alkanoyl, C1-6alkoxycarbonyl, C1-6alkylsulfonyl, C1-6alkylsulfinyl, C1-6alkylsulfonyloxy, C1-6alkylsulfonylC1-6alkyl, arylsulfonyl, arylsulfonyloxy, arylsulfonylC1-6alkyl, C1-6alkylsulfonamido, C1-6alkylamido, C1-6alkylsulfonamidoC1-6alkyl, C1-6alkylamidoC1-6alkyl, arylsulfonamido, arylcarboxamido, arylsulfonamidoC1-6alkyl, arylcarboxamidoC1-6alkyl, aroyl, aroylC1-6alkyl, arylC1-6alkanoyl, a group R3OCO(CH¿2?)s, R?3CON(R4)(CH¿2)s, R3R4NCO(CH¿2?)s or R?3R4NSO¿2(CH2) where each of R?3 and R4¿ independently represents a hydrogen atom or C¿1-4?alkyl or R?3 and R4¿ form part of a C¿3-?6azacyloalkane or C3-6(2-oxo)azacycloalkane ring and s represents zero or an integer from 1 to 4, and a group Ar?1¿ Z, wherein Z represents a single bond, O, S or CH¿2? and Ar?1¿ represents a pheyl or a monocyclic heteroaromatic group, said Ar1 group being optionally substituted by 1-3 substituents, which may be the same or different, and which are selected from the group consisting of a halogen, hydroxy, cyano, trifluoromethyl, C¿1-6?alkyl, C1-6alkoxy or C1-6alkanoyl; when Ar is a phenyl or a monocyclic heteroaromatic group, substitutens positioned ortho to one another may be linked to form a 5- or 6-membered ring; R?1¿ is hydrogen, C¿1-6?alkyl, C3-6alkenyl, C3-6alkynyl or arylC1-6alkyl; R?2¿ is halogen, C¿1-6?alkyl, cyano, CF3, C1-6alkanoyl, C1-6alkoxy or hydroxy; X is CH or N; Y is a single bond, O, or C=O; p is 0, 1 or 2; r is 0, 1, 2 or 3; m is 2, 3 or 4; n and q are independently 1 or 2. Processes for preparing the compounds, pharmaceutical compositions containing them and their use as medicaments for various CNS disorders, including deression and/or anxiety, are also disclosed.

Description

Benzoxazinone derivatives, their preparation and use
The present invention relates to novel compounds, processes for their preparation, pharmaceutical compositions containing the same and their use as medicaments. More particularly this invention relates to novel benzoxazinone derivatives and their utility in the treatment and/or prophylaxis of CNS and other disorders.
WO 97/45419 discloses a series of benzoxazinone compounds as dopamine D4 receptor antagonists which are claimed to be useful in the treatment of psychosis and schizophrenia. EP 0900 792 Al discloses a series of piperazine and piperidine derivatives as 5-HT; receptor agonists which are claimed to be useful for treating CNS disorders.
Artigas (Trends in Pharmacological Sciences, Vol. 14, 262, 1993) suggests that the co-administration of a 5-HT]A receptor antagonist and a selective serotonin reuptake inhibitor (SSRI) may give rise to an improvement in anti-depressant efficacy. Patent applications WO 00/40580 and WO 00/40581 both disclose a series of benzoxazine derivatives that are claimed to possess such a combined activity profile.
A novel series of benzoxazinone compounds has now been found that possess high affinity for 5-HTι_ type receptors and / or potent serotonin reuptake inhibition activity. The present invention therefore provides, in a first aspect, a compound of formula (I) or a pharmaceutically acceptable salt thereof:
Figure imgf000002_0001
(I) in which
Ar is phenyl, naphthyl, a monocychc heteroaromatic group or a bicyclic heteroaromatic group, said Ar group being optionally substituted by 1 - 4 substituents, which may be the same or different, and which are selected from the group consisting of:
halogen, hydroxy, cyano, nitro, trifluoromethyl, trifluoromethoxy, Ci .galkyl, trifluoromethanesulfonyloxy, pentafluoroethyl, C^alkoxy, arylC \ .galkoxy, Ci.galkylthio, Ci.galkoxyCi .galkyl, C .ycycloalkylCi.galkoxy,
C i .galkanoyl, Cj.galkoxycarbonyl, C \ .galkylsulfonyl, C 1.galkylsulfinyl, Cj.galkylsulfonyloxy, Ci .galkylsulfonylCi .galkyl, arylsulfonyl, arylsulfonyloxy, arylsulfonylCj.galkyl, Ci.galkylsulfonamido, C _ galkylamido, C \ .galkylsulfonamidoC .βalkyl, C i.galkylamidoC .galkyl, arylsulfonamido, arylcarboxamido, arylsulfonamidoCi .galkyl, arylcarboxamidoC i .galkyl, aroyl, aroylCj .galkyl, arylC j .galkanoyl, a group R30C0(CH2)S, R3CON(R4)(CH2)s, R3R4NCO(CH2)s or R3R4 SO2(CH2)S where each of R3 and R4 independently represents a hydrogen atom or Cj_4alkyl or R3 and R4 form part of a C3_gazacyloalkane or C3_g(2- oxo)azacycloalkane ring and s represents zero or an integer from 1 to 4, and a group Aχl - Z, wherein Z represents a single bond, O, S or CH2 and Ar* represents a phenyl or a monocychc heteroaromatic group, said Ar^ group being optionally substituted by 1 - 3 substituents, which may be the same or different, and which are selected from the group consisting of a halogen, hydroxy, cyano, trifluoromethyl, C .galkyl, C j.galkoxy or C \ .galkanoyl;
when Ar is a phenyl or a monocychc heteroaromatic group, substituents positioned ortho to one another may be linked to form a 5- or 6- membered ring;
R' is hydrogen, C] .galkyl, C3_galkenyl, C3_galkynyl or arylCj .galkyl;
R- is halogen, C i -galkyl, cyano, CF3, C^ .galkanoyl, Cj-galkoxy or hydroxy;
X is CH or N; Y is a single bond, 0, or C=0; p is 0, 1 or 2; r is 0, 1, 2 or 3; m is 2, 3 or 4; n and q are independently 1 or 2.
Alkyl groups which may be employed, whether alone or part of another group, include methyl, ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl and any branched isomers thereof such as isopropyl, t-butyl, sec-butyl, and the like. "C galkyl" and "C|. galkyl" respectively refer to alkyl groups having from one to four and from one to six carbon atoms, in all isomeric forms. Thus, Cj^alkyl would include: methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl and tert-butyl. Cj .galkyl would include, in addition, pentyl, neopentyl, sec-pentyl, n-pentyl, isopentyl, tert-pentyl and hexyl.
The term "halogen" is used herein to describe, unless otherwise stated, a group selected from fluorine, chlorine, bromine and iodine.
Where used herein the term "aryl", whether alone or as part of another group, is intended, unless otherwise stated, to denote an aromatic carbocyclic or heterocyclic group such as phenyl, pyrimidine, pyrazine or naphthyl, optionally substituted by one or more halogen, C^-galkyl, CF3, cyano, hydroxy, C[-galkanoyl, or Cj-galkoxy. Where used herein the term naphthyl, whether alone or as part of another group, is intended, unless otherwise stated, to denote both 1 -naphthyl and 2-naphthyl groups.
The term "monocychc heteroaromatic group" is used to describe stable 5 or 6 membered heteroaromatic rings containing 1 to 4 heteroatoms selected from oxygen, nitrogen and sulfur. Suitable examples of such groups include thienyl, furanyl, pyrrolyl, triazolyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, oxadiazolyl, isothiazolyl, isoxazolyl, thiadiazolyl, pyridyl, pyrimidyl, triazinyl, pyridazyl and pyrazinyl. The term "bicyclic heteroaromatic group" is used to describe stable 6,5 and 6,6 heteroaromatic rings containing 1 to 4 heteroatoms selected from oxygen, nitrogen and sulfur. Suitable examples of such groups include indolyl, quinolinyl, isoquinolinyl, benzofuranyl, benzothienyl, benzimidazolyl, indazolyl, 4-, 5-, 6- or 7-azaindolyl, benzothiazolyl, benzoxazolyl, benzisoxazolyl, benzisothiazolyl, quinazolinyl, quinoxalinyl, cinnolinyl and naphthyridinyl.
The term "Cj .galkoxy" refers to a straight chain or branched chain alkoxy (or " alkyloxy") group having from one to six carbon atoms, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, tert-butoxy, pentoxy, neopentoxy, sec-pentoxy, n-pentoxy, isopentoxy, tert-pentoxy and hexoxy.
The term " C \ .galkylthio" refers to a straight chain or branched chain alkylthio group having from one to six carbon atoms, such as methylthio, ethylthio, propylthio, isopropylthio, butylthio, isobutylthio, sec-butylthio, tert-butylthio, pentylthio, neopentylthio, sec-pentylthio, n-pentylthio, isopentylthio, tert-pentylthio and hexylthio.
The term "arylC].galkoxy" refers to an aryl group which is linked by a Cι _ galkoxy group. Examples include phenylmethoxy, phenylethoxy, naphthymethoxy, naphthylethoxy, phenylpropoxy, naphthylpropoxy, phenylbutoxy and naphthylpentoxy.
The term " C3.7cycloalkylC \. galkoxy" refers to a cycloalkyl group consisting of from 3 to 7 carbon atoms (for example cyclopropane, cyclobutane, cyclopentane, cyclohexane and cycloheptane) attached to an C [.galkoxy group.
The term " Ci .galkanoyl" refers to an alkanoyl group having from 1 to 6 carbon atoms, such as methanoyl (or " formyl" ), ethanoyl (or " acetyl"), propanoyl, butanoyl, pentanoyl and hexanoyl. The term "aroyl" refers to a group having the formula "aryl-CO" wherein " aryl" is as defined above.
The term " C3_gazacyloalkane ring" refers to a cycloalkane ring containing from 3 to 6 carbon atoms, wherein one or more of the carbon atoms may be replaced by a nitrogen atom. Examples include aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl and azepanyl.
The term "C3_g(2-oxo)azacycloalkane ring" refers to a C3_gazacyloalkane ring which also contains a C=O group, e.g. a cyclic amide or a lactam. Examples include aziridin- 2-one, azetidinone, pyrrolidinone, piperidinone and azepanone.
The term "C3_galkenyl" refers to an unsaturated hydrocarbon group containing one or more C=C bonds and having from three to six carbon atoms, in all isomeric forms, such as propenyl, butenyl, pentenyl, and hexenyl.
The term "C3_galkynyl" refers to an unsaturated hydrocarbon group containing one or more triple C-C bonds, having from three to six carbon atoms, in all isomeric forms, such as propynyl, butanediylidyne, butenylidyne, butylidyne, pentenynyl, and pentylidyne.
Preferably Ar is phenyl, naphthyl, indolyl, quinolinyl, quinazolinyl, indazolyl, isoquinolinyl, cinnolinyl or benzofuranyl, said groups being optionally substituted as defined above.
When a substituent on Ar is a further group Ar^-Z, Ar* is preferably a monocyclic heteroaromatic group (particularly isoxazolyl), optionally substituted as defined above. Preferably Z is a single bond. When the group Ar is phenyl or a monocyclic heteroaromatic group and optional substituents on the group Ar are positioned ortho to one another are linked to form a 5- or 6- membered ring, preferred examples of the resulting bicyclic system include 2,3-dihydrobenzo[b]furanyl, 3,4-dihydro-2H-benzo[b]pyranyl, 2,2-dimethyl- 2,3-dihydrobenzo[b]furanyl, 2,2-dimethyl-3,4-dihydro-2H-benzo[b]pyranyl, or 5-oxo- 5,6,7,8-tetrahydronaphthyl, the said groups being optionally further substituted as defined above.
Preferred optional substituents for Ar are halogen (particularly fluoro or chloro), C j -galkyl (particularly methyl, ethyl and propyl), cyano, CF3, Ci -galkoxy (particularly methoxy, ethoxy or isopropoxy), Cj-galkanoyl or a group Ar^-Z as defined above.
Particularly preferred Ar groups, including optional substituents, are 4-indolyl, 4-indolyl(2-CN), 5-quinolinyl, 5-quinolinyl(2-Me), 8-quinolinyl, 1-isoquinolinyl, naphthyl, phenyl(2-CN), phenyl(2,3-dichloro), phenyl(3-Br), phenyl(3-Me), phenyl(3- CF3), phenyl(2-propyl), phenyl(2-CN, 4-F), phenyl(2-(5-isoxazolyl), phenyl(3-ethyl-4- Cl), 2,2-dimethyl-2,3-dihydrobenzo[b]furan-7-yl, (5-F)-2,2-dimethyl-2,3- dihydrobenzo[b]furan-7-yl, (6-F)-3,4-dihydro-2H-benzo[b]pyranyl, (2,2-dimethyl)3,4- dihydro-2H-benzo[b]pyranyl, 5-oxo-5,6J,8-tetrahydronaphth-l-yl, 7-(2,3- dihydrobenzofuranyl), 7-(2-methyl)benzo[b]furanyl, 7-benzo[b]furanyl, 5-quinolinyl(2- Me, 8-C1), 5-quinolinyl(2-Me, 8-F), 5-quinolinyl(2-Me, 7-C1), 5-quinolinyl(2-Me, 7-F) and 5-quinazolinyl(2-Me).
Most particularly preferred Ar groups, including optional substituents, are 5- quinolinyl(2-Me), 5-quinolinyl(2-Me, 7-C1), 5-quinolinyl(2-Me, 7-F) and 5- quinazolinyl(2-Me).
When R^ is C ] -galkyl a preferred group is methyl. Preferably R^ is hydrogen or methyl. When r is other than 0, preferred substituents include halogen (particularly fluoro or chloro), C\ -galkyl (particularly methyl or ethyl), cyano, Ci-galkanoyl or CF3.
Preferably m is 2.
When n is 2, preferably q is 1.
Preferably, r is 0, 1 or 2.
Preferably R^ is halogen, particularly fluoro.
Preferably Y is oxygen or is a single bond. When Y is oxygen, preferably p is 0 or 1. When Y is a single bond, it is preferred that p is 1, so that X and the benzoxazinone group are linked by a CH2 group.
Preferred compounds of this invention are examples El - El 67 (as described below) and pharmaceutically acceptable salts thereof. Particularly preferred compounds according to this invention are:
6-(4-(l-(2-(4-lH-Indolyloxy)ethyl)piperidinyl)oxy)-4H-benzo[l,4]oxazin-3-one,
6-(4-(l-(2-(4-(2-Cyano)-lH-indolyloxy)ethyl)piperidinyl)oxy)-4H-benzo[l,4]oxazin-3- one,
6-(4-(l-(3-(2-(5-Isoxazolyl)phenoxy)propyl)piperidinyl)oxy)-4H-benzo[l,4]oxazin-3- one, 6-(4-(l-(2-(5-Quinolinyloxy)ethyl)piperidinyl)methyl)-4H-benzo[l,4]oxazin-3-one,
6-(4-(l-(3-(2-Cyanophenoxy)propyl)piperidinyl)oxy)-4H-benzo[l,4]oxazin-3-one,
6-(4-(l-(3-(7-(2,2-Dimethyl-2,3-dihydro)benzo[b]furanyloxy)propyl)piperidinyl)-oxy)-
4H-benzo[l ,4]oxazin-3-one,
6-(4-(l-(2-(7-(2,2-Dimethyl-2,3-dihydro)benzo[b]furanyloxy)ethyl)piperidinyl)oxy)-4- methy l-4H-benzo [ 1 ,4]oxazin-3 -one, 6-(4-( 1 -(2-( 1 -naphthy loxy)ethy l)piperidiny l)oxy)-4-methyl-4H-benzo [ 1 ,4]oxazin-3 - one,
(+)-6-(3-(l-(3-(2-Cyanophenoxy)propyl)piperidinyl)methoxy)-4H-benzo[l,4]oxazin-3- one, (+)-6-(3-(l-(3-(2-Cyanophenoxy)propyl)pyrrolidinyl)methoxy)-4H-benzo[l,4]oxazin-
3 -one,
6-(4-(l-(3-(2-(5-Isoxazolyl)phenoxy)propyl)piperazinyl)methyl)-4H-benzo[l,4]oxazin-
3-one,
6-(4-(l-(2-(5-(2-Methyl)quinolinyloxy)ethyl)piperidinyl)methyl)-4H-benzo[l,4]oxazin- 3 -one,
6-(4-(l-(2-(5-(3-Methyl)quinolinyloxy)ethyl)piperidinyl)methyl)-4H-benzo[l,4]oxazin-3-one,
6-(4-(l-(2-(5-Cinnolinyloxy)ethyl)piperidinyl)methyl)-4H-benzo[l,4]oxazin-3-one,
6-(4-( 1 -(2-(4-( 1 ,2-Dihydro)benzo [b]furanyloxy)ethyl)piperidinyl)methyl)-4H- benzo [ 1 ,4]oxazin-3 -one, 6-(4-(l-(2-(4-(lH)-Indazolyloxy)ethyl)piperidinyl)methyl)-4H-benzo[l,4]oxazin-3-one,
6-(4-(l-(2-(5-(2-Methyl)quinolinyloxy)ethyl)piperidinyl)oxy)-4H-benzo[l,4]oxazin-3- one,
4-Methyl-6-(4-(l-(2-(5-(2-methyl)quinolinyloxy)ethyl)piperidinyl)oxy)-4H- benzo[l ,3]oxazin-3-one, 6-(4-(l-(2-(5-(2-Methyl)quinolinyloxy)ethyl)piperazinyl)methyl)-4H- benzo[l,4]oxazin-3-one,
6-(4-(l-(3-(5-(2-Methyl)quinolinyloxy)propyl)piperidinyl)methyl)-4H- benzo[l,4]oxazin-3-one,
6-(4-(l-(3-(5-(2-Methyl)quinolinyloxy)propyl)piperazinyl)methyl)-4H- benzo[l,4]oxazin-3-one,
6-(4-(l-(3-(5-(2-Methyl)quinolinyloxy)propyl)piperidinyl)oxy)-4H-benzo[l,4]oxazin-
3 -one,
4-Methyl-6-(4-(l -(3-(5-(2-methyl)quinolinyloxy)propyl)piperidinyl)oxy)-4H- benzo[l,4]oxazin-3-one. 4-Methyl-6-(4-(l-(2-(5-(2-methyl)quinolinyloxy)ethyl)piperidinyl)methyl)-4H- benzo[l,4]oxazin-3-one,
6-(4-(l-(2-(5-(8-Chloro-2-methyl)quinolinyloxy)ethyl)piperidinyl)methyl)-4H- benzo [ 1 ,4] oxazin-3 -one, 4-Methyl-6-(4-(l-(3-(5-(2-methyl)quinolinyloxy)propyl)piperidinyl)-methyl)-4H- benzo [ 1 ,4]oxazin-3 -one,
6-(4-(l-(2-(5-(8-Chloro-2-methyl)quinolinyloxy)ethyl)piperidinyl)methyl)-4-methyl-
4H-benzo[l,4]oxazin-3-one,
6-(4-(l-(2-(5-(8-Fluoro-2-methyl)quinolinyloxy)ethyl)piperidinyl)methyl)-4H- benzo[l,4]oxazin-3-one,
6-(4-(l-(2-(5-(8-Fluoro-2-methyl)quinolinyloxy)ethyl)piperidinyl)methyl)-4-methyl-
4H-benzo[l ,4] oxazin-3 -one,
6-(4-(l-(2-(5-(8-Fluoro-2-methyl)quinolinyloxy)ethyl)piperidinyl)oxy)-4H- benzo[l ,4]oxazin-3-one, 6-(4-(l-(2-(5-(8-Fluoro-2-methyl)quinolinyloxy)ethyl)piperidinyl)oxy)-4-methyl-4H- benzo [ 1 ,4] oxazin-3 -one,
6-(4-(l-(2-(5-(7-Chloro-2-methyl)quinolinyloxy)ethyl)piperidinyl)methyl)-4H- benzo [ 1 ,4] oxazin-3 -one,
6-(4-(l-(2-(5-(7-Chloro-2-methyl)quinolinyloxy)ethyl)piperidinyl)methyl)-4-methyl- 4H-benzo[l,4]oxazin-3-one,
6-(4-(l-(2-(5-(7-Chloro-2-methyl)quinolinyloxy)ethyl)piperidinyl)oxy)-4H- benzo[l ,4]oxazin-3-one,
6-(4-(l-(2-(5-(7-Chloro-2-methyl)quinolinyloxy)ethyl)piperidinyl)oxy)-4-methyl-4H- benzo[l ,4]oxazin-3-one, 6-(4-( 1 -(2-(5-(7-Chloro-2-methyl)quinolinyloxy)ethyl)piperazinyl)methyl)-4H- benzo [ 1 ,4]oxazin-3 -one,
6-(4-(l-(3-(5-(7-Chloro-2-methyl)quinolinyloxy)propyl)piperidinyl)oxy)-4H- benzo[l ,4]oxazin-3-one,
6-(4-(l-(3-(5-(7-Chloro-2-methyl)quinolinyloxy)propyl)piperidinyl)oxy)-4-methyl-4H- benzo[l ,4]oxazine-3-one, 6-(4-(l-(2-(5-(2-Methyl)quinolinyloxy)ethyl)piperidinyl)methyl)-4-(2-propyl)-4H- benzo [ 1 ,4]oxazin-3 -one,
6-(4-(l-(2-(5-(2-Methyl)quinazolinyloxy)ethyl)piperidinyl)methyl)-4H-benzo[l,4]- oxazin-3-one, 6-(4-(l-(2-(5-(7-Fluoro-2-methyl)quinolinyloxy)ethyl)piperidinyl)methyl)-4H- benzo [ 1 ,4]oxazin-3 -one,
7-Fluoro-6-(4-(l-(2-(5-(2-methyl)quinolinyloxy)ethyl)piperidinyl)methyl)-4H- benzo[l,4]oxazin-3-one,
8-Fluoro-4-methyl-6-(4-(l-(2-(5-(2-methyl)quinolinyloxy)ethyl)piperidinyl) methyl)- 4H-benzo[ 1,4] oxazin-3 -one,
8-Fluoro-6-(4-(l-(2-(5-(2-methyl)quinolinyloxy)ethyl)piperidinyl)methyl)-4H- benzo [ 1 ,4] oxazin-3 -one,
7,8-Difluoro-6-(4-(l-(2-(5-(2-methyl)quinolinyloxy)ethyl)piperazinyl)methyl)-4H- berrzo [1,4] oxazin-3 -one, 4-Ethyl-6-{ l-[2-(2-methyl-quinolin-5-yloxy)-ethyl]-piperidin-4-ylmethyl}-4Η- benzo [ 1 ,4] oxazin-3 -one
and pharmaceutically acceptable salts thereof.
The compounds of formula (I) can form acid addition salts thereof. It will be appreciated that for use in medicine the salts of the compounds of formula (I) should be pharmaceutically acceptable. Suitable pharmaceutically acceptable salts will be apparent to those skilled in the art and include those described in d. Pharm. Sci., 1977, 66, 1-19, such as acid addition salts formed with inorganic acids e.g. hydrochloric, hydrobromic, sulfuric, nitric or phosphoric acid; and organic acids e.g. succinic, maleic, acetic, fumaric, citric, tartaric, benzoic, p-toluenesulfonic, methanesulfonic or naphthalenesulfonic acid. Certain of the compounds of formula (I) may form acid addition salts with one or more equivalents of the acid. The present invention includes within its scope all possible stoichiometric and non-stoichiometric forms. The compounds of formula (I) may be prepared in crystalline or non-crystalline form, and, if crystalline, may optionally be hydrated or solvated. This invention includes within its scope stoichiometric hydrates or solvates as well as compounds containing variable amounts of water and/or solvent.
Certain compounds of formula (I) are capable of existing in stereoisomeric forms (e.g. geometric or (" cis-trans") isomers, diastereomers and enantiomers) and the invention extends to each of these stereoisomeric forms and to mixtures thereof including racemates. The different stereoisomeric forms may be separated one from the other by the usual methods, or any given isomer may be obtained by stereospecific or asymmetric synthesis. The invention also extends to any tautomeric forms and mixtures thereof. For compounds of formula (I) where R is a C3_galkenyl group, the compounds may also exist as geometric isomers around the double bond. The present invention includes within its scope all such isomers, including mixtures.
In a further aspect, this invention provides a process for the preparation of a compound of formula (I) or a pharmaceutically acceptable salt thereof, which process comprises:
(a) the coupling of a compound of formula (II):
Figure imgf000012_0001
(II)
in which R , R2, Y, n, p, q and r are defined in formula (I), with a compound of formula (III):
Figure imgf000013_0001
(III) in which Ar and m are as defined for formula (I) and L is a leaving group; or
(b) reacting a compound of formula (II) as defined above with a compound of formula (IV)
Figure imgf000013_0002
(IV) in which Ar and m are defined in formula (I), in the presence of a reducing agent; or
(c) for a compound of formula (I) wherein X is N, reacting a compound of formula (V):
R1
Figure imgf000013_0003
(
(V) in which p, R2, r and R1 are as defined in formula (I), with a compound of formula (VI):
Figure imgf000013_0004
(VI) in which Ar, m, q and n are as defined in formula (I), in the presence of a reducing agent; and optionally thereafter for each of process (a), (b) or (c): • removing any protecting groups, and/or • converting a compound of formula (I) into another compound of formula (1), and/or o forming a pharmaceutically acceptable salt.
For process (a), suitable leaving groups include halogen (particularly chloro or bromo), methylsulfonyloxy and 4-toluenesulfonyloxy (tosylate). The reactions of compounds of formula (II) and (III) are typically carried out in the presence of a base, such as diisopropylethylamine or sodium bicarbonate, in a suitable solvent such as isopropanol or dimethylformamide.
For processes (b) and (c), the reactions of a compounds of formula (II) and (IV) and of formula (V) and (VI) are carried out in the presence of a reducing agent, such as sodium triacetoxyborohydride, in a suitable solvent, such as dichloroethane or dichloromethane.
Compounds of formula (I) can be converted into further compounds of formula (I) using standard techniques. For example, and by way of illustration rather than limitation, for compounds of formula (I) wherein R is hydrogen it may be possible to introduce a Ci .galkyl group by conventional alkylation using 1 molar equivalent of a C].galkylhalide and 1 molar equivalent of a suitable base in an inert solvent. Further, compounds of formula (I) may be converted to further compounds of formula (I) by interconversion of either of substituents R?- or those on group Ar.
Compounds of formulae (II), (III) and (IV) are commercially available, may be prepared according to procedures described herein, by known literature methods, or by analogous procedures thereto.
It will be appreciated by those skilled in the art that it may be necessary to protect certain reactive substituents during some of the above procedures. Standard protection and deprotection techniques, such as those described in Greene T.W.
Protective groups in organic synthesis, New York, Wiley (1981), can be used. For example, primary amines can be protected as phthalimide, benzyl, t-butyloxycarbonyl, benzyloxycarbonyl or trityl derivatives. Carboxylic acid groups can be protected as esters. Aldehyde or ketone groups can be protected as acetals, ketals, thioacetals or thioketals. Deprotection of such groups is achieved using conventional procedures well known in the art. For example, protecting groups such as t-butyloxycarbonyl may be removed using an acid such as hydrochloric or trifluroroacetic acid in a suitable solvent such as dichloromethane, diethylether, isopropanol or mixtures thereof.
It will be further appreciated that compounds of formula (II), (III) and (IV) and any precursors thereto may have one or more chiral centres. Enantiomeric or diastereomeric mixtures of such compounds may be separated using conventional methods, for example by chromatography or by resolution by means of diastereomeric salt formation.
Pharmaceutically acceptable salts may be prepared conventionally by reaction with the appropriate acid or acid derivative.
The affinities of the compounds of this invention for 5-HT^, 5-HTiβ and
5-HT1 receptors can be determined by the radioligand binding assay as described in
WO 99/07700. The intrinsic activity of the compounds of this invention can be determined according to the [35s]GTPγS functional assay which is also described in
WO 99/07700.
All compounds tested according to the radioligand binding assay described above were found to have pKi values > 6.0 at 5-HTJ A receptors, with many showing a considerably higher affinity (having pKi values in the range 8.0 — 9.5). Certain compounds of this invention also demonstrate comparable affinity for 5-HT|β an<J
5-HTi rj receptors. It has been found, using the [35s]GTPγS functional assay, that certain compounds of formula (I) appear to be antagonists at 5-HT] type receptors whilst others appear to be inverse agonists, agonists or partial agonists.
The efficacy of the compounds of this invention to inhibit the re-uptake of serotonin can be measured in a 5-HT uptake assay by measurement of uptake of [3H]- 5-HT into rat cortical synaptosomes as described in Thomas, D.R.; Nelson, D.R.; and Johnson, A.M. Psychopharmacology 93: 193-200 (1987). All compounds tested according to this uptake assay were found to have potency at the uptake site of pKi > 6.0, with many showing a considerably higher potency (having pKi values > 8.0).
Certain compounds of formula (I) demonstrate both affinity for the 5-HTJ A receptor (or affinity for 5-HT j , 5-HTJ B and 5-HTI J receptors) and potency at the uptake site in the higher ranges indicated above.
Compounds of formula (I) and their pharmaceutically acceptable salts are of use in the treatment or prophylaxis of certain CNS disorders such as depression, which term is used herein to include bipolar depression, unipolar depression, single or recurrent major depressive episodes with or without psychotic features, catatonic features, melancholic features, atypical features or postpartum onset, seasonal affective disorder, dysthymic disorders with early or late onset and with or without atypical features, neurotic depression and social phobia, depression accompanying dementia for example of the Alzheimer's type, vascular dementia with depressed mood, schizoaffective disorder or the depressed type, and depressive disorders resulting from general medical conditions including, but not limited to, myocardial infarction, diabetes, miscarriage or abortion, etc. Other CNS disorders which may be treated or prevented include anxiety disorders, including generalised anxiety, schizophrenia, panic disorder, agoraphobia, social phobia, obsessive compulsive disorder and post-traumatic stress disorder, pain (particularly neuropathic pain), memory disorders, including dementia, amnesic disorders and age-associated memory impairment, disorders of eating behaviours, including anorexia nervosa and bulimia nervosa, sexual dysfunction, sleep disorders (including disturbances of circadian rhythm, dyssomnia, insomnia, sleep apnea and narcolepsy), withdrawal from abuse of drugs such as of cocaine, ethanol, nicotine, benzodiazepines, alcohol, caffeine, phencyclidine (phencyclidine-like compounds), opiates (e.g. cannabis, heroin, morphine), sedative ipnotic, amphetamine or amphetamine-related drugs (e.g. dextroamphetamine, methylamphetamine) or a combination thereof, motor disorders such as Parkinson's disease, dementia in Parkinson's disease, neuroleptic-induced Parkinsonism and tardive dyskinesias, as well as other psychiatric disorders.
Compounds of formula (I) may also have utility in the treatment of certain gastrointestinal disorders such as irritable bowel syndrome, Crohn's disease, ulcerative colitis, non-steroidal anti-inflammatory drug induced damage.
Thus the invention also provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, for use as a therapeutic substance, in particular in the treatment or prophylaxis of the above disorders. In particular the invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof for use as a therapeutic substance in the treatment or prophylaxis of depression.
Compounds of the invention may be administered in combination with other active substances such as 5HT3 antagonists, NK-1 antagonists, serotonin agonists, selective serotonin reuptake inhibitors (SSRI), noradrenaline re-uptake inhibitors (SNRI), tricyclic antidepressants and/or dopaminergic antidepressants.
Suitable 5HT3 antagonists which may be used in combination of the compounds of the inventions include for example ondansetron, granisetron, metoclopramide. Suitable serotonin agonists which may be used in combination with the compounds of the invention include sumatriptan, rauwolscine, yohimbine, metoclopramide.
Suitable SSRIs which may be used in combination with the compounds of the invention include fluoxetine, citalopram, femoxetine, fluvoxamine, paroxetine, indalpine, sertraline, zimeldine.
Suitable SNRIs which may be used in combination with the compounds of the invention include venlafaxine and reboxetine.
Suitable tricyclic antidepressants which may be used in combination with a compound of the invention include imipramine, amitriptiline, chlomipramine and nortriptiline.
Suitable dopaminergic antidepressants which may be used in combination with a compound of the invention include bupropion and amineptine.
It will be appreciated that the compounds of the combination or composition may be administered simultaneously (either in the same or different pharmaceutical formulations), separately or sequentially.
The invention further provides a method of treatment or prophylaxis of the above disorders in mammals including humans, which comprises administering to the sufferer a therapeutically safe and effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.
In another aspect, the invention provides for the use of a compound of formula (1) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in the treatment or prophylaxis of the above disorders. In order to use the compounds of formula (I) in therapy, they will normally be formulated into a pharmaceutical composition in accordance with standard pharmaceutical practice. The present invention also provides a pharmaceutical composition, which comprises a compound of formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient. In a further aspect, the present invention provides a process for preparing a pharmaceutical composition, the process comprising mixing a compound of formula (I) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or excipient.
A pharmaceutical composition of the invention, which may be prepared by admixture, suitably at ambient temperature and atmospheric pressure, is usually adapted for oral, parenteral or rectal administration and, as such, may be in the form of tablets, capsules, oral liquid preparations, powders, granules, lozenges, reconstitutable powders, injectable or infusible solutions or suspensions or suppositories. Orally administrable compositions are generally preferred.
Tablets and capsules for oral administration may be in unit dose form, and may contain conventional excipients, such as binding agents (e.g. pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose);, fillers (e.g. lactose, microcrystalline cellulose or calcium hydrogen phosphate);, tabletting lubricants lubricants (e.g. magnesium stearate, talc or silica);, disintegrants (e.g. potato starch or sodium starch glycollate); and acceptable wetting agents (e.g. sodium lauryl sulphate). The tablets may be coated according to methods well known in normal pharmaceutical practice.
Oral liquid preparations may be in the form of, for example, aqueous or oily suspension, solutions, emulsions, syrups or elixirs, or may be in the form of a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents (e.g. sorbitol syrup, cellulose derivatives or hydrogenated edible fats), emulsifying agents (e.g. lecithin or acacia), non-aqueous vehicles (which may include edible oils e.g. almond oil, oily esters, ethyl alcohol or fractionated vegetable oils), preservatives (e.g. methyl or propyl-p-hydroxybenzoates or sorbic acid), and, if desired, conventional flavourings or colorants, buffer salts and sweetening agents as appropriate. Preparations for oral administration may be suitably formulated to give controlled release of the active compound.
For parenteral administration, fluid unit dosage forms are prepared utilising a compound of the invention or pharmaceutically acceptable salt thereof and a sterile vehicle. Formulations for injection may be presented in unit dosage form e.g. in ampoules or in multi-dose, utilising a compound of the invention or pharmaceutically acceptable salt thereof and a sterile vehicle, optionally with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilising and/or dispersing agents. Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, e.g. sterile pyrogen-free water, before use. The compound, depending on the vehicle and concentration used, can be either suspended or dissolved in the vehicle. In preparing solutions, the compound can be dissolved for injection and filter sterilised before filling into a suitable vial or ampoule and sealing. Advantageously, adjuvants such as a local anaesthetic, preservatives and buffering agents are dissolved in the vehicle. To enhance the stability, the composition can be frozen after filling into the vial and the water removed under vacuum. Parenteral suspensions are prepared in substantially the same manner, except that the compound is suspended in the vehicle instead of being dissolved, and sterilisation cannot be accomplished by filtration. The compound can be sterilised by exposure to ethylene oxide before suspension in a sterile vehicle. Advantageously, a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound. Lotions may be formulated with an aqueous or oily base and will in general also contain one or more emulsifying agents, stabilising agents, dispersing agents, suspending agents, thickening agents, or colouring agents. Drops may be formulated with an aqueous or non-aqueous base also comprising one or more dispersing agents, stabilising agents, solubilising agents or suspending agents. They may also contain a preservative.
The compounds of the invention may also be formulated in rectal compositions such as suppositories or retention enemas, e.g. containing conventional suppository bases such as cocoa butter or other glycerides.
The compounds of the invention may also be formulated as depot preparations. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the compounds of the invention may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.
For intranasal administration, the compounds of the invention may be formulated as solutions for administration via a suitable metered or unitary dose device or alternatively as a powder mix with a suitable carrier for administration using a suitable delivery device. Thus compounds of formula (I) may be formulated for oral, buccal, parenteral, topical (including ophthalmic and nasal), depot or rectal administration or in a form suitable for administration by inhalation or insufflation (either through the mouth or nose).
The compounds of the invention may be formulated for topical administration in the form of ointments, creams, gels, lotions, pessaries, aerosols or drops (e.g. eye, ear or nose drops). Ointments and creams may, for example, be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agents. Ointments for administration to the eye may be manufactured in a sterile manner using sterilised components.
The composition may contain from 0.1% to 99% by weight, preferably from 10 to 60% by weight, of the active material, depending on the method of administration. The dose of the compound used in the treatment of the aforementioned disorders will vary in the usual way with the seriousness of the disorders, the weight of the sufferer, and other similar factors. However, as a general guide suitable unit doses may be 0.05 to 1000 mg, more suitably 1.0 to 200 mg, and such unit doses may be administered more than once a day, for example two or three times a day. Such therapy may extend for a number of weeks or months.
All publications, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference as if each individual publication were specifically and individually indicated to be incorporated by reference herein as though fully set forth.
The following Descriptions and Examples illustrate the preparation of the compounds of the invention.
Description 1 4-Hydroxy-3-nitrophenyl benzoate (Dl)
To a stirred solution of 4-hydroxyphenyl benzoate (10 g, 47 mmol) in acetic acid (250 mL) was added, dropwise with external ice-bath cooling, nitric acid (d = 1.42, 2.9 mL) (T = 10 °C). The mixture was warmed to 20 °C and stirred for a further 56 h. The solution was evaporated in vacuo and water added to the residue. The resulting yellow solid was collected by filtration, washed with water and dried in vacuo to give the title compound (1 1.8 g, 97%). lH NMR (CDCI3) δ: 7.23 (1H, d), 7.53 (3H, m), 7.67 (1H, m), 8.00 (1H, d), 8.17 (2H, m), 10.52 (lH, s).
Description 2 4-MethoxycarbonyImethyI-3-nitrophenyI benzoate (D2)
A mixture of 4-hydroxy-3-nitrophenyl benzoate (48.8 g, 0.19 mol), methyl bromoacetate (28.8 g, 0.19 mmol), anhydrous potassium carbonate (33.8 g, 0.24 mol) and acetone (700 mL) was heated at reflux for 24 h. The mixture was evaporated in vacuo and the residue partitioned between aqueous NaOH (1 M, 1 L) and dichloromethane (3 x 200 mL). The combined organic extracts were washed with aqueous NaOH (1 M, 500 mL), water (500 mL) and brine (250 mL), then dried (Na SO4) and evaporated in vacuo to give a solid. Crystallisation from methanol with charcoal treatment gave the title compound (38 g, 61%) as pale yellow needles. H NMR (CDCI3) δ: 3.83 (3H, s), 4.82 (2H, s), 7.08 (1H, d, J - 9 Hz), 7.45 (1H, dd, J = 9, 2 Hz), 7.56 (2H, m), 7.67 (1H, m), 7.83 (1H, d, J = 2 Hz), 8.19 (2H, m).
Description 3 4-MethoxycarbonylmethyI-3-nitrophenoI (D3)
To a stirred suspension of 4-methoxycarbonylmethyl-3-nitrophenyl benzoate (26.2 g, 79 mmol) in methanol (600 mL) at 20 °C was added, dropwise over 0.3 h, a solution of sodium methoxide (4.7 g, 87 mmol) in methanol (300 mL). The resulting mixture was stirred at 20 °C for 2 h then at 50 °C for 1 h. The solution was concentrated to 200 mL in vacuo, then poured into water (1 L) and extracted with ether-hexane (1:5, 500 mL). The aqueous phase was neutralised with 2 M hydrochloric acid, then extracted with dichloromethane (6 x 300 mL). The combined dichloromethane extracts were dried (Na Sθ4) and evaporated in vacuo to give a semi-solid, which was triturated with ether-hexane (1 :3, 2 x 100 mL) to give the title compound (15.3 g, 85%) as a yellow solid.
! H NMR (CDCI3) δ: 2.00 (1H, br s), 3.80 (3H, s), 4.70 (2H, s), 6.95 (1H, d, J = 9 Hz), 7.01 (1 H, dd, J = 9, 2 Hz), 7.33 (1 H, d, J = 2 Hz).
99 Description 4
4-(4-(N-(t-ButyloxycarbonyI)piperidinyl)oxy)-2-nitrophenoxyacetic acid, methyl ester (D4) To a stirred solution of 4-methoxycarbonylmethyl-3-nitrophenol (6.0 g, 26.8 mmol), 1- (t-butyloxycarbonyl)-4-hydroxypiperidine (13.8 g, 68.9 mmol) and triphenylphosphine (18.0 g, 68.9 mmol) in tetrahydrofuran (80 mL) at 20 °C under argon was added diisopropyl azodicarboxylate (13.9 g, 68.9 mmol), dropwise over 0.75 h. The resulting solution was stirred at 20 °C for 4 h, then evaporated in vacuo. Chromatography of the residue on silica (400 g) eluting with 5 - 50% ether in hexane gave the title compound (10.1 g, 93%) as a yellow oil. l H NMR (CDC13) δ: 1.48 (9H, s), 1.65 - 2.00 (4H, m), 3.34 (2H, m), 3.69 (2H, m), 3.81 (3H, s), 4.44 (IH, m), 4.72 (2H, s), 7.02 (IH, d, J = 9 Hz), 7.10 (IH, d, J = 9, 2 Hz), 7.43 (IH, d, J = 2 Hz).
The following compounds were prepared in a similar manner to Description 4
(a) (+)-4-(3-(7V-(t-Butyloxycarbonyl)pyrroIidinyl)methoxy)-2- nitrophenoxyacetic acid, methyl ester Ϊ H NMR CDC^): δ 1.47 (9H, s), 1.78 (IH, m), 2.07 (IH, m), 2.66 (IH, m), 3.20 (IH, m), 3.70 - 3.65 (3H, m), 3.80 (3H, s), 3.91 (2H, m), 4.72 (2H, s), 7.03 (IH, d, J - 9 Hz), 7.08 (IH, dd, J = 9, 2 Hz), 7.39 (IH, d, J = 2 Hz).
(b) (±)-4-(3-(/V-(t-Butyloxycarbonyl)piperidinyl)methoxy)-2-nitrophenoxyacetic acid, methyl ester
1 H NMR (CDCl3) δ: 1.35 (l H, m), 1.45 (9H, s), 1.70 (lH, m), 1.89 (IH, m), 2.04 (IH, m), 1.60 - 3.00 (2H, m), 3.75 - 3.95 (4H, m), 3.80 (3H, s), 4.07 (IH, m), 4.72 (2H, s), 7.02 (1 H, d, J = 9 Hz), 7.09 (1 H, dd, J = 9, 2 Hz), 7.38 (1 H. d, J = 2 Hz). (c) (±)-4-(3-(N-(t-Butyloxycarbonyl)pyrrolidinyl)oxy)-2-nitrophenoxyacetic acid, methyl ester
1H NMR (CDC13) δ: 1.47 (9H, s), 2.15 (2H, m), 3.53 (4H, m), 3.80 (3H, s), 4.73 (2H, s), 4.85 (IH, m), 7.03 (2H, m), 7.37 (IH, d, J = 2 Hz).
(d) (+)-4-(3-(N-(t-Buryloxycarbonyl)piperidinyl)oxy)-2-nitrophenoxyacetic acid, methyl ester
' H NMR CDC^) δ: 1.41 (9H, s), 1.54 (IH, m), 1.68 - 1.92 (3H, m), 3.20 - 3.59 (4H, m) 3.80 (3H5 s), 4.22 (IH, m), 4.72 (2H, s), 7.01 (IH, d, J = 9 Hz), 7.10 (IH, dd, J = 9, 2 Hz), 7.41 (IH, d, J = 2 Hz).
Description 5 6-(4-(N-(t-BuryloxycarbonyI)piperidinyI)oxy)-4H-benzo[l,4]oxazin-3-one (D5)
A mixture of 4-(4-(N-(/-butyloxycarbonyl)piperidinyl)oxy)-2-nitrophenoxyacetic acid, methyl ester (10.1 g, 24.6 mmol), 10% palladium on carbon (1.0 g) and methanol (300 L) was hydrogenated at 20 °C and 1 bar for 4 h. Catalyst was removed by filtration and the filtrate was evaporated in vacuo to give an oily residue, which was dissolved in toluene. The resulting solution was heated at reflux for 2 h then evaporated in vacuo. Chromatography of the residue on silica with 25 - 100%) ethyl acetate - hexane gradient elution gave the title compound (7.2 g, 84%) as a colourless solid. lH ΝMR (CDC13) δ: 1.49 (9Η, s), 1.74 (2H, m), 1.89 (2H, m), 3.02 (2H, m), 3.68 (2H, m), 4.34 (IH, m), 4.55 (2H, s), 6.44 (IH, d, J = 2 Hz), 6.53 (IH, dd, J = 9, 2 Hz), 6.89 (I H, d, J = 9 Hz), 8.82 (lH, br s).
The following compounds were prepared in a similar manner to Description 5.
(a) 6-(4-(N-(t-ButyloxycarbonyI)piperidinyl)methyl)-4H-benzo[l,4]oxazin-3- one ΪH NMR (CDCI3) δ: 1.45 (9H, s), 1.60 (5H, m), 2.46 (2H, m), 2.63 (2H, m), 4.07 (2H, m), 4.60 (2H, s), 6.57 (IH, d, J = 2 Hz), 6.74 (IH, dd, J = 9, 2 Hz), 6.89 (IH, d, J = 9 Hz), 8.29 (IH, br s).
(b) 6-(4-(/V-(t-ButyIoxycarbonyl)piperidinyl)carbonyl)-4H-benzo[l,4]oxazin-3- one
Mass spectrum (API"): Found 359 ([M-H]"). Cj9H24N O5 requires 360.
(c) (±)-6-(3-(N-(t-ButyloxycarbonyL)pyrrolidinyl)methoxy)-4H- benzo[l,4]oxazin-3-one
ΪΗ NMR fCDC^) δ: 1.47 (9Η, s), 1.79 (IH, m), 2.05 (IH, m), 2.65 (IH, m), 3.19 (IH, m), 3.25 - 3.66 (3H, m), 3.85 (2H, m), 4.55 (2H, s), 6.44 (IH, d, J = 2 Hz), 6.50 (IH, dd, J = 9, 2 Hz), 6.87 (IH, d, J = 9 Hz), 9.02 (IH, br s).
(d) (±)-6-(3-(N-(t-BuryIoxycarbonyl)piperidinyl)methoxy)-4H- benzo[l,4]oxazin-3-one
Mass spectrum (API"): Found 361 ([M-Η]"). Ci9Η2gN O5 requires 362.
(e) (±)-6-(3-(N-(t-ButyloxycarbonyI)pyrrolidinyl)oxy)-4H-benzo[l,4]oxazin-3- one
Mass spectrum (API"): Found 333 ([M-Η]-). Cj 7Η22N2θ5 requires 334.
(f) (±)-6-(3-(/V-(t-ButyIoxycarbonyl)piperidinyl)oxy)-4H-benzo[l,4]oxazin-3- one Mass spectrum (API"): Found 347 ([M-Η]"). C 18Η24N 05 requires 348.
(g) (±)-6-(3-( V-(t-ButyloxycarbonyI)piperidinyl))-4H-benzo[l,4joxazin-3-one
Mass spectrum (API"): Found 331 ([M-Η]"). C1 8Η94N O4 requires 332. Description 6
6-(4-Piperidinyloxy)-4H-benzo[l,4]oxazin-3-one, hydrochloride (D6)
A mixture of 6-(4-(N-(t-butyloxycarbonyl)piperidinyl)oxy)-4H-benzo[l,4]oxazin-3-one (3.78 g, 10.9 mmol), ethereal hydrogen chloride (50 mL) and dichloromethane (20 mL) was heated at 40 °C for 2 h, then allowed to stir at 20 °C for 18 h. The resulting colourless solid was collected by filtration to give the title compound (2.72 g, 88%>). ! Η NMR (CD3OD) δ: 1.95 - 2.25 (4Η, m), 3.24 (2H, m), 3.40 (2H, m), 4.53 (2H, s), 4.60 (IH, m), 6.60 (IH, d, J = 2 Hz), 6.65 (IH, dd, J = 9, 2 Hz), 6.92 (IH, d, J = 9 Hz).
The following compounds were prepared in a similar manner to Description 6
(a) 4-Methyl-6-(4-piperidinyloxy)-4H-benzo[l,4]oxazin-3-one, hydrochloride
Mass spectrum (API+): Found 263 (MΗ+). C14H18N 3 requires 262.
(b) 6-(4-PiperidinyImethyl)-4H-benzo[l,4]oxazin-3-one, hydrochloride
Mass spectrum (API+): Found 247 (MΗ+). Cj4Hi 8N2O2 requires 246.
(c) 4- ethyl-6-(4-piperidinylmethyI)-4H-benzo[l,4]oxazin-3-one, hydrochloride Mass spectrum (API+): Found 261 (MΗ+). C ι5H?oN2O2 requires 260.
(d) 6-(4-(Piperidinylcarbonyl)-4H-benzo[l,4]oxazin-3-one, hydrochloride
Mass spectrum (API+): Found 261 (MH+). C ^HigN^ requires 260.
(e) (±)-6-(3-Pyrrolidinylmethoxy)-4H-benzo[l,4]oxazin-3-one, hydrochloride
Mass spectrum (API4"): Found 249 (MΗ+). Ci3HιgN O3 requires 248.
(f) (±)-6-(3-Piperidinylmethoxy)-4H-benzo[l,4]oxazin-3-one, hydrochloride
Mass spectrum (API+): Found 263 (MΗ+). C14H1 N O3 requires 262. (g) (±)-6-(3-Pyrrolidinyloxy)-4H-benzo[l,4]oxazin-3-one, hydrochloride
Mass spectrum (API4"): Found 235 (MΗ+). Ci2Hi4N2O3 requires 234.
(h) (+)-6-(3-Piperidinyloxy)-4H-benzo[l,4]oxazin-3-one, hydrochloride Mass spectrum (API"): Found 247 ([M-Η]"). C^ΗigN^ requires 248.
(i) (±)-6-(3-Piperidinyl)-4H-benzo[l,4]oxazin-3-one, hydrochloride
Mass spectrum (API4"): Found 233 (MΗ+). C]3HιgN2O2 requires 232.
(j) 6-(l-Piperazinylmethyl)-4H-benzo[l,4]oxazin-3-one, dihydrochloride
Mass spectrum (API4"): Found 248 (MΗ4"). C]3Ηi7N3θ2 requires 247.
(k) 6-(l-Piperazinyl)-4H-benzo[l,4]oxazin-3-one, dihydrochloride
Mass spectrum (API4"): Found 234 (MΗ+). Cι2Hi5N O2 requires 233.
Description 7 6-(4-(N-(t-Butyloxycarbonyl)piperidinyl)oxy)-4-methyI-4H-benzo[l,4]oxazin-3-one
(D7)
6-(4-(/V-(t-Butyloxycarbonyl)piperidinyl)oxy)-4H-benzo[l,4]oxazin-3-one (2.50 g, 7.18 mmol) in dimethylformamide (30 mL) was added to a suspension of sodium hydride (60% dispersion in oil, 346 mg, 8.64 mmol) in DMF (10 mL) cooled in an ice-bath to 5 °C. The resulting mixture was stirred at 20 °C under argon for 1 h, then a solution of methyl iodide (2 g, 14.1 mmol) in DMF (5 mL) was added dropwise, with ice-bath cooling over 0.2 h. The resulting mixture was stirred at 20 °C for 18 h. The reaction mixture was poured into water (100 mL) and extracted with ether (3 x 75 mL). The combined organic extracts were washed with water (100 mL), dried (Na SO4) and evaporated in vacuo to give the title compound (2.60 g, 100%) as a pale brown oil. i Η NMR (CDC13) δ: 1.47 (9Η, s), 1.75 (2H, m), 1.92 (2H, m), 3.32 (5H, m), 3.72 (2FI, m), 4.38 (1 H, m), 4.56 (2H, s), 6.64 (2H, m), 6.88 (1 H, d, J = 9 Hz). The following compound was prepared in a similar manner to Description 7.
(a) 6-(4-(N-(t-Buryloxycarbonyl)piperidinyl)methyl)-4-methyI-4H- benzo[l,4]oxazin-3-one i Η NMR CDC^) δ: 1.45 (9Η, s), 1.61 (5H, m), 2.51 (2H, m), 2.64 (2H, m), 3.36 (3H, s), 4.07 (2H, m), 4.59 (2H, s), 6.75 (2H, m), 6.89 (IH, d, J = 9 Hz).
Description 8 4-(4-Hydroxy)benzoylpiperidine (D8)
A solution of 4-(4-methoxy)benzoylpiperidine hydrochloride (3.0 g, 1 1.7 mmol), in 48%) HBr (aq) (16 mL), and acetic acid (16 mL) was heated at reflux for 48 h. The reaction mixture was evaporated to dryness in vacuo to give an off-white solid which was suspended in saturated NaHCO3 (aq). The resulting precipitate was collected by filtration, washed with water, and dried to give the title compound (1.76 g, 73%) as an off-white solid. Mass spectrum (API4"): Found 206 (MH+). Cι H] 5N02 requires 205.
Description 9 l-(t-Butyloxycarbonyl)-4-(4-hydroxy-3-nitro)benzoylpiperidine (D9)
A solution of 4-(4-hydroxy)benzoylpiperidine (l .52g, 7.4 mmol) in acetic acid (20 mL) was treated with cone. HNO3 (0.54 mL) in acetic acid (2 mL), and the resulting mixture was stirred at 100 °C for 2 h. Reaction mixture was cooled and evaporated in vacuo to give an orange / brown solid (2.0 g), which was dissolved in a mixture of THF (15 mL), water (4 mL), and triethylamine (1.2 mL), and treated with di-tert-butyldicarbonate (1.62 g, 7.4 mmol). The mixture was stirred at room temperature for 2 h, then evaporated in vacuo, and the residue partitioned between ethyl acetate (100 mL) and water (100 mL). The organic layer was separated and washed twice more with water (2 x 50 mL), then dried a Sθ4) and evaporated in vacuo to give a brown oil (2.4 g) which was purified by chromatography on silica gel (20 g) eluting with 50 - 100% EtOAc in hexane to give the title compound (1.86, 72%) as a yellow oil. lK NMR (CDC13) δ: 1.47 (9H, s), 1.66 - 1.89 (4H, m), 2.95 (2H, m), 3.37 (IH, m), 4.18 (2H, m), 7.27 (IH, d, J = 9 Hz), 8.20 (IH, dd, J = 9, 2 Hz), 8.71 (IH, d, J = 2 Hz), 10.92 (IH, br s).
Description 10
4-(4-(l-(t-Butyloxycarbonyl)piperidinyl)carbonyl)-2-nitrophenoxyacetic acid, methyl ester (D10) A mixture of l-(t-butoxycarbonyl)-4-(4-hydroxy-3-nitro)benzoylpiperidine (1.50 g, 4.3 mmol), potassium carbonate (0.77 g, 5.6 mmol), and methyl bromoacetate (0.66 g, 4.3 mmol) in acetone (20 mL) was stirred at reflux for 18 h. The reaction mixture was cooled and evaporated in vacuo, and the residue partitioned between water (20 mL) and dichloromethane (20 mL). The organic layer was separated and washed with IN NaOH (aq) (20 mL), water (20 mL), and brine (10 mL), dried (Na2SO4) and evaporated in vacuo to give crude product which was purified by chromatography on silica gel (~20 g) eluting with 10 - 100%) EtOAc in hexane to give the title compound (0.85 g, 47%) as a yellow oil. ! H NMR (CDCI3) δ: 1.47 (9H, s), 1.62 - 1.89 (4H, m), 2.91 (2H, m), 3.35 (IH, m), 3.82 (3H, s), 4.17 (2H, m), 4.88 (2H, s), 7.04 (IH, d, J = 9 Hz), 8.13 (IH, dd, J = 9, 2 Hz), 8.44 (lH, d, J =2 Hz).
The following compound was prepared in a similar manner to Description 10
(a) 4-(4-(l-(t-ButyloxycarbonyI)piperidinyl)methyI)-2-nitrophenoxyacetic acid, methyl ester
Ϊ H NMR CDC^) δ: 1.45 (9H, s), 1.59 (5H, m), 2.54 (2H, m), 2.64 (2H, m), 3.80 (3H, s), 4.08 (2H, m), 4.76 (2H, s), 6.92 (I H, d, J = 9 Hz), 7.28 (I H, dd, J = 9, 2 Hz), 7.65 (I H, d, J = 2 Hz). Description 11 (±)-4-(3-(l-(t-Butyloxycarbonyl)piperidinyI))-2-nitrophenol (Dll)
A solution of 3-(4-hydroxyphenyl)piperidine [B. Macchia et al, Eur. d. Med. Chem. Chim. Ther. 1995, 30, 869] (3.8 g, 21.6 mmol) in acetic acid (50 mL) was treated with cone, nitric acid (2 mL), and the resulting mixture stirred at room temperature for 16 h. Reaction mixture was evaporated in vacuo to give an orange oil which was dissolved in a mixture of THF (50 mL), water (13 mL), and triethylamine (3.6 mL) and treated with di-tert-butyl dicarbonate (4.7 g, 21.6 mmol). The resulting mixture was stirred at room temperature for 18 h, then partitioned between ethyl acetate (100 mL) and water (100 mL). The organic layer was separated, dried (Na SO4) and evaporated in vacuo to give the crude product, which was purified by chromatography on silica gel (200 g) eluting with 50 - 100%) EtOAc in hexane to give the title compound (1.97 g, 28%) as a brown oil. Ϊ H NMR (CDC13) δ: 1.48 (9H, s), 1.58 (2H, m), 2.01 (IH, m), 2.61 - 2.87 (4H, m), 4.11 (2H, m), 7.12 (IH, d, J = 9 Hz), 7.47 (IH, dd, J - 9, 2 Hz), 7.78 (IH, d, J = 2 Hz), 1 1.02 (IH, br s).
Description 12
(±)-4-(3-(l-(t-ButyIoxycarbonyl)piperidinyl))-2-nitrophenoxyacetic acid, methyl ester (D12)
The title compound was prepared in a similar manner to Description 10, in 80% yield. !H NMR (CDCI3) δ: 1.47 (9H, s), 1.51 - 1.79 (3H, m), 2.65 - 2.87 (4H, m), 3.81 (3H, s), 4.08 (2H, m), 4.78 (2H, s), 6.94 (IH, d, J = 9 Hz), 7.39 (I H, dd, J = 9, 2 Hz), 7.73 (lH, d, J = 2 Hz).
Description 13 6-(4-Pyridyl)-4H-benzo[l,4]oxazin-3-one (D13)
A mixture of 6-bromo-4H-benzo[l,4]oxazin-3-one [N. Mazharuddin et al, Indian d. Chem. 1969, 7, 658] (1.37 g, 6 mmol), pyridine-4-boronic acid (0.72 g, 6 mmol), sodium bicarbonate (1.51 g, 18 mmol), (tetrαA y-triphenylphosphine)palladium (0) (348 mg, 0.3 mmol) in water (18 mL), and 1,2-dimethoxyethane (30 mL), was stirred at reflux under an argon atmosphere for 72 h. Reaction mixture was cooled and partitioned between ethyl acetate (100 mL) and water (100 mL). The organic layer was separated and dried (Na2SO4) and evaporated in vacuo to give a brown solid which was purified by chromatography on silica gel (30 g) eluting with 0 - 5% MeOH in EtOAc to give the title compound (0.58 g, 43%) as a yellow solid. Mass spectrum (API4"): Found 227 (MH+). C I 3HIQN O2 requires 226.
Description 14
6-(4-Piperidinyl)-4H-benzo[l,4]oxazin-3-one (D14)
A solution of 6-(4-pyridyl)-4H-benzo[l,4]oxazin-3-one (0.57 g, 2.52 mmol), in methanol (15 mL) was treated with platinum (IV) oxide (50 mg, 0.22 mmol) and 1M ΗC1 in ether (2.7 mL) and stirred at room temperature under an atmosphere of hydrogen for 24 h. The reaction mixture was filtered through celite and the filtrate evaporated in vacuo to give the title compound (0.59 g, 87%>) as a pale yellow solid. Mass spectrum (API4"): Found 233 (MΗ+). Cj3HιgN2O2 requires 232.
Description 15 6-Formyl-4H-benzo[l,4]oxazin-3-one (D15)
A mixture of 4-hydroxy-3-nitrobenzaldehyde (3.05 g, 18.3 mmol), ethyl bromoacetate (3.20 g, 19.2 mmol), potassium carbonate (2.77 g, 20.1 mmol) and N,N- dimethylformamide (100 mL) was stirred at 20 °C for 40 h. The resulting solution was partitioned between water (300 mL) and ethyl acetate (300 mL), and the organic phase was washed with water (2 x 200 mL) and brine (100 mL), then dried (MgSO4) and evaporated in vacuo to give a solid (3.85 g). An aliquot of this solid (0.65 g) was dissolved in acetic acid (16 mL) and iron powder (2.85 g, 50.9 mmol) was added. The mixture was heated to 60 °C for 20 h, then the mixture was cooled and filtered through celite. The filtrate was evaporated in vacuo and the residue was partitioned between ethyl acetate (100 mL) and saturated aqueous NaHCO3. The organic phase was dried (Na2SO4) and evaporated in vacuo to give the title compound (0.31 g, 57%). IH NMR (DMSO-dg) δ: 4.72 (2H, s), 7.14 (IH, d, J = 8 Hz), 7.38 (IH, d, J = 2 Hz), 7.54 (IH, dd, J = 8, 2 Hz), 9.84 (I H, s), 10.98 (1Η, br s).
Description 16
6-(4-(l-(t-Buryloxycarbonyl)piperazinyl)methyl)-4H-benzo[l,4]oxazin-3-one (D16) A mixture of 6-formyl-4H-benzo[l ,4]oxazin-3-one (1.91 g, 10.8 mmol) and N-(t- butoxycarbonyl)piperazine (2.0 g, 10.8 mmol) in 1 ,2-dichloroethane (120 mL), was cooled in an ice-bath, and treated portionwise with sodium triacetoxyborohydride (3.43 g, 16.2 mmol) over 0.3 h, with stirring under argon. The resulting mixture was stirred at room temperature for 4 h, then partitioned between dichloromethane (100 mL) and saturated aqueous sodium bicarbonate. The organic layer was separated, dried (Νa2S04) and evaporated in vacuo to give the title compound (3.52 g, 94%) as a yellow oil. lU NMR (CDC13) δ: 1.46 (9Η, s), 2.36 (4H, m), 3.42 (6H, m), 4.61 (2H, s), 6.82 (IH, m), 6.90 (2H, m), 8.86 (IH, br s).
Description 17 l-(t-Butyloxycarbonyl)-4-(4-hydroxy-3-nitro)phenylpiperazine (D17)
To a solution of 1 -(4-hydroxy)phenylpiperazine (10.0 g, 56.2 mmol) in cone, sulfuric acid (300 mL) was added potassium nitrate (6.8 g, 67.4 mmol) portionwise. The reaction mixture was stirred at 60 °C for 1.5 h and allowed to cool to room temperature, then was poured onto crushed ice (~1 L). The mixture was carefully neutralized to pH 7 using .880 ammonia solution and allowed to stand for 16 h. The black slurry was extracted with ethyl acetate. The aqueous phase was separated and evaporated in vacuo to give a brown slurry which was dissolved in tetrahydrofuran (700 mL) and triethylamine (8.6 mL). The solution was treated with di-tert-butyl dicarbonate (12.25 g, 56.2 mmol), and the reaction mixture was stirred at room temperature for 3 h, then evaporated in vacuo. The residue was partitioned between ethyl acetate (200 mL) and water (200 mL). The organic layer was dried (Na2SO4) and evaporated in vacuo to give the title compound (10.3 g, 57%) as a dark oil.
] H NMR (CDC13) δ: 1.49 (9H, s), 3.06 (4H, m), 3.59 (4H, m), 7.09 (IH, d, J = 9 Hz), 7.30 (IH, dd, J = 9, 2 Hz), 7.50 (IH, d, J = 2 Hz), 10.31 (IH, br s).
Description 18
4-(4-(l-(t-Butyloxycarbonyl)piperazinyl))-2-nitrophenoxyacetic acid, methyl ester (D18)
The title compound was prepared in a similar manner to Description 10, in 90% yield. lH NMR (CDCI3) δ: 1.48 (9H, s), 3.10 (4H, m), 3.58 (4H, m), 3.80 (3H, s), 4.71 (2H, s), 6.99 (IH, d, J = 9 Hz), 7.08 (IH, dd, J = 9, 2 Hz), 7.38 (IH, d, J = 2 Hz).
Description 19
4-(4-Hydroxybenzyl)piperidine hydrogen sulfate (D19) A mixture of 4-(4-methoxyphenyl)pyridine (23.27 g, 0.117 mol), 48% HBr (150 mL) and acetic acid (150 mL) was stirred at reflux for 24 h. The reaction mixture was cooled and evaporated to dryness in vacuo to give a brown solid which was suspended in saturated aqueous NaHCO3 (to pH 8). The resulting solid was collected by filtration, washed with water, and dried to give a yellow solid (20.7 g) which was dissolved in methanol (600 mL) and treated with cone. H9SO4 (10.9 g) and platinum (IV) oxide (600 mg). The reaction mixture was stirred under an atmosphere of hydrogen at 20 °C and 1 bar for 18 h, then filtered through celite. The filtrate was evaporated in vacuo to give the title compound (32.3 g, 100%) as a yellow oil. Mass spectrum (API4"): Found 192 (MH+). Cι2H17NO requires 191.
Description 20 l-(t-Butyloxycarbonyl)-4-(4-hydroxy-3-nitro)benzylpiperidine (D20)
A mixture of 4-(4-hydroxybenzyl)piperidine hydrogen sulfate (32.2 g, 0.1 11 mol) in glacial acetic acid (330 mL), was treated dropwise with a solution of 70% nitric acid (20 mL) in glacial acetic acid (20 mL) with stirring. The resulting mixture was stirred at room temperature for 0.5 h then evaporated in vacuo to give a dark oil (49 g) which was dissolved in a mixture of water (170 mL), tetrahydrofuran (270 mL) and triethylamine (40 mL). A solution of di-tert-butyldicarbonate (26.3 g, 0.12 mol) in tetrahydrofuran (100 mL) was added slowly under argon with stirring. The reaction mixture was stirred at room temperature for 18 h and then partitioned between ethyl acetate (3 x 200 mL) and water (200 mL). The combined organic extracts were dried (Na2SO4) and evaporated in vacuo to give the title compound (37.30 g, 100%) as a dark oil. Mass spectrum (APP): Found 335 ([M-H]"). Cj7H 4N2O5 requires 336.
Description 21
8-Quinolinyloxyacetaldehyde (D21)
To a suspension of sodium hydride (60%) oil dispersion, 3.0 g, 75 mmol) in DMF (100 mL) at 0 °C under argon, was added a solution of 8-hydroxyquinoline (9.2 g, 64 mmol) in DMF (20 mL) dropwise. The mixture was allowed to stir for 0.5 h, then allyl bromide (6.6 mL, 77 mmol) was added dropwise. The mixture was stirred at room temperature for 20 h, then was poured into ice/water (400 mL) and extracted with ether (3 x 300 mL). Combined organic extracts were washed with water (500 mL) and evaporated in vacuo. The crude residue was purified by silica gel chromatography (ethyl acetate in hexane 25%> - 75%> gradient) to give 8-allyloxyquinoline (8.5 g, 72%>) as an oil.
A solution of osmium tetroxide (2.1 mmol) in tert-butanol (26 mL) was added to a stirred mixture of 8-allyloxyquinoline (3.7 g, 20 mmol), sodium periodate (15 g, 70 mmol), THF (90 mL), methanol (4 mL) and water (2 mL). The mixture was stirred at room temperature for 20 h, then was extracted with dichloromethane (100 mL). The aqueous layer was basified with the addition of sodium hydrogen carbonate then was extracted with dichloromethane (2 x 200 mL). The combined organic extracts were washed with 20% w/w sodium sulfite solution (200 mL), then dried over sodium sulfate and evaporated in vacuo to give the title compound (1.1 g, 30%) as an amber oil. Mass spectrum (API4"): Found 188 (MH+). C ιH9NO2 requires 187.
Description 22 1-Isoquinolinyloxyacetaldehyde (D22) To a stirred suspension of sodium hydride (60%) oil dispersion, 1.2 g, 30 mmol) in DMF (6 mL) was added dropwise 2-hydroxyacetaldehyde dimethyl acetal (3.2 g, 30 mmol). The resulting mixture was left to stir for 0.5 h, then a solution of 1- chloroisoquinoline (1.6 g, 10 mmol) in DMF (2 mL) was added and the mixture was stirred at 80 °C for 24 h. The mixture was then poured into water (150 mL) and extracted with ether (2 x 150 mL). The combined organic extracts were dried over sodium sulfate and evaporated in vacuo. The residue was purified by silica gel chromatography (10%> ethyl acetate in hexane) to give 1-isoquinolinyloxyacetaldehyde dimethyl acetal (1.5 g, 64%).
A mixture of 1-isoquinolinyloxyacetaldehyde dimethyl acetal (0.93 g, 4 mmol), dioxane (10 mL), water (15 mL) and cone, sulfuric acid (2 mmol) was heated at 85 °C for 2 h, then was quenched with saturated aqueous sodium hydrogen carbonate (100 mL). The resulting mixture was extracted with dichloromethane (2 x 100 mL) and the combined organic extracts were washed with saturated aqueous sodium hydrogen carbonate (50 mL), dried over sodium sulfate and evaporated in vacuo to give the title compound (0.43 g, 57%). Mass spectrum (API4"): Found 188 (MH+). Cj ιH9NO requires 187.
Description 23 4-(2-Cyano)indolyloxyacetaldehyde (D23)
The title compound was prepared from 2-cyano-4-hydroxyindole [ .G. Estep, Synth. Commun., 1995, 25, 507] using a procedure similar to that described in H. Sasai et al, Tetrahedron 1994, 43, 12313. Other aryloxyacetaldehydes are known in the literature or were prepared by analogous methods
Description 24 2-(5-Quinolinyloxy)ethyl bromide (D24)
A mixture of 5-hydroxyquinoline (0.3 g, 2.1 mmol), 1 ,2-dibromoethane (3.9 g, 21 mmol) and potassium carbonate (1.5- g, 1 1 mmol) in methyl ethyl ketone (15 mL) was allowed to stir at 85 °C for 24 h. The mixture was evaporated in vacuo and the residue was partitioned between ether (200 mL) and water (200 mL). The organic layer was dried over sodium sulfate and evaporated in vacuo to give the title compound (0.53 g). l R NMR (CDC13) δ: 3.80 (2H, m), 4.49 (2H, m), 6.86 (IH, d, J = 8 Hz), 7.41 (IH, dd, J = 8, 4 Hz), 7.61 (IH, t, J = 8 Hz), 7.73 (IH, d, J = 8 Hz), 8.64 (IH, d, J = 8 Hz), 8.91 (IH, m).
Description 25
5-Hydroxy-2-methylquinoIine (D25)
A mixture of 2-methyl-5,6J,8-tetrahydroquinolin-5-one [E.Reimann, J. Freisinger, Arch. Pharm. (Weinheim), 318, 871 (1985)] (0.57 g, 3.5 mmol) and 48% aqueous HBr (3.5 mL) was warmed to 60 °C and treated dropwise with bromine (0.19 mL, 0.59 g, 3.6 mmol), with vigorous stirring. The resulting mixture was stirred at 60 °C for 1 h, then evaporated in vacuo. The residue was treated with isopropanol with stirring, then the mixture was evaporated in vacuo to give a waxy solid, which was triturated with 1 : 1 isopropanol - ether to give a beige powder (0.9 g). A mixture of this material, lithium carbonate (0.48 g, 6.7 mmol), lithium bromide (0.28 g, 3.2 mmol) and N,N- dimethylformamide (10 mL) was heated at 150 °C under argon with stirring for 2 h. The mixture was cooled then evaporated in vacuo. Chromatography of the residue on silica with 0 - 100% ethyl acetate - hexane gradient elution gave the title compound (0.28 g, 49%) as a solid. Mass spectrum (API4"): Found 160 (MH4"). C10H9 O requires 159. Description 26
2-(5-(2-Methyl)quinoIinyloxy)ethyI bromide (D26)
The title compound was prepared from 5-hydroxy-2-methylquinoline and 1 ,2- dibromoethane using a similar procedure to Description 24, in 91% yield. Mass spectrum (API4"): Found 266 (MH+). C 1 2H1 79BΓNO requires 265.
The following aryloxyethyl bromides were prepared from the corresponding phenol and either 1 ,2-dibromoethane or 1,3-dibromopropane, using a procedure similar to that of Description 24.
a) 2-( J-(2,2-DimethyI-2,3-dihydro)benzo[b]furanyl)oxyethyl bromide b) 3-( 7-(2,2-Dimethyl-2,3-dihydro)benzo[b]furanyI)oxypropyl bromide c) 2-( 5- -Isoxazolyl)phenoxyethyl bromide d) 3-( 5. -IsoxazoIyI)phenoxypropyl bromide e) 2-0 8-(6-FIuoro-3,4-dihydro)-2H-benzo[b]pyranyl)oxy ethyl bromide » 3-( l-(5-Oxo-5,6J,8-tetrahydro)naphthyl)oxypropyl bromide g) 2-( 7-(2,3-Dihydro)benzo[b]furanyl)oxy ethyl bromide h) 2-( 7-Benzo[b]furanyl)oxyethyl bromide i) 2-( 8-(2,2-Dimethyl-3,4-dihydro)-2H-benzo [b] pyranyl)oxyethyl bromide j) 3-( 8, -(2,2-Dimethyl-3,4-dihydro)-2H-benzo[b]pyranyl)oxypropyl bromide k) 2-( 7-(2-Methyl)benzo[b]furanyl)oxy ethyl bromide
1) 3-( 7-(2-Methyl)benzo[b]furanyl)oxypropyl bromide m) 2-( 7-(2,2-Dimethyl-2,3-dihydro-3-fluoro)benzo[b]furanyI)oxyethyl bromide n 3-( J-(2,2-Dimethyl-2,3-dihydro-3-fluoro)benzo[b]furanyl)oxypropyl bromide o) 3-( 2-Cyano-4-fluoro)phenoxypropyl bromide
P) 2-( 5-(3-IVIethyl)quinolinyl)oxyethyl bromide q) 2-( 5-Cinnolinyl)oxyethyl bromide r) 2-( 4-(2,3-Dihydro)benzo[b]furanyl)oxyethyI bromide s) 2-( 4-Benzo[b]furanyl)oxyethyl bromide t) 3-(5-(2-Methyl)quinoxalinyl)oxypropyI bromide u) 3-(2-(5-(3-Methyl)isoxazolyl)phenoxy)propyl bromide v) 2-(5-(7-Fluoro-2-methyl)quinolinyl)oxyethyI bromide w) 2-(5-(2-Methyl)quinazolinyl)oxyethyl bromide
Other aryloxyalkyl bromides are known in the literature or were prepared by analogous methods.
Description 27 3-(5-(2- ethyl)quinolinyl)oxypropyl bromide (D27)
The title compound was prepared from 5-hydroxy-2-methylquinoline and 1,3- dibromopropane using a similar procedure to Description 24. Mass spectrum (API4"): Found 280 (MH+). C13Hi479BrNO requires 279.
Description 28
2-(5-(8-Chloro-2-methyl)quinolinyl)oxyethyl bromide (D28)
The title compound was prepared from 8-chloro-5-hydroxy 2-methylquinoline and
1 ,2-dibromoethane using a similar procedure to Description 24.
Mass spectrum (API4"): Found 300 (MH+). C 2Hπ79Br35ciNO requires 299.
Description 29
2-(5-(8-Fluoro-2-methyl)quinolinyl)oxyethyl bromide (D29)
The title compound was prepared from 8-fluoro-5-hydroxy-2-methylquinoline and 1 ,2- dibromoethane using a similar procedure to Description 24. Mass spectrum (API4"): Found 284 (MH+). C19H1 j^BrFNO requires 283.
Description 30
2-(5-(7-Chloro-2-methyl)quinolinyl)oxyethyI bromide (D30)
The title compound was prepared from 7-chloro-5-hydroxy-2-methylquinoline and 1 ,2-dibromoethane using a similar procedure to Description 24. Mass spectrum (API4"): Found 300 (MH+). C1 Hι ^Br^ClNO requires 299.
Description 31
3-(5-(7-Chloro-2-methyl)quinolinyl)oxypropyl bromide (D31) The title compound was prepared from 7-chloro-5-hydroxy-2-methylquinoline and 1 ,3-dibromopropane using a similar procedure to Description 24. Mass spectrum (API+): Found 314 (MH+). C13Hι3 79Br 5ClNO requires 313.
Description 32 2-(4-(l-Acetyl)-indazolyI)oxyethyl iodide (D32)
A mixture of 2-(4-(l-acetyl)-l-H-indazolyl)oxyethyl chloride (1.1 g, 4.6 mmol), and sodium iodide (0.69 g, 4.6 mmol) in acetone (10 mL), was stirred at 45°C for 16 h and then evaporated in vacuo. The residue was partitioned between dichloromethane (10 mL), and water (10 mL). The organic layer was dried (Na2SO4) and evaporated in vacuo to give a brown oil (0.91 g, 60%). lΗ NMR (CDC1 ) δ: 2.32 (3Η, s), 3.82 (2H, m), 4.23 (2H, m), 6.69 (IH, m), 7.45 (IH, m), 8.03 (lH, m), 8.23 (lH, m).
Description 33 2-(4-(lH)-Indazolyl)oxyethyl chloride (D33)
Prepared in a similar manner to that described in R.E. Mewshaw et al, Bioorg. Med.
Chem. Lett. (1999), 9 (17), 2593-2598.
Mass spectrum (API4"): Found 239 (MΗ+). CπH] \ 35C1N202 requires 238.
Description 34
8-Chloro-5-hydroxy-2-methylquinoline (D34)
Crotonaldehyde (17.5 mL, 0.21 mol) was added dropwise to a refluxing solution of 2- chloro-5-methoxyaniline hydrochloride (10.36 g, 53.4 mmol) in 5 N hydrochloric acid
(450 mL) and reflux continued for a further 0.5 h. The reaction mixture was cooled and diluted with water (500 mL), then extracted with ether (400 mL). The aqueous layer was separated and basified using 50%) aqueous NaOH (pH 14), and then extracted into dichloromethane (3 x 300mL). The combined organic phases were dried (N SO4) and evaporated in vacuo to give a dark oil which was purified by chromatography on silica gel (-200 g) eluting with 20%> EtOAc in hexane to give a brown oil (5.17 g) which was heated at reflux in a mixture of acetic acid (30 mL) and 48%> hydrobromic acid (30 mL) for 66 h. Reaction mixture was evaporated in vacuo and the residue suspended in sat. NaHCθ3 (aq), then extracted into dichloromethane (3 x 50 mL). The combined organic phases were dried (Na2S04) and evaporated in vacuo to give a brown solid (2.90 g, 28%). Mass spectrum (API4"): Found 194 (MH+). Cι oH 35CINO requires 193.
Description 35
8-FIuoro-5-hydroxy-2-methylquinoline (D35)
The title compound was prepared from 2-fluoro-5-methoxyaniline using a similar procedure to Description 34, in 43% yield.
Mass spectrum (API4"): Found 178 (MH+). C I QHSFNO requires 177.
Description 36 2-Fluoro-5-methoxyaniIine (D36) To a stirred mixture of 2,6-dibrorno-4-fluoroanisole (52.5 g, 0.185 mol) in 98% sulfuric acid (152 mL) at 15 °C was added, dropwise over 0.5 h, a solution of nitric acid (9.2 mL) and sulfuric acid ( 152 mL) with external ice-bath cooling. The mixture was stirred at 20 °C over 4 h, then was poured into ice water (1 kg) and extracted with dichloromethane (3 x 150 mL). The combined extracts were dried (Na SO4) and evaporated in vacuo to give a brown oil. Chromatography on silica with 1 - 50% ether in hexane gradient elution gave an off-white solid, a solution of which in ethanol (250 mL) was hydrogenated at 20 °C and 4 bar over 10%) palladium on carbon (3.5 g) for 18 h. Catalyst was removed by filtration and the filtrate was evaporated in vacuo to give a residue which was partitioned between saturated aqueous NaHC03 (300 mL) and dichloromethane (3 x 100 mL). The combined organic extracts were dried (Na2SO4) and evaporated in vacuo to give an oil. Chromatography on silica with 20 - 50% ether in hexane gradient elution gave the title compound (15.3 g, 59%>) as an oil. Mass spectrum (API4"): Found 142 (MH+). CyHsFNO requires 141.
Description 37
7-Chloro-5-hydroxy-2-methyIquinoline (D37)
The title compound was prepared from 3-chloro-5-methoxyaniline using a similar procedure to Description 34, in 26% yield.
Mass spectrum (API4"): Found 194 (MH+). C10H835C1NO requires 193.
Description 38 5-Hydroxy-3-methyIquinoIine (D38)
To a stirred solution of N-pivaloyl-3-methoxyaniline (4.14 g, 20 mmol) in dry tetrahydrofuran (80 mL) at 0 °C under argon was added a solution of sec-butyllithium in cyclohexane (1.4 M, 35.7 mL, 50 mmol), dropwise over 0.2 h (T < 0 °C) and the resulting mixture was stirred at 0 - 5 °C for 2 h. The mixture was cooled to -5 °C then dry NN-dimethylformamide (2.3 mL, 30 mmol) was added dropwise, and the resulting solution stirred at 0 °C for 1 h then at 20 °C for 20 h. The mixture was cooled to 0 °C and propionaldehyde (1.17 g, 20.2 mmol) was added dropwise followed by a solution of potassium hexamethyldisilazide in toluene (0.5 M, 80 mL, 40 mmol) dropwise over 0.2 h. The mixture was stirred at 0 °C for 0.25 h, then at 20 °C for 2 h and at 30 °C for 1 h. The resulting mixture was partitioned between saturated aqueous ΝH4CI (200 mL) and ether (3 x 50 mL), and the combined organic extracts dried (Na2SO4) and evaporated in vacuo. Chromatography of the residue on silica with 20 - 100%o ether in hexane gradient elution gave 5-methoxy-3-methylquinoline (0.16 g, 5%) as an oil. A mixture of 5-methoxy-3-methylquinoline (0.16 g, 0.92 mmol) and pyridine hydrochloride (0.064 g, 5.5 mmol) was heated under argon at 200 °C with stirring for 2.5 h, then cooled and partitioned between saturated aqueous NaHCO3 (30 mL) and dichloromethane (5 x 30 mL). Combined organic extracts were dried (Na2SO4) and evaporated in vacuo to give a solid which was purified by chromatography on silica eluting with ethyl acetate to give the title compound (0.089 g, 60%) as a solid. Mass spectrum (API4"): Found 160 (MH+). C 10H9NO requires 159.
Description 39
5-Hydroxycinnoline (D39)
To a mixture of 4-methoxyindole (1.26 g, 8.57 mmol), powdered potassium hydroxide (10.05 g, 0.179 mol) and dry dimethylformamide (20 mL) at 15 °C under argon was added, portionwise over 0.2 h, hydroxylamine-O-sulfonic acid. Internal temperature was kept < 30 °C by external ice bath cooling. The mixture was stirred at 20 °C for 4 h, then was extracted with toluene (4 x 50 mL). The combined extracts were washed with water (4 x 50 mL) and brine (50 mL), then dried (Na2SO4) and evaporated in vacuo to give an oil. Chromatography of the residue on silica with 5 - 50%) ether in hexane gradient elution gave l-amino-4-methoxyindole (0.79 g, 56%). A mixture of 1-amino- 4-methoxyindole (0.78 g, 4.8 mmol), nitrobenzene (3.4 g, 27.8 mmol), and methanolic HC1 (3% w/w, 180 mL) was heated at reflux for 76 h, then cooled and partitioned between 10%> aqueous NaOH (50 mL) and dichloromethane (3 x 30 mL). The combined oranic extracts were dried (Na2SO4) and evaporated in vacuo to give an oil which was purified by chromatography on silica with 5 - 100% ether in hexane gradient elution. The resulting 5-methoxycinnoline (0.56 g, 3.5 mmol) was mixed with 48%> aqueous HBr (35 mL) and the resulting solution heated at reflux for 18 h. The mixture was cooled, then evaporated in vacuo, and the residue dissolved in water (10 mL). Aqueous ammonia (d = .880) was added until pH 6 was obtained, and the resulting mxiture cooled to 0 °C. The precipitated solid was collected by filtration and purified by charcoal - methanol treatment to give the title compound (0.37 g, 53%) as a yellow solid. Mass spectrum (API4"): Found 147 (MH+). CgHgN20 requires 146.
Description 40 5-Methoxy-2-methylquinazoline (D40) To a stirred solution of 2-amino-6-methoxybenzaldehyde [K. Tsuda et al, Chem. Pharm. Bull. 1962, 10, 856] (1.3 g, 8.6 mmol), pyridine (0.81 g, 10.3 mmol) and toluene (60 mL) was added acetic anhydride (0.97 g, 9.5 mmol). The resulting mixture was heated at reflux for 18 h, cooled, then partitioned between saturated aqueous NaHCθ3 (100 mL) and ether (50 mL). The organic phase was dried (Na2SO4) and evaporated in vacuo to give a solid which was purified by chromatography on silica with 0 - 50% ether in hexane gradient elution to give a colourless solid (1.28 g). The latter was dissolved in 2 M methanolic ammonia (100 mL) and the solution heated at reflux for 3 h, cooled, then evaporated in vacuo. Chromatography of the residue on silica with 0 - 100%) ether in dichloromethane gradient elution gave the title compound (0.92 g, 62%) as a colourless solid.
Mass spectrum (API+): Found 175 (MH+). C IQHI ON O requires 174. iH NMR ^DC^) δ: 2.89 (3H, s), 4.02 (3H, s), 6.86 (IH, d, J = 8 Hz), 7.49 (IH, d, J = 8 Hz), 7.76 (IH, t, J = 8 Hz), 9.65 (IH, s).
Description 41
5-Hydroxy-2-methyIquinazoIine (D41)
To a stirred solution of 5-methoxy-2-methylquinazoline (0.22 g, 1.26 mmol) in dichloromethane (20 mL) at 0 °C under argon was added a solution of boron tribromide in dichloromethane (IM, 3.8 mL), dropwise over 0.01 h. The resulting mixture was stirred at 20 °C for 48 h then poured into a mixture of ice (50 g) and .880 aqueous ammonia (50 mL) and stirred for 0.5 h. Organic phase was separated and aqueous phase washed with dichloromethane (3 x 30 mL). The aqueous phase was acidified (pH 6) with citric acid and the resulting mixture extracted with ethyl acetate (3 x 50 mL). The combined ethyl acetate extracts were dried Na SO4) and evaporated in vacuo to give the title compound (0.030 g, 15%) as an oil which was used without further purification. Mass spectrum (API+): Found 161 (MH+). C9H8N O requires 160.
Description 42 7-Fluoro-5-hydroxy-2-methylquinoline hydrobromide (D42)
Crotonaldehyde (28 mL, 0.33 mol) was added dropwise to a refluxing solution of 3,5- difluoroaniline (10.75 g, 0.083 mol) in 5 N hydrochloric acid (450 mL) and reflux was continued for a further 0.5 h. Reaction mixture was cooled, diluted with water (200 mL) and washed with ether (200 mL). The aqueous layer was basified (pH 14) with 50%) NaOH (aq) and extracted into MDC (3 x 200 mL). The combined organic phases were dried Na S04) and evaporated in vacuo to give a dark oil which was purified by chromatography on silica gel (-^100 g) with 50 - 100% ethyl acetate in hexane gradient elution to give 5J-difluoro-2-methylquinoline as a brown solid (6.57 g, 44%). A mixture of 5J-difiuoro-2-methylquinoline (1.0 g, 5.6 mmol) and sodium methoxide (1.62 g, 30 mmol) in methanol (50 mL), was stirred at reflux for 18 h, cooled, and most of the methanol removed in vacuo. The residue was partitioned between ethyl acetate (100 mL), and water (100 mL). The organic phase was dried (Na2SO4) and evaporated in vacuo to give a brown oil which was purified by chromatography on silica gel (~60 g) with 20 - 30% ethyl acetate hexane gradient elution to give a yellow solid (0.57 g) which was suspended in 48%) HBr (aq) (5 mL) and heated at reflux for 18 h. Reaction mixture was cooled and evaporated in vacuo to give the title compound as a brown solid (0.67 g, 46%). Mass spectrum (API4"): Found 178 (MH+). CI QHSFNO requires 177.
Description 43
7-Iodo-2-methyl-quinolin-5-ol (D43)
The title compound was prepared from 3-iodo-5-methoxyaniline in a similar manner to
Description 34 Mass spectrum (API+): Found 286 (MH+). C I QHSINO requires 285.
Description 44 6-Bromo-4-fluoro-3-methoxyaniline (D44)
A mixture of 4-fluoro-3-methoxyaniline (9.87 g, 70 mmol) and N-bromosuccinimide (12.46g, 70 mmol) in dichloromethane (150 ml) was stirred at room temperature for 1 h (exothermic). The reaction mixture was evaporated in vacuo to give a dark slurry which was chromatographed on silica gel (~β50 g) using a gradient elution 20-50 % ethyl acetate in hexane to give the title compound as a brown solid (12.70 g, 82 %). Mass spectrum (API): Found 220 (MH+). C H ^BrFNO requires 219. l H NMR (CDC13) - 3.82 (3H, s), 6.39 (IH, d, J = 8 Hz), 7.14 (IH, d, J = 1 1 Hz).
Description 45 8-Bromo-6-fluoro-5-methoxy-2-methylquinoline (D45)
To 6-bromo-4-fluoro-3-methoxyaniline (7.0g, 32 mmol) was added cone. HC1 (10 ml) followed by p-chloranil (7.80g, 32 mmol), then nbutanol (10 ml) was added and the whole mix heated up to reflux, with stirring. A solution of crotonaldehyde (2.7g 38.4 mmol) in nbutanol (5 ml), was added slowly over 0.5h, and reflux continued for a further 0.5 h. The reaction mixture was allowed to cool, and the basified to pH14 using 50%) NaOH solution. The reaction mixture was diluted with water (200 ml) and extracted with dichloromethane (3 x 100 ml). The combined organic extracts were dried over Na S04 and evaporated in vacuo to give a dark oil which was chromatographed on silica gel (~200g) eluting from 20 % ethyl acetate in hexane to give the title compound as a brown oil (2.97g, 34 %>). Mass spectrum (API): Found 270 (MH4"). Ci ^^BrFNO requires 269. lU NMR (CDCI3) δ: 2.79 (3H, s), 4.13 (3H, m), 7.34 (IH, d, J = 9 Hz), 7.82 (IH, d, J = 1 1 Hz), 8.40 (IH, d, J = 9 Hz).
Description 46 6-Fluoro-5-methoxy-2-methylquinoIine (D46) A solution of 2-methyl-5-methoxy-6-fluoro-8-bromoquinoline (2.95 g, 10.9 mmol) in ethanol (100 ml) was charged with 10 % palladium on charcoal (250 g) and stirred at room temperature and pressure under an atmosphere of hydrogen for 2 h. The mixture was then filtered through a pad of kieselguhr and the filtrate evaporated in vacuo to give the title compound as a brown solid (2.09 g, 100 %). Mass spectrum (API): Found 192 (MPl+). C\ ιH10FNO requires 191. ! H NMR (CDCI3) δ: 3.23 (3H, s), 4.31 (3H, m), 7.62 (IH, d, J = 9 Hz), 7.77 (IH, m), 8.77 (IH, m), 9.02 (IH, d, J = 9 Hz).
Description 47 6-Fluoro-5-hydroxy-2-methylquinoline (D47)
A mixture of 2-methyl-5-methoxy-6-fluoroquinoline (2.07g, 10.8 mmol) and 48 % hydrobromic acid (30 ml) was stirred at reflux for 24 h. The reaction mix was reduced to minimum volume in vacuo and partitioned between dichloromethane (50 ml) and sat. aqueous sodium bicarbonate solution (50 ml). The organic layer was dried over sodium sulfate, filtered and evaporated in vacuo to give the title compound as a brown solid
(1.39 g, 73 %).
Mass spectrum (API): Found 178 (MH+). CioHgFNO requires 177.
[R NMR (DMSO-d6) δ: 2.62 (3H, s), 7.41 (2H, m), 7.58 (IH, m), 8.43 (IH, d, J - 9
Hz).
Description 48
5-(2-Bromoethoxy)-6-fluoro-2-methylquinoIine (D48)
The title compound was prepared using a similar procedure to Description 24.
Mass spectrum (API): Found 284 (MH+). Cι2Hι ι79BrFNO requires 283. iH NMR (CDCI3) δ: 2.73 (3H, s), 3.72 (2H, t, J = 6 Hz), 4.61 (2H, m), 7.33 (IH, d, J =
9 Hz), 7.45 (IH, m), 7.74 (IH, m), 8.54 (IH, d, J = 9 Hz).
Description 49 7,8-Difluoro-2-methyl-quinolin-5-ol (D49) The title compound was prepared from 2,3,5 trifluoroaniline in a similar manner to Description 42.
Mass spectrum (API): Found 198 (MH+). Ci ()HgF3N requires 197. ! H NMR (CDCI3) δ: 2.81 (3H, s), 7.09 (IH, m), 7.38 (IH, d, J = 9 Hz), 8.26 (I H, d, J = 9 Hz). Description 50 5(2-Bromoethoxy)-7,8-difluoro-2-methylquinoline (D50)
The title compound was prepared using the procedure described in Description 24. Mass spectrum (API): Found 302 (MH+). C12Hι 0 79BrF NO requires 301. H NMR (CDC13) δ: 2.78 (3H, s), 3.68 (2H, m), 4.55 (2H, m), 7.00 (IH, m), 7.29 (IH, m), 8.21 (IH, m).
Description 51 2,3-Difluoro-4-hydroxy-5-nitro-benzoic acid methyl ester (D51)
Concentrated nitric acid (70%) w/w) (0J2mL, 11.2mmol) in glacial acetic acid (2mL) was added dropwise to a solution of 2,3-difluoro-4-hydroxy-benzoic acid methyl ester [Gonzales, Javier et al., PCT Int. Appl. (1999), 551 pp. WO 9901423 Al 199901 14]
(2g, 10.6mmol) in glacial acetic acid (28mL). The mixture was stirred at 45 C for 0.5 hour and then at room temperature overnight before it was evaporated to a quarter of the volume in vacuo. Water was added to the concentrate to give a solid precipitate which was filtered, washed with water twice and dried to give the title compound (2.2g, 88%) as a colourless solid. H NMR (DMSO-dg) δ: 3.86 (3H, s), 8.27 (IH, dd, J = 10, 3Hz).
Description 52
5-Amino-2,3-difluoro-4-hydroxy-benzoic acid methyl ester (D52)
A solution of 2,3-difluoro-4-hydroxy-5-nitro-benzoic acid methyl ester (2.2g, 9.4mmol) in methanol (lOOmL) was stirred under atmospheric hydrogen at ambient temperature in the presence of 10% palladium on charcoal (0.8g) for 3 hours. The mixture was filtered and the filtrate was evaporated in vacuo to give the title compound (1.9g, 100%)) as a colourless solid. H NMR
Figure imgf000048_0001
10, 3Hz). Description 53 7,8-Difluoro-6-methoxycarbonyl-4H-benzo[l,4]oxazine-3-one (D53)
A mixture of 5-amino-2,3-difluoro-4-hydroxy-benzoic acid methyl ester (5.5g, 27.1 mmol) and benzyl-triethylammonium chloride (6.2g) in chloroform (300mL) was warmed and sonicated until most of the solid was dissolved. The mixture was cooled in an ice bath and sodium hydrogen carbonate (lOg) was added, followed by chloroacetyl chloride (2.4mL, 29mmol). The combined mixture was stirred in cold for 1 hour and then under reflux for approximatly 9 hours. It was then evaporated in vacuo and the resulting residue was treated with water and chlorform to give a solid. This solid was collected by filtration, washed with water, diethyl ether and dried in vacuo to give the title compound (3Jg, 56%>). 1ΗNMR (DMSO-dg) δ: 3.85 (3H, s), 4.78 (2H, s), 7.21 (IH, dd, J = 10, 3 Hz).
Description 54 7,8-Difluoro-4H-benzo[l,4]oxazine-3-one-6-carboxylic acid (D54)
A 2M solution of aqueous sodium hydroxide (30mL) was added to a suspension of 7,8- difluoro-6-methoxycarbonyl-4H-benzo[l,4]oxazine-3-one (4.8g, 19.8mmoL) in TΗF (lOOmL). The mixture was allowed to stir for 3 hours and the total volume was then reduced in vacuo to half. It was treated with 2M hydrochloric acid to caused a solid precipitate which was filtered, washed with water three times and then dried in vacuo to give the title compound (3.6g, 80%).
!Η NMR (DMSO-dg) δ: 4J9 (2H, s), 7.22 (IH, dd, j - 10, 3Hz), 1 1.05 (IH, br s), 13.41 (IH, br s).
Description 55
7,8-Difluoro-6-hydroxymethyl-4H-benzo[l,4]oxazin-3-one (D55)
Triethylamine (2.4mL, 17.3mmol) was added to a suspension of 7,8-difluoro-4H- benzo[l ,4]oxazine-3-one-6-carboxylic acid (3.6g, lSJmmol) in anhydrous TΗF
(250mL). Isobutyl chloroformate (2.2mL, 17.3mmol) was added to the mixture at ice cold temperature over 0.5 hour. Stirring was continued for further 2 hours at room temperature. It was then cooled in ice and the solid was removed by filtration. The filtrate was added to a cold solution of sodium borohydride (3.2g) in water. The mixture was stirred in cold for 1 hour before it was concentrated in vacuo to half and acidified with 2M hydrochloric acid. The resulting solid precipitate was collected by filtration and dried to give the title compound (1.15g, 22%).
! H NMR (DMSO-dg) δ: 4.47 (IH, d, J = 8 Hz), 4.68 (2H, s), 5.38 (I H, t, J = 9 Hz), 6.79 (IH, dd, J = 10, 3Hz), 10.92 (IH, br s).
Description 56 7,8-Difluoro-6-formyl-3-oxo-3,4-dihydro-4H-benzo[l,4]oxazin-3-one (D56)
Manganese dioxide (2.3g, 26.3mmol) was added to a mixture of 7,8-difmoro-6- hydroxymethyl-4H-benzo[ 1,4] oxazin-3 -one (1.13g, 5.25mmol), dichloromethane (70mL) and TΗF (50mL). The mixture was stirred for 6 hours and then filtered through celite. The filtrate was evaporated in vacuo to give the title compound (1.02g, 80%) as a pale yellow solid.
*Η NMR (DMSO-dg) δ: 4.84 (2H, s), 7.10 (IH, dd, J = 10, 3Hz), 10.07 (IH, s), 11.14 (IH, br s).
Description 57 Diethyl 3-fluoro-4-methoxybenzyl phosphonate (D57)
A mixture of 3 -fluoro-4-mefhoxy benzyl chloride [Cervena, Irena; Holubek, Jiri; Svatek,
Emil; Valchar, Martin; Protiva, Miroslav; Collect.Czech.Chem.Commun.; 52; 10;
1987; 2564-2571.] (6g, 35mmol) and triethylphosphite (23g, 140mmol) was stirred under reflux for 16 hours. Removal of the excess triethylphosphite in vacuo gave the title compound (1 1.2g, 100%) as an amber oil.
Mass spectrum (API4"): Found 277 (MH+). C 1 H18FO4P requires 276.
* H NMR (CDCI3) δ: 1.26 (6H, m), 3.06 (2H, d, J = 21 Hz), 3.87 (3H, s), 3.90-4.10
(4H, m). 6.90 (I H, t, J = 8 Hz), 6.95-7.05 (2H, m). Description 58
4-(3-Fluoro-4-methoxy-benzylidene)-piperidine-l-carboxylic acid tert-butyl ester
(D58)
A IM solution of potassium tert-butoxide in THF (24mL, 24mmol) was added dropwise to a stirring solution of diethyl 3-fluoro-4-methoxybenzyl phosphonate (6g, 22mmol) in anhydrous THF (lOmL) at room temperature. Upon completion of the addition, stirring was continued for 45 mins. 4-oxo- piperidine-1-carboxylic acid tert-butyl ester (4.8g, 24.2mmol) in anhydrous THF (lOmL) was added. The mixture was left to stir for 16 hours before it was quenched with saturated ammonium chloride (250mL). Extraction with diethyl ether (200mL) twice and evaporation of the combined organic layer gave a crude oil. Silica gel chromatography eluting with ethyl acetate in hexane (5- 15%)) gave the title compound (4Jg, 66%) as a colourless oil. iH NMR (CDC13) δ: 1.48 (9H, s), 2.31 (2H, m), 2.44 (2H, m), 3.40 (2H, m), 3.50 (2H, m), 3.88 (3H, s), 6.25 (IH, s), 6.80-7.00 (3H, m).
Description 59
4-(3-Fluoro-4-methoxy-benzyl)-piperidine-l-carboxyIic acid tert-butyl ester (D59)
A solution of 4-(3-fluoro-4-methoxy-benzylidene)-piperidine-l-carboxylic acid ter/-butyl ester (4Jg, 14.6mmol) in methanol (400mL) was allowed to stir under atmospheric pressure of hydrogen at room temperature in the presence of 10%) palladium on carbon (0.8g) for 16 hours. Removal of the catalyst by filtration and evaporation of the filtrate gave a crude oil. Silica gel chromatography eluting with ethyl acetate in hexane (10%) gave the title compound (4.3g, 99%) as a colourless oil.
1 H NMR (CDCI3) δ: 1.05- 1.20 (2H, m), 1.45 (9H, s), 1.55- 1.65 (3H, m), 2.46 (2H, d, J = 6 Hz), 2.60-2.70 (2H, m), 3.86 (3H, s), 4.00-4.15 (2H, m), 6.75-6.90 (3H, m).
Description 60 2-Fluoro-4-piperidin-4-ylmethyl-phenol, hydrogen sulfate salt (D60)
A solution of 4-(3-fluoro-4-methoxy-benzyl)-piperidine-l-carboxylic acid tert- butyl ester (0.26g, 0.81mmol) in methanol (lmL) and diethyl ether (5mL) was allowed to stir under reflux in the presence' of concentrated sulfuric acid (0.088g) for 1.5 hours. The solvents were removed in vacuo to give a colourless oil which was treated with glacial acetic acid (lOmL) and 48% w/w hydrobromic acid (lOmL). The mixture was heated under reflux for 4 hours before it was evaporated to dryness in vacuo to give an amber solid (0.24g, 100%). Mass spectrum (API4"): Found 210 (MH+). Cι2H]gFNO requires 209.
IH NMR (CD3OD) δ: 1.30-1.45 (2H, m), 1.75-1.95 (3H, m), 2.52 (2H, d, J = 7Hz), 2.80-3.00 (2H, m), 3.30-3.40 (2H, m), 6.975-8.00 (3H, m).
Description 61 4-(3-Fluoro-4-hydroxy-5-nitro-benzyl)-piperidine-l-carboxyIic acid tert- butyl ester (D61)
A solution of 70%) w/w nitric acid (0.08g, 0.81mmol) in glacial acetic acid (0.5mL) was added dropwise to a stirred solution of 2-fluoro-4-piperidin-4- ylmethyl-phenol hydrogen sulfate (0.24g, 0.81mmol) and acetic anhydride (0.099g, 0.097mmol) at room temperature. The mixture was left to stir for 16 hours before it was evaporated in vacuo. The residue was dissolved in water (15mL) and basified with sodium bicarbonate before being treated with triethylamine (2mL) and di-tert-butyl dicarbonate (0.21 g, 0.97 mmol) in THF (lOmL). After 16 hours of stirring, the mixture was partitioned between ethyl acetate (80mL) and water (60mL). The aqueous layer was extracted with more ethyl acetate (80mL). The combined organic layer was dried (Na2Sθ4) and evaporated in vacuo. Chromatography of the residue on silica eluting with ethyl acetate in hexane (10%>-50%>) gave the title compound (60mg, 21%) as a yellow solid. Mass spectrum (API"): Found 353 ([M-H]"). C17H23FN9O5 requires 354. iH NMR (CDCI3) δ: 1.10-1.25 (2H, m), 1.45 (9H, s), 1.55-1.65 (3H, m), 2.53 (2H, d, J = 7 Hz), 2.55-2.65 (2H, m), 4.00-4.20 (2H, m), 7.23 (IH, dd, J = 10, 2 Hz), 7.68 (IH, m).
Description 62
4-(3-Fluoro-4-methoxycarbonylmethoxy-5-nitro-benzyl)-piperidine-l-carboxylic acid tert-butyl ester (D62)
The title compound was prepared in a similar manner to Description 10. ΪH NMR fCDCls) δ: 1.10-1.25 (2H, m), 1.45 (9H, s), 1.55-1.75 (3H, m), 2.55 (2H, d. J = 7 Hz), 2.60-2.75 (2H, m), 3.79 (3H, s), 4.05-4.20 (2H, m), 4.79 (2H, s), 7.12 (IH, dd, J = 10, 2 Hz), 7.40 (lH, m).
Description 63
6-(4-(N-(t-Butyloxycarbonyl)piperidinyI)methyI)-8-fluoro-4H-benzo[l,4]oxazin-3- one (D63)
The title compound was prepared in a similar manner to Description 5. lΗ NMR (CDCl3) δ: 1.05-1.20 (2Η, m), 1.45 (9H, s), 1.50-1.70 (3H, m), 2.44 (2H, d, J
= 7 Hz), 2.55-2.70 (2H, m), 4.00-4.15 (2H, m), 4.66 (2H, s), 6.36 (IH, s), 6.60 (IH, dd,
J = 10, 2 Hz), 8.1 1 (lH, s).
Description 64
6-(4-(PiperidinylmethyI)-8-fluoro-4H-benzo[l,4]oxazin-3-one hydrochloride (D64)
The title compound was prepared in a similar manner to Description 6.
! Η NMR (DMSO-dg) δ: 1.20-1.40 (2H, m), 1.60-1.80 (3H, m), 2.40-2.46 (2H, m), 2.70-2.90 (2H, m), 3.15-3.30 (2H, m), 4.62 ((2H, s), 6.51 (IH, s), 6.74 (I H, dd, J = 1 1 ,
2 Hz), 8.30-8.80 (2H, br. m), 10.87 (I H, s).
Description 65 6-(4-(N-(t-BuryloxycarbonyI)piperidinyl)methyl)-8-fluoro-4-methyI-4H- benzo[l,4]oxazin-3-one (D65)
The title compound was prepared in a similar manner to Description 7. *H NMR (CDCI3) δ: 1.05-1.20 (2H, m), 1.45 (9H, s), 1.60-1.70 (3H, m), 2.49 (2H, d, J = 8 Hz), 2.60-2.75 (2H, m), 3.35 (3H, s), 4.00-4.15 (2H, m), 4.66 (2H, s), 6.51 (IH, s), 6.64 (lH, dd, J = 10, 2 Hz).
Description 66
8-Fluoro-4-methyl-6-(4-(piperidinylmethyl)-4H-benzo[l,4]oxazin-3-one hydrochloride (D66)
The title compound was prepared in a similar manner to Description 6.
*Η NMR (DMSO-dg) δ: 1.20-1.40 (2H, m), 1.60-1.75 (2H, m), 1.78-1.90 (IH, m),
2.75-2.90 (2H, m), 3.20-3.27 (2H, m), 3.30 (3H, s), 4.70 (2H, s), 6.80-6.90 (2H, m),
8.35 (IH, br. s), 8.65 (IH, br. s).
Description 67
Diethyl 2-fluoro-4-methoxybenzyl phosphonate (D67)
The title compound was prepared in a similar manner to Description 57.
Mass spectrum (API4"): Found-277 (MH+). C1 H18FO4P requires 276. !H NMR (CDCI3) δ: 1.27 (6H, t, J = 5 Hz), 3.06 (2H, d, J = 21 Hz), 3.78 (3H, s), 4.00
(4H, m), 6.60-6.75 (2H, m), 7.20-7.30 (IH, m).
Description 68
4-(2-FIuoro-4-methoxy-benzylidene)-piperidine-l-carboxylic acid tert-butyl ester (D68)
The title compound was prepared in a similar manner to Description 58. l H NMR (CDCI3) δ: 1.47 (9H, s), 2.25-2.40 (4H, m), 3.35-3.45 (2H, m), 3.45-3.55
(2H, m), 3.79 (3H, s), 6.20 (I H, s), 6.55-6.70 (2H, m), 7.07 (IH, t, J = 9 Hz). Description 69
4-(2-Fluoro-4-methoxy-benzyI)-piperidine-l-carboxyIic acid tert-butyl ester (D69) The title compound was prepared in a similar manner to Description 59. ΪH NMR (CDCI3) δ: 1.05-1.20 (2H, m), 1.45 (9H, s), 1.55-1 JO (3H, m), 2.50 (2H, d, j = 6 Hz), 2.55-2.70 (2H, m), 3.78 (3H, s), 4.00-4.15 (2H, m), 6.55-6.65 (2H, m), 7.00 (lH, t, J = 9 Hz).
Description 70
3-Fluoro-4-piperidin-4-ylmethyl-phenoI, hydrogen sulfate salt (D70) The title compound was prepared in a similar manner to Description 60.
Mass spectrum (API4"): Found 210 (MH+). Cι HιgFNO requires 209.
]H NMR (DMSO-dg) δ: 1.20-1.40 (2H, m), 1.65-1.80 (3H, m), 2.44 (2H, d, j = 6 Hz),
2.75-2.85 (2H, m), 3.15-3.30 (2H, m), 6.45-6.60 (2H, m), 7.03 (IH, t, J = 8 Hz), 8.10
(IH, br s), 8.42 (IH, br s), 9.67 (IH, br s).
Description 71
4-(2-FIuoro-4-hydroxy-5-nitro-benzyl)-piperidine-l-carboxylic acid tert- butyl ester (D71)
The title compound was prepared in a similar manner to Description 61. Mass spectrum (API"): Found 353 ([M-H]"). Cι7H23FN2O5 requires 354.
Ϊ H NMR^CDC^) δ: 1.10-1.25 (2H, m), 1.45 (9H, s), 1.55-1.75 (3H, m), 2.55 (2H, d, J
= 7 Hz), 2.60-2J5 (2H, m), 4.00-4.20 (2H, m), 6.82 (IH, d, J = 10 Hz), 7.94 (IH, d, J =
8 Hz).
Description 72
4-(2-Fluoro-4-methoxycarbonylmethoxy-5-nitro-benzyl)-piperidine-l-carboxylic acid tert-butyl ester (D72)
The title compound was prepared in a similar manner to Description 10. i H NMR (CDCI3) δ: 1.10-1.25 (2H, m), 1.45 (9H, s), 1.55-1.75 (3H, m), 2.56 (2H, d, J = 7 Hz), 2.60-2.70 (2H, m), 3.83 (3H, s), 4.05-4.20 (2H, m), 4.76 (2H, s), 6.67 (IH, d, J = 10 Hz), 7.79 (lH, d, J = 7 Hz).
Description 73
6-(4-(N-(t-Butyloxycarbonyl)piperidinyl)methyl)-7-fluoro-4H-benzo[l,4]oxazin-3- one (D73)
The title compound was prepared in a similar manner to Description 5. iΗ NMR
Figure imgf000056_0001
δ: 1.05-1.20 (2Η, m), 1.45 (9H, s), 1.55-1.75 (3H, m), 2.49 (2H, d, J = 7 Hz), 2.60-2.70 (2H, m), 4.00-4.10 (2H, m), 4.60 (2H, s), 6.58 (IH, d, J = 8 Hz), 6.90 (IH, d, J = 10, 2 Hz), 8.85 (IH, s).
Description 74
6-(4-(Piperidinylmethyl)-7-fluoro-4H-benzo[l,4]oxazin-3-one hydrochloride (D74) The title compound was prepared in a similar manner to Description 6. Mass spectrum (API4"): Found 265 (MH+). Cj4HπFN202 requires 264.
Example 1 6-(4-(l-(2-(4-lH-IndolyIoxy)ethyl)piperidinyl)oxy)-4H-benzo[l,4]oxazin-3-one (El)
A mixture of 6-(4-piperidinyloxy)-4H-benzo[l,4]oxazin-3-one hydrochloride (0.10 g, 0.35 mmol), 4-lH-indolyloxyacetaldehyde [Η. Sasai et al., Tetrahedron 1994, 43, 12313] (0.062 g, 0.35 mmol) and sodium triacetoxyborohydride (0.1 1 g, 0.53 mmol) in 1,2-dichloroethane (10 mL) was stirred at 20 °C for 18 h. The mixture was then partitioned between saturated NaΗC03 aq (20 mL) and dichloromethane (3 x 15 mL). Combined organic extracts were dried (Na S04) and evaporated in vacuo. Chromatography of the residue on Si02 eluting with 0-20% methanol in ethyl acetate gave the title compound (0.090 g, 63%) as an oil. Mass spectrum (API4"): Found 408 (MH+). C93H95N3O4 requires 407. ! H NMR (CDCI3) δ: 1.84 (2H, m), 2.01 (2H, m), 2.54 (2H, m), 2.85 - 3.00 (4H, m), 4.21 (IH, m), 4.29 (2H, d, J = 6 Hz), 4.56 (2H, s), 6.37 (IH, d, J - 3 Hz), 6.52 (2H, m), 6.64 (IH, m), 6.87 (IH, d, J = 9 Hz), 7.00 - 7.13 (3H, m), 8.15 (IH, br s), 8.21 (IH, br s).
Example 2
6-(4-(l-(2-(4-(2-Cyano)-lH-indoIylόxy)ethyl)piperidinyI)oxy)-4H- benzo[l,4]oxazin-3-one (E2)
The title compound was prepared in a similar manner to Example 1. Mass spectrum (API4"): Found 433 (MΗ+). C 4H 4N4U4 requires 432. lH NMR (CDCI3) δ: 1.84 (2H, m), 2.01 (2H, m), 2.53 (2H, m), 2.93 (4H, m), 4.26 (3H, m), 4.55 (2H, s), 6.38 (IH, d, J - 2 Hz), 6.53 (2H, m), 6.88 (IH, d, J - 9 Hz), 6.98 (IH, d, J = 8 Hz), 7.23 (2H, m), 8.07 (IH, br s), 8.97 (IH, br s).
Example 3
6-(4-(l-(3-(2-(5-IsoxazolyI)phenoxy)propyl)piperidinyl)oxy)-4H-benzo[l,4]oxazin- 3-one (E3)
A mixture of 6-(4-(piperidinyl)oxy)-4H-benzo[ 1,4] oxazin-3 -one hydrochloride (100 mg, 0.35 mmol), 3-(2-(5-isoxazolyl)phenoxy)propyl bromide (99 mg, 0.39 mmol), diisopropylethylamine (149 mg, 1.155 mmol) in isopropyl alcohol (8 mL) was heated at reflux with stirring in a reaction block for 48 h. The reaction mixture was cooled, and the isopropyl alcohol evaporated in vacuo. The residue was partitioned between dichloromethane (5 mL), and water (5 mL). The organic layer was added onto a 10 g pre-packed silica column and eluted with 0-10% methanol in ethyl acetate. Fractions containing desired material were combined and evaporated in vacuo to give the title compound (50 mg, 32%) as a colourless oil.
Mass spectrum (API4"): Found 450 (MΗ+). C 5H9.7N3O5 requires 449. lH NMR (CDCI3) δ: 1.82 (2H, m), 1.95 (2H, m), 2.10 (2H, m), 2.31 (2H, m), 2.57 (2H, m), 2.75 (2H, m), 4.19 (3H, m), 4.56 (2H, s), 6.39 (IH, d, J = 2 Hz), 6.52 (I H, dd, J = 9, 2 Hz), 6.80 (IH, d, J = 2 Hz), 6.88 (IH, d, J = 9 Hz), 7.05 (2H, m) 7.37 (IH, m), 7.99 (IH, dd, J = 8, 2 Hz), 8.03 (IH, br s), 8.30 (IH, d, J = 2 Hz).
Example 4 6-(4-(l-(2-(5-Quinolinyloxy)ethyl)piperidinyl)methyl)-4H-benzo[l,4]oxazin-3-one
(E4)
A mixture of 6-(4-piperidinylmethyl)-4H-benzo[ 1,4] oxazin-3 -one hydrochloride (0.1 1 g, 0.4 mmol), 2-(5-quinolinyloxy)ethyl bromide (0.1 g, 0.4 mmol) and diisopropylethylamine (0.16 g, 1.2 mmol) in isopropanol (5 mL) was heated under reflux for 48 hours. The isopropanol was evaporated in vacuo. Chromatography of the residue on silica gel eluting with methanol in ethyl acetate (0%> - 5%) followed by 0.880 ammonia/methanol/ethyl acetate (5/5/90) gave the title compound (0.03 g, 18%). Mass spectrum (API4"): Found 418 (MΗ+). C 5H2yN3θ3 requires 417. i H NMR (CDC1 ) δ: 1.31 - 1.38 (2H, m), 1.49 (IH, m), 1.64 (2H, m), 2.14 (2H, m), 2.46 (2H, d, J = 7 Hz), 2.94 (2H, t, J = 5 Hz), 3.05 (2H, m), 4.29 (2H, t, J = 5 Hz), 4.58 (2H, s), 6.55 (IH, s), 6.74 (IH, d, J = 8 Hz), 6.87 (2H, m), 7.37 (IH, dd, J = 8, 4 Hz), 7.60 (IH, t, J = 8 Hz), 7.69 (IH, d, J = 8 Hz), 8.04 (IH, s), 8.55 (IH, d, J = 8 Hz), 8.90 (lH, m).
Example 5
6-(4-(l-(3-(2-Cyanophenoxy)propyl)piperidinyl)oxy)-4H-benzo[l,4]oxazin-3-one
(E5)
The title compound was prepared in a similar manner to Example 3. Mass spectrum (API4"): Found 408 (MΗ+). C93H95N3O4 requires 407.
1 H NMR (CDCI3) δ: 1.78 (2H, m), 1.99 (4H, m), 2.27 (2H, m), 2.56 (2H, t, J = 7 Hz), 2.77 (2H, m), 4.17 (3H, m), 4.56 (2H, s), 6.40 (1 H, d, J = 3 Hz), 6.52 (1 H, dd, J = 9 Hz,
3 Hz), 6.87 (I H, d, J = 9 Hz), 6.99 (2H, m), 7.52 (2H, m), 8.15 (IH, br s).
Example 6 6-(4-(l-(3-(7-(2,2-Dimethyl-2,3-dihydro)benzo[b]furanyloxy)propyl)piperidinyl)- oxy)-4H-benzo [ 1 ,4] oxazin-3-one (E6)
The title compound was prepared in a similar manner to Example 3. Mass spectrum (API4"): Found 453 (MΗ+). C H32N2O5 requires 452. iH NMR (CDCI3) δ: 1.49 (6H, s), 1.80 (2H, m), 1.88 - 2.07 (4H, m), 2.29 (2H, m),
2.54 (2H, t, J = 6 Hz), 2.75 (2H, m), 3.01 (2H, s), 4.12 (2H, t, J = 6 Hz), 4.18 (IH, m),
4.55 (2H, s), 6.43 (IH, d, J = 3 Hz), 6.52 (IH, dd, J - 9, 3 Hz), 6.75 (3H, m), 6.85 (IH, d, J = 9 Hz), 9.00 (lH, br s).
Example 7
6-(4-(l-(2-(7-(2,2-Dimethyl-2,3- dihydro)benzo[b]furanyloxy)ethyl)piperidinyl)oxy)-4-methyl-4H- benzo[l,4]oxazin-3-one (E7)
The title compound was prepared in a similar manner to Example 3. Mass spectrum (API4"): Found 453 (MH+). C2gH3 N2θ5 requires 452.
* H NMR (CDCI3) δ: 1.49 (6H, s), 1.82 (2H, m), 1.98 (2H, m), 2.43 (2H, m), 2.84 (4H, m), 3.01 (2H, s), 3.33 (3H, s), 4.22 (3H, m), 4.55 (2H, s), 6.53 (2H, m), 6.76 (3H, m),
6.88 (lH, d, J = 9 Hz).
Example 8
6-(4-(l-(2-(l-naphthyloxy)ethyl)piperidinyl)oxy)-4-methyl-4H-benzo[l,4]oxazin-3- one (E8)
The title compound was prepared in a similar manner to Example 3.
Mass spectrum (API4"): Found 433 (MH+). C2gH2δN θ4 requires 432. i H NMR CDC^) δ: 1.84 (2H, m), 2.01 (2H, m), 2.51 (2H, m), 2.97 (4H, m), 3.31 (3H, s), 4.27 (3H, m), 4.55 (2H, s), 6.53 (2H, m),6.84 (2H, m), 7.43 (4H, m), 7.79 (IH, m),
8.24 (l H, m).
Example 9 (+)-6-(3-(l-(3-(2-Cyanophenoxy)propyl)piperidinyl)methoxy)-4H- benzo[l,4]oxazin-3-one (E9)
The title compound was prepared in a similar manner to Example 3. Mass spectrum (API4"): Found 422 (MΗ+). C24H 7N3θ4 requires 421. lH NMR (CDCl3) δ: 1.16 (lH, m), 1.53 - 1.83 (4H, m), 1.97 (lH, m), 1.99 - 2.12 (3H, m), 2.55 (2H, t, J = 6 Hz), 2.80 (IH, m), 2.97 (IH, m), 3.79 (2H, m), 4.12 (2H, t, J = 6 Hz), 4.54 (2H, s), 6.39 (IH, d, J = 3 Hz), 6.49 (IH, dd, J = 9, 3 Hz), 6.86 (IH, d, J = 9 Hz), 6.92 - 7.02 (2H, m), 7.44 - 7.58 (2H, m), 8.12 (IH, br s).
Example 10
(+)-6-(3-(l-(3-(2-Cyanophenoxy)propyl)pyrrolidinyl)methoxy)-4H- benzo[l,4]oxazin-3-one (E10)
The title compound was prepared using a similar method to Example 3.
Mass spectrum (API4"): Found 408 (MΗ+). C23H 5N3θ4 requires 407. iH NMR (CDC1 ) δ: 1.61 (2H, m), 2.06 (2H, m), 2.49 (IH, m), 2.56 - 2.81 (6H, m),
3.83 (2H, d, J = 7 Hz), 4.14 (2H, t, J = 6 Hz), 4.56 (2H, s), 6.37 (IH, d, J = 3 Hz), 6.50
(IH, dd, J = 9, 3 Hz), 6.88 (IH, d, J = 9 Hz), 6.97 (2H, m), 7.46 - 7.58 (2H, m), 7.89
(lH, br s).
Example 11
6-(4-(l-(3-(2-(5-Isoxazolyl)phenoxy)propyl)piperazinyl)methyl)-4H- benzo[l,4]oxazin-3-one (Ell)
A mixture of 6-(4-piperazinylmethyl)-4H-benzo[l,4]oxazin-3-one dihydrochloride (550 mg, 1.72 mmol), 3-(2-(5-isoxazolyl)phenoxy)propyl bromide (485 mg, 1.72 mmol), diesopropylethylamine (1.2 mL, 6.9 mmol,) in isopropyl alcohol (30 mL) was heated at reflux with stirring in a reaction block for 48 h. The reaction mixture was cooled, and the isopropyl alcohol evaporated in vacuo. The residue was partitioned between dichloromethane (25 mL) and water (25 mL). The organic layer was added onto silica gel (30 g) and eluted with 0-10% methanol in ethyl acetate. Fractions containing desired material were combined and evaporated in vacuo to give the title compound as a yellow oil (2.80 mg, 36%).
Mass spectrum (API4"): Found 449 (MH+). C25H28N4O4 requires 448. ] H NMR (CDCI3) δ: 2.1 1 (2H. m), 2.52 ( 10H. m), 3.43 (2H. s), 4.14 (2H, m), 4.61 (2H, s), 6J9 (2H, m), 6.91 (2H, s), 7.03 (2H. m). 7.38 ( I H. m), 7.99 (I H, dd. j = 8, 2 Hz), 8.07 (1 H, br s , 8.29 (1 H, d, j = 2 Hz).
The examples of Tables 1 - 6 were prepared in a similar manner to Example 1 or Example 3.
Table 1
Figure imgf000061_0001
Figure imgf000061_0002
Figure imgf000062_0001
C24H2gN2θ5 requires 422.
E34 H Found 467 (Mir).
C27H34N2O5 requires 466.
Figure imgf000063_0001
E35 7-(2-mcthyl)benzo[b]furanyl H Found 437 (MH+).
C25H2 N2O5 requires 436.
E36 Me Found 481 (MIT).
C2gH3gN2θ5 requires 480.
Figure imgf000063_0002
E37 7-(2-methyl)benzo[b]furanyl Me Found 451 (MH ). 26H30N2O5 requires 450.
E38 7-(2-methyl)benzo[b]ftιranyl Me Found 437 (MH+).
C95H98N2O5 requires 436.
E39 H Found 453 (MH+).
C2 H32N2θ5 requires 452.
E4ϋ Me Found 467 (MIT
C27H34N2O5 requires 466.
Figure imgf000063_0003
E41 5-quinolinyl Me Found 434 (MH+).
C25H97N3O4 requires 433.
E42 Me Found 471 (MHH
C2gH31FN2O5 requires 470.
E43 H Found 457 (MET).
C25H29FN2O5 requires 456.
Figure imgf000063_0004
E138 4-benzofuranvl H Found 409 (MHT).
C23H 4N2O5 requires 408.
E139 Me
4-benzofuranvl Found 423 (MHT).
C24H2gN2U5 requires 422.
Figure imgf000064_0002
Table 2
Figure imgf000064_0001
Figure imgf000064_0003
Figure imgf000065_0002
Table 3
Figure imgf000065_0001
Figure imgf000065_0003
Table 4
Figure imgf000066_0001
Figure imgf000066_0002
Figure imgf000067_0002
Table 5
Figure imgf000067_0001
Figure imgf000067_0003
Figure imgf000068_0002
Table 6
Figure imgf000068_0001
Figure imgf000068_0003
Figure imgf000069_0001
Example 108
6-(4-(l-(2-(5-(2-MethyI)quinoliπyloxy)ethyl)piperidinyI)methyI)-4H- benzoj l,4]oxazin-3-one (E 108)
Figure imgf000070_0001
A mixture of 6-(4-piperidinylmethyl)-4H-benzo[l,4]oxazin-3-one hydrochloride (0.10 g, 0.35 mmol). 2-(5-(2-methyl)quinolinyloxy)ethyl bromide (0.1 1 g, 0.42 mmol). diisopropylethylamine (1 mL) and isopropanol (10 mL) was heated at reflux under argon for 48 h, cooled, then evaporated in vacua. The residue was partitioned between saturated aqueous NaΗCθ3 (50 mL) and dichloromethane (3 x 30 mL) and the combined organic extracts were dried (Na2Sθ4) and evaporated in vacuo. The resulting oil was purified by chromatography on silica eluting with 50% ethyl acetate - hexane followed by 0 - 25% methanol - ethyl acetate gradient elution, to give the title compound (0.04 g, 26%) as an oil.
Mass spectrum (API4"): Found 432 (MH+). C2gH29N3U3 requires 431. iH NMR (CDC13) δ: 1.25 - 1.38 (2H, m), 1.49 (IH, m), 1.65 (2H, m), 2.14 (2H, m), 2.45 (2H, d, J = 7 Hz), 2.72 (3H, s), 2.94 (2H, t, J = 6 Hz), 3.05 (2H, m), 4.27 (2H, t, J = 6 Hz), 4.58 (2H, s), 6.56 (IH, d, J = 2 Hz), 6.73 (IH, dd, J = 7, 2 Hz), 6.78 (IH, d, J = 8 Hz), 7.86 (IH, d. J = 7 Hz), 7.23 (I H, d, J = 8 Hz), 7.50 - 7.64 (2H, m), 8.42 (IH, d, J = 8 Hz), 8.75 ( lH. br s).
Example 108a
6-(4-(l-(2-(5-(2-Methyl)quinolinyloxy)ethyl)piperidinyI)methyl)-4H- benzo[l,4]oxazin-3-one dihydrochloride(E108a) A mixture of 6-(4-piperidinylmethyl)-4H-benzo[l ,4]oxazin-3-one hydrochloride (9.0 g, 29.5 mmol), 2-(5-(2-methyl)quinolinyloxy)ethyl bromide (9.29 g, 34.9 mmol), diisopropylethylamine (93 mL) and isopropanol (250 mL) was heated at reflux under argon for 48 h. cooled, then evaporated in vacuo. The residue was partitioned between 5 5% aqueous NaOΗ (300 mL) and dichloromethane (3 x 150 mL) and the combined organic extracts were dried Na2Sθ4_) and evaporated in vacuo. The resulting oil was purified by chromatography on silica with 0 - 20% methanol/ethyl acetate gradient elution, to give the free base of the title compound (10.8 g. 85%) as a colourless solid. This material was dissolved in 2-propanol at reflux, then 35% hydrochloric acid (5.36 0 mL) was added dropwise over 0.1 h. The mixture was stirred for 3 h and simultaneously allowed to cool to 20 °C, whereupon the resulting solid was collected by filtration and dried in vacuo at 80 - 90 °C to give the title compound (1 1.71 g. 95%) as a pale yellow solid. ΗPLC purity 98.6% 5 Mass spectrum (API4"): Found 432 (MΗ+). C2 H29N3θ3 requires 431.
Example 109
6-(4-(l-(2-(5-(3-Methyl)quinolinyloxy)ethyl)piρeridinyl)methyl)-4H- benzo[l,4]oxazin-3-one (E109) 0 The title compound was prepared in a similar manner to Example 3. Mass spectrum (API4"): Found 432 (MΗ+). C2gH29N3θ3 requires 431. 1 H NMR (CDCl3) δ: 1.34 (2H. m), 1.52 (lH, m), 1.65 (2H, m), 2.15 (2H, m), 2.47 (2H, d. J = 7 Hz), 2.61 (3H, s). 2.94 (2H, t. J = 6 Hz). 3.05 (2H, m), 4.26 (2H, t, J = 6 Hz), 4.56 (2H. s), 6.56 (IH, d, J = 1 Hz), 6.75 (IH, dd, J = 8, 1 Hz), 6.83 (IH, d, J = 8 Hz), ς 6.85 (I H, d. J = 8 Hz), 7.50 ( IH, t, J = 8 Hz), 7.65 (IH, d, J = 8 Hz), 8.29 (IH, d, J = 2 Hz), 8.85 ( 1 H, d, J = 2 Hz), 8.99 (1 H, br s).
Example 1 10
6-(4-(l-(2-(5-Cinnolinyloxy)ethyl)piperidinyl)methyl)-4H-benzo[l,4]oxazin-3-one 0 (EUO) The title compound was prepared in a similar manner to Example 3. Mass spectrum (API4"): Found 419 (MH+). C 4H2gN θ3 requires 418. 1HNMR(CDCl3)δ: 1.31 (2H. m), 1.52 (lH,m), 1.67 (2H, m), 2.17 (2H, m).2.46 (2H, d, J = 7 Hz), 2.95 (2H, d, J = 6 Hz), 3.05 (2H, m), 4.31 (2H, t, J = 6 Hz), 4.58 (2H. s), 6.57 (IH. s).6.74 (IH. d. J = 8 Hz), 6.86 (IH, d, J = 8 Hz), 6.99 (IH, d, J = 8 Hz), 7.74 (IH, t, J = 8 Hz), 8.11 (IH. d, J = 8 Hz).8.17 (IH, d. J = 6 Hz), 8.42 (IH, br s), 9.29 (IH, d, J = 6Hz).
Example 111 6-(4-(l-(2-(4-(l,2-Dihydro)benzo[b]furanyloxy)ethyl)piperidinyl)methyl)-4H- benzo[l,4]oxazin-3-one (Elll)
The title compound was prepared in a similar manner to Example 3. Mass spectrum (API4"): Found 409 (MΗ+). C24H28N O4 requires 408. 1HNMR(CDCl3)δ: 1.33 (2H,m), 1.49 (lH,m), 1.65 (2H, m).2.09 (2H, m), 2.46 (2H. d, J = 7 Hz), 2.78 (2H. m), 3.00 (2H, m), 3.12 (2H, t, J = 9 Hz), 4.13 (2H, m), 4.56 (4H, m), 6.37 (IH, d, J = 8 Hz), 6.45 (IH, d, J = 8 Hz), 6.56 (IH, s), 6.74 (IH, d, J = 8 Hz), 6.87 (IH, d, J = 8 Hz), 7.03 (IH, t, J = 8 Hz), 8.14 (IH, br s).
Example 112 6-(4-(l-(2-(4-(lH)-IndazolyIoxy)ethyl)piperidinyl)methyl)-4H-benzo[l,4]oxazin-3- one (E112)
The title compound was prepared in a similar manner to Example 3.
Mass spectrum (API4"): Found 407 (MΗ+). C23H2gN4θ3 requires 406. lH NMR(CDC13) δ: 1.32 (2H, m), 1.48 (IH, m), 1.63 (2H, m), 2.13 (2H, m), 2.45 (2H, m), 2.93 (2H, m), 3.06 (2H, m), 4.29 (2H, m), 4.58 (2H, s), 6.47 (IH, d, J = 8 Hz), 6.55
(IH. d, J - 2 Hz), 6.73 (IH, dd, J = 8, 2 Hz), 6.87 (IH, d, J = 8 Hz), 7.06 (IH, d. J = 8
Hz), 7.27 (2H, m), 8.10 (IH. m), 8.49 (IH, m).
Example 113 6-(4-(l-(2-(5-(2-Methyl)quinolinyIoxy)ethyI)piperidinyl)oxy)-4H-benzo[l,4]oxazin- 3-one (EU3)
The title compound was prepared in a similar manner to Example 3. Mass spectrum (API4"): Found 434 (MΗ4"). C25Η97N3O4 requires 433. 1 H NMR (CDCI3) δ: 1.85 (2H, m), 1.99 (2H, ), 2.54 (2H, m), 2.74 (3H, s), 2.90 (2H, m), 2.96 (2H, m). 4.23 (IH, m), 4.30 (2H, m), 4.56 (2H, s), 6.37 (I H, d, J = 2 Hz), 6.52 (I H, dd, J = 9 Hz), 6.79 (I H, d, J = 8 Hz), 6.87 (IH, d, J = 9 Hz). 7.25 (IH, m), 7.56 (2H. m), 8.22 (I H, br s), 8.45 (I H. d, J = 8 Hz).
Example 114
4-Methyl-6-(4-(l-(2-(5-(2-methyl)quinolinyloxy)ethyl)piperidinyl)oxy)-4H- benzo[l,3]oxazin-3-one (E114)
The title compound was prepared in a similar manner to Example 3.
Mass spectrum (API4*): Found 448 (MΗ+). C2gH29N3U4 requires 447. l U NMR (CDCl3)δ: 1.86 (2H, m), 2.01 (2H, m). 2.55 (2H, m), 2.75 (3H, s), 2.93 (2H, m), 3.00 (2H, m), 3.33 (3H, s), 4.20 - 4.34 (3H, m), 4.56 (2H, s), 6.55 (2H, m), 6.82
(I H, d, J = 7 Hz), 6.89 (I H, d, J = 7 Hz), 7.26 (IH, d, J = 7 Hz), 7.59 (2H, m), 8.45 (IH, d, J = 8 Hz).
Example 115
6-(4-(l-(2-(5-(2-Methyl)quinolinyloxy)ethyl)piperazinyl)methyl)-4H- benzo[l,4]oxazin-3-one (El 15)
The title compound was prepared in a similar manner to Example 3.
Mass spectrum (API4"): Found 433 (MΗ+). C25H28N4O3 requires 432. [ H NMR (CDCI3) δ: 2.50 (4H, m), 2.69 (4H, m), 2.73 (3H, m), 2.97 (2H, ti J = 6 Hz),
3.54 (2H, s), 4.30 (2H, t, J = 6 Hz), 4.61 (2H, s), 6.79 (2H, m), 6.92 (2H, s), 7.24 (I H, d, J = 8 Hz), 7.59 (2H, m), 7.87 (I H, br s), 8.43 (I H, d, J = 8 Hz).
Example 116 6-(4-(l-(3-(5-(2-Methyl)quinoIinyIoxy)propyl)piperidinyl)methyl)-4H- benzo[l,4]oxazin-3-one (EU6)
The title compound was prepared in a similar manner to Example 3. Mass spectrum (API4"): Found 446 (MΗ+). C97H3 1N3O3 requires 445. ! H NMR (CDCI3) δ: 1.40 - 1.60 (3H, m), 1.69 (2H. m) 2.14 (2H, m), 2.22 (2H. m), 2.50 (2H, d, J - 6 Hz), 2.73 (5H, m), 3.14 (2H. m), 4.19 (2H, m). 4.6Q (2H. s), 6.59 ( I H, s), 6.75 (1 H, d, J = 8 Hz), 6.79 (IH, d. J = 8 Hz), 6.89 (I H, d, J = 8 Hz), 7.24 (I H, d. J = 8 Hz), 7.56 (2H. m). 8.39 (1 H, br s), 8.43 ( 1 H, d, J = 8 Hz).
Example 117
6-(4-(l-(3-(5-(2-Methyl)quinoIinyIoxy)propyl)piperazinyl)methyl)-4H- benzo[l,4]oxazin-3-one (E117)
The title compound was prepared in a similar manner to Example 3.
Mass spectrum (API4"): Found 447 (MΗ+). 2gH3fjN4θ3 requires 446. i H NMR (CDCI3) δ: 2.09 (2H. m), 2.50 (8H, m), 2.61 (2H, m). 2.73 (3H, s), 3.42 (2H, s). 4.18 (2H, m), 4 60 (2H, s), 6.80 (2H, m), 6.90 (2H, m), 7.24 ( IH, d, J = 9 Hz), 7.55
(2H, m), 8.32 (IH, br s), 8.44 (1 H, d, J = 9 Hz).
Example 118 6-(4-(l-(3-(5-(2-Methyl)quinolinyloxy)propyl)piperidinyl)oxy)-4H- benzo[l,4]oxazin-3-one (E118)
The title compound was prepared in a similar manner to Example 3.
Mass spectrum (API4"): Found 448 (MΗ+). C2gH29N3U4 requires 447.
1 H NMR (CDCl3) δ: 1.81 (2H, m), 1.97 (2H, m), 2.1 1 (2H, m), 2.34 (2H, m), 2.63 (2H, m), 2.73 (3H, s), 2.76 (2H, m). 4.20 (3H, m), 4.56 (2H, s). 6.41 ( IH. d. J = 3 Hz). 6.53
( I LL dd, J = 9, 3 Hz). 6.81 (IH, dd. J = 7, 2 Hz), 6.88 (I H. d, J - 9 Hz), 7.24 (I H, m),
7.56 (2H, m), 8.46 ( 1 H, d, J = 9 Hz). 8.55 (1 H, br s).
Example 119 4-Methyl-6-(4-(l-(3-(5-(2-methyl)quinolinyloxy)propyl)piperidinyl)oxy)-4H- benzo[l,4]oxazin-3-one (E119)
The title compound was prepared in a similar manner to Example 3. Mass spectrum (API4"): Found 462 (MΗ+). C27H31N3O4 requires 461. H-I NMR (CDC1 ) δ: 1.83 (2H. m), 1.99 (2H, m), 2.12 (2H, m), 2.35 (2H, m). 2.63 (2H, m). 2.73 (3H, s). 2.80 (2H. m), 3.33 (3H, s), 4.21 (2H, m), 4.25 ( I H. m). 4.56 (2H, s), 6.54 (JH, m), 6.81 (I H. dd. .1 = 7, 2 Hz), 6.88 ( I H, d. J = 9 Hz), 7.24 (IH, m), 7.55 (2H, m), 8.46 (I H, d, J = 9 Hz).
Example 120
4-Methyl-6-(4-(l-(2-(5-(2-methyl)quinoIinyloxy)ethyl)piperidinyl)methyl)-4H- benzo[l,4]oxazin-3-one (E120)
Figure imgf000075_0001
A solution of 2-(5-(2-methyl)quinolinyl)oxyethyl bromide (0.15 g, 0.62 mmol), 4- methyl-6-(4-piperidinylmethyl)-4H-benzo[l,4]oxazin-3-one hydrochloride (0.19 g, 0.62 mmol) and diisopropylethylamine (0.6 mL, 3.4 mmol) in isopropyl alcohol (8 mL) was stirred at 78 °C for 48 h. The mixture was concentrated in vacuo to approximately 1 mL and applied to silica gel column. Gradient elution with methanol (0-10%) in ethyl acetate gave the title compound (0.15 g, 52%) as a colourless oil.
Mass spectrum (API4"): Found 446 (MΗ+). C27H31N3O3 requires 445. ! H NMR (CDC13) δ: 1.40 (2H, m), 1.55 (I H, m), 1.70 (2H, m), 2.10 (2H, m), 2.62 (2H, d. J = 7 Hz), 2.74 (3H, s), 3.13 (4H, m), 3.34 (3H, s), 4.57 (2H, s), 4.70 (2H, m), 6.71 - 6.78 (2H. m), 6.86 (I H, d, J = 6.5 Liz), 6.91 (I H, d, J = 8 Hz), 7.26 (I H, d, J = 8 Hz), 7.58 ( 1 H, t, J = 8 Hz), 7.67 ( 1 H, d, J = 8 Hz), 8.33 ( 1 H, d. J = 8 Hz). Example 121
6-(4-(l-(2-(5-(8-Chloro-2-methyl)quinolinyloxy)ethyl)piperidinyl)methyl)-4H- benzo[l,4]oxazin-3-one (E121)
A solution of 2-(5-(8-chloro-2-methyl)quinolinyl)oxyethyl bromide (0.10 g, 0.33 mmol). 6-(4-piperidinylmethyl)-4H-benzo[l ,4]oxazin-3-one hydrochloride (0.093 g,
0.33 mmol) and diisopropylethylamine (0.25 mL, 1.43 mmol) in isopropyl alcohol (10 mL) was stirred at reflux for 48 h. The reaction mixture was cooled and evaporated in vacuo. The residue was partitioned between dichloromethane (5 mL) and water (5 mL), and the organic layer was added onto a pre-packed silica column (10 g) which was then eluted with 0 - 20% methanol in ethyl acetate. The fractions containing the title compound were combined and evaporated to dryness in vacuo to give the title compound (0.035 g, 23%) as an oil.
Mass spectrum (API4"): Found 466 (MΗ+). C2gH2835ClN3θ3 requires 465.
HT NMR tCDC^ δ: 132 (2H, m), 1.48 (I H, m), 1.66 (2H, m). 2.12 (2H. m). 2.46 (2H. m), 2.80 (3H, s). 2.92 (2H, m). 3.03 (2H. m), 4.25 (2H, m), 4.58 (2H, s), 6.55 (IH, d, J
= 2 Hz). 6.72 (2H, m). 6.87 (IH. d, J = 8 Hz), 7.30 (I H, d, J = 9 Hz), 7.65 (IH, d. J = 8
Hz), 8.35 (I H. br s), 8.43 (I H, d, J = 9 Hz).
Example 122 4-Methyl-6-(4-(l-(3-(5-(2-methyl)quinolinyloxy)propyl)piperidinyl)-methyl)-4H- benzo[l,4]oxazin-3-one (E122)
The title compound was prepared in a similar manner to Example 3. Mass spectrum (API4"): Found 460 (MΗ+). C .8H33N3O3 requires 459 1 H NMR (CDCI3) δ: 1.34 (2H, m), 1.52 (1 H, m), 1.63 (2H, m), 1.94 (2H, m), 2.09 (2H, m), 2.52 (2H, d, J = 13 Hz), 2.58 (2H, m), 2.73 (3H, s), 2.97 (2H, m), 3.36 (3H, s), 4.18 (2FI, m), 4.59 (2H, s), 6.70 - 8.86 (3H, m), 6.89 (I H, d, J - 8 Hz), 7.24 (IH, d, J = 8 Hz), 7.50 - 7.60 (2H, m), 8.43 (I H, d, J = 8 Hz).
Example 123 6-(4-(l-(2-(5-(8-Chloro-2-methyl)quinolinyloxy)ethyl)piperidinyl)methyl)-4- methyl-4H-benzo[l,41oxazin-3-one (E122)
The title compound was prepared in a similar manner to Example 3. Mass spectrum (API4"): Found 480 (MΗ+). C27H30 35ClN O3 requires 479. 1 H NMR (CDCl3) δ: 1.35 (2H, m), 1.51 (I H, m), 1.66 (2H, m), 2.13 (2H. m), 2.52 (2H, m). 2.80 (3H. s), 2.92 (2H, m). 3.03 (2H, m). 3.35 (3FI, s). 4.25 (2H. m), 4.59 (2H, s), 6J5 (3H, m), 6.89 (IH. d, j = 8 Hz), 7.31 (IH. d, J = 9 Hz). 7.66 (IH, d. J = 8 Hz). 8.44 ( l H, d, J = 9 Hz).
Example 124
6-(4-(l-(2-(5-(8-Fluoro-2-methyl)quinolinyloxy)ethyl)piperidinyl)methyl)-4H- benzo[l,4]oxazin-3-one (E124)
A mixture of 6-(4-piperidinylmethyl)-4H-benzo[l ,4]oxazin-3-one hydrochloride (1.2 g, 3.93 mmol). 2-(5-(8-fluoro-2-methyl)quinolinyloxy)ethyl bromide (1.32 g, 4.65 mmol), diisopropylethylamine (12.4 mL) and isopropanol (50 mL) was heated at reflux under argon for 36 h, cooled, then evaporated in vacuo. The residue was partitioned between water (100 mL) 50% aqueous sodium hydroxide (20 mL) and dichloromethane (3 x 50 mL). The combined organic extracts were dried (Na2Sθ4) and evaporated in vacuo to give a solid (2.2 g). Chromatography on silica with 0 - 20% methanol/ethyl acetate gradient elution gave the title compound (1.38 g, 68%) as a colourless solid. Mass spectrum (API4"): Found 450 (MΗ+). C2 H28FN3θ3 requires 449. J H NMR ^DC^) δ: 1.29 (2H, m), 1.50 (IH, m), 1.65 (2H, m), 2.15 (2H, m), 2.45 (2H, d, J = 6 FIz), 2.79 (3H, s), 2.92 (2H. m), 3.04 (2H, m), 4.24 (2H, m), 4.58 (2H, s), 6.55 (I H, s), 6.66 (I H, m), 6.75 (I H, d, J = 9 Hz), 6.87 (IH, d, j = 9 Hz), 7.21 - 7.34 (2H, m), 8.35 (I H, br s), 8.42 (IH, d, J = 8 Hz).
Example 125
6-(4-(l-(2-(5-(8-Fluoro-2-methyl)quinolinyloxy)ethyl)piperidinyl)methyl)-4- methyl-4H-benzo[l,4]oxazin-3-one (E125) The title compound was prepared in a similar manner to Example 3. Mass spectrum (API4-): Found 464 (MH4"). C27H30FN3O3 requires 463. i NMR (CDC13) δ: 1.35 (2H, m), 1.54 (IH, m), 1.67 (2H, m), 2.15 (2H. m). 2.53 (2H, d, J = 6 Hz), 2.79 (3H. s), 2.92 (2H. m), 3.05 (2H, m), 3.35 (3H, s), 4.24 (2H. m), 4.58 (2H. s). 6.67 ( I H, m), 6.73 (I H, s), 6.77 (IH, d. .1 = 8 Hz). 6.87 (I H, d. J = 8 Hz), 7.20 - 7.34 (2H, m). 8.42 (I H, d, J = 8 Hz).
Example 126
6-(4-(l-(2-(5-(8-Fluoro-2-methyl)quinolinyloxy)ethyl)piperidinyl)oxy)-4H- benzo[l,4]oxazin-3-one (E126) The title compound was prepared in a similar manner to Example 3.
Mass spectrum (API4"): Found 452 (MΗ+). C25H26 N3O4 requires 451. lH NMR (CDC13) δ: 1.81 (2H, m). 1.97 (2H. m), 2.52 (2H. m), 2.80 (3H, s), 2.89 (2H, m), 2.96 (2H, t, J = 6 Hz), 4.25 (3H, m), 4.56 (2H, s). 6.43 (I H, d, J = 2 Hz), 6.53 (IH, dd. J = 9, 2 Hz), 6.71 (IH, dd, J = 9, 3 Hz), 6.88 ( IH, d. J = 9 Hz), 7.22 - 7.35 (2H, m), 8.45 (I H, d, J = 9 Hz), 8.47 (IH, br s).
Example 127
6-(4-(l-(2-(5-(8-Fluoro-2-methyl)quinolinyloxy)ethyl)piperidinyl)oxy)-4-methyl-
4H-benzo[l,4]oxazin-3-one (E127) The title compound was prepared in a similar manner to Example 3.
Mass spectrum (API4"): Found 466 (MΗ+). C2gH2δFN3θ4 requires 465.
^ NMR (CDCI3) δ: 1.86 (2H, m), 2.02 (2H. m), 2.52 (2H, m), 2.79 (3H, s), 2.93 (2H, m), 2.96 (2H, t, J = 6 Hz), 3.35 (3H, s), 4.28 (3H, m), 4.56 (2H, s), 6.55 (2H, m), 6.70
(1 H, dd, J = 9, 2 Hz), 6.90 (1 H, d. J = 9 Hz), 7.22 - 7.36 (2H, m), 8.45 (IH, d, J = 8 Hz).
Example 128
6-(4-(l-(2-(5-(7-Chloro-2-methyl)quinolinyloxy)ethyl)piperidinyl)methyl)-4H- benzo[l,4]oxazin-3-one (E128)
Figure imgf000079_0001
A solution of 2-(5-(7-chloro-2-methyl)quinolinyl)oxyethyl bromide (0.64 g, 2.13 mmol), 6-(4-piperidinylmethyl)-4H-benzo[1.4]oxazin-3-one hydrochloride (0.60 g, 2.13 mmol) and diisopropylamine ( 1.50 mL. 8.62 mmol) in isopropyl alcohol (60 mL) was stirred at reflux for 48 h. The reaction mixture was cooled and evaporated in vacuo. The residue was partitioned between dichloromethane (30 mL) and water (30 mL). The organic layer was dried over anhydrous sodium sulfate and evaporated in vacuo to give a brown oil which was purified by chromatography on silica gel (30 g) eluting with 0 - 15% methanol in ethyl acetate to give the title compound (0.46 g, 47%o) as a brown solid.
Mass spectrum (API+): Found 466 (MΗ+). C2gH2835ClN θ3 requires 465. ^I NMR fCDCf ) δ: 1.33 (2H, m), 1.47 (IH, m), 1.63 (2H, m), 2.15 (2H, m), 2.46 (2H, d. J = 7 Hz), 2.68 (3H, s), 2.87 (2H, t, J = 6 Hz), 2.97 (2H, m), 4.24 (2H, t, J = 6 Hz), 4.55 (2H. s), 6.50 (IH, d, J = 2 Hz), 6.72 (IH, dd, J = 8, 2 Hz), 6.78 (IH, d, J = 2 Hz), 6.85 (IH, d, J = 8 Hz), 7.17 (IH, d, J = 9 Hz), 7.56 (2H, m), 8.32 (IH, d, J = 9 Hz).
Example 129
6-(4-(l-(2-(5-(7-ChIoro-2-methyl)quinolinyIoxy)ethyl)piperidinyl)methyl)-4- methyl-4H-benzo[l,4]oxazin-3-one (E129) The title compound was prepared in a similar manner to Example 3.
Mass spectrum (API4"): Found 480 (MΗ4"). C27Η3035C1N3U3 requires 479.
] H NMR (CDC1 ) δ: 1.35 (2H, m), 1.50 (I H, m), 1.67 (2H, m), 2.14 (2H. m), 2.52 (2H. m), 2.71 (3H, s), 2.92 (2H, m). 3.03 (2H, m), 3.35 (3H, s), 4.25 (2H, m). 4.59 (2 H, s),
6.76 (3H. m), 6.89 ( I H, d, J = 8 Hz), 7.22 (I H, d. J = 9 Hz). 7.60 (IH, d, J = 1 Hz), 8.35 ( 1 H, d, J = 9 Hz). Example 130
6-(4-(l-(2-(5-(7-Chloro-2-methyl)quinolinyloxy)ethyl)piperidinyf)oxy)-4H- benzo[l,4]oxazin-3-one (E130)
The title compound was prepared in a similar manner to Example 3. Mass spectrum (API4"): Found 468 (MΗ4"). C25Η2 35ClN3θ requires 467.
1 H NMR (CDCl3) δ: 1.81 (2H, m), 1.97 (2H, m), 2.51 (2H, m), 2.71 (3H, s), 2.88 (2H, m), 2.97 (2H. m), 4.23 (3H, m), 4.56 (2H, s), 6.40 (IH, d, J = 3 Hz), 6.53 (IH. dd, J = 9,
3 FIz), 6.78 (I H, d, J = 2 Hz), 6.88 (IH, d, J = 9 Hz), 7.24 (IH, d. J = 9 Hz), 7.60 (IH, m), 8.37 (IH. d. J = 9 Hz), 8.50 (I H, br s).
Example 131
6-(4-(l-(2-(5-(7-Chloro-2-methyl)quinolinyloxy)ethyl)piperidinyl)oxy)-4-methyl-
4H-benzo[l,4]oxazin-3-one (E131)
The title compound was prepared in a similar manner to Example 3. Mass spectrum (API4"): Found 482 (MΗ+). C2 H2835ClN θ4 requires 481. H NMR (CDC13) δ: 1.84 (2H. m), 2.02 (2H, m), 2.52 (2H, m), 2.72 (3H, s), 2.91 (2H, ). 2.98 (2H, m), 3.32 (3H, s), 4.27 (3H, m), 4.56 (2H, s), 6.54 (2H, m), 6.76 (IH, m),
6.89 (IH, d, J = 8 Hz), 7.24 (IH, d, J = 8 Hz), 7.60 (IH, m), 8.37 (IH, d, J = 9 Hz).
Example 132
6-(4-(l-(2-(5-(7-Chloro-2-methyl)quinolinyIoxy)ethyl)piperazinyl)methyI)-4H- benzo[l,4]oxazin-3-one (E132)
The title compound was prepared in a similar manner to Example 3.
Mass spectrum (API4"): Found 467 (MΗ4"). C2sΗ2735ClN4θ3 requires 466. l H NMR (CDCl3) δ: 2.49 (4H, m), 2.67 (4H, m), 2.71 (3FI, s), 2.93 (2H, m), 3.42 (2H, s), 4.26 (2H, m), 4.60 (2H, s), 6.78 (2H, m), 6.90 (2H, m), 7.22 (IH, d, J = 9 Hz), 7.60
( 1 H, m), 8.20 ( 1 H, br s), 8.35 (1 H, d, J = 9 Hz).
Example 133 6-(4-(l-(3-(5-(7-ChIoro-2-methyl)quinolinyIoxy)propyl)piperidinyI)oxy)-4H- benzo[l,4]oxazin-3-one (E133)
The title compound was prepared in a similar manner to Example 3. Mass spectrum (API4"): Found 482 (MΗ+). C2 H2835 lN3°4 requires 481. 1 H NMR (CDCl3) δ: 1.81 (2H. m). 1.97 (2H, m), 2.1 1 (2H. m). 2.34 (2H, m), 2.60 (2H, m), 2J2 (3H, s). 2J7 (2H, m), 4.22 (3H, m), 4.57 (2H, s). 6.41 (IH, d. I = 3 Hz), 6.53 (I H, dd, J = 9, 3 Hz), 6.79 (I H, d, J = 2 Hz),6.88 (IH, d, J = 9 Hz), 7.24 (IH, d, j = 9 Hz), 7.59 (IH, d, J = 2 Hz), 8.38 (IH, d, j = 9 Hz), 8.48 (IH, br s).
Example 134
6-(4-(l-(3-(5-(7-Chloro-2-methyl)quinolinyloxy)propyl)piperidinyl)oxy)-4-methyl-
4H-benzo[l,4]oxazine-3-one (E134)
The title compound was prepared in a similar manner to Example 3.
Mass spectrum (API4-): Found 496 (MΗ+). C27H3035ClN3θ4 requires 495. -I NMR CDC^) δ: 1.82 (2H, m), 1.98 (2H, m), 2.1 1 (2H, m), 2.34 (2H, m), 2.61 (2H, m), 2J1 (3H, s), 2.79 (2H, m), 3.33 (3H, s), 4.17 (2H, m), 4.26 (IH, m), 4.56 (2H, s),
6.54 (2H, m), 6.79 (IH, d, j = 2 Hz). 6.88 (IH, d, J = 8 Hz), 7.23 (IH, d, J = 9 Hz), 7.59
(1 H, d, J = 2 Hz), 8.38 (1 H, d, j = 9 Hz).
Example 135
6-(4-(l-(2-(5-(2-Methyl)quinolinyloxy)ethyl)piperidinyl)methyl)-4-(2-propyl)-4H- benzo[l,4]oxazin-3-one (E135)
The title compound was prepared in a similar manner to Example 3.
Mass spectrum (API4"): Found 474 (MΗ+). C29H35N3O3 requires 473. 1 H MR (CDCl3) δ: 1.30 (2H, m), 1.49 (lH, m), 1.55 (6H, d, j = 7 Hz), 1.67 (2H, m),
2.15 (2H, m), 2.52 (2H, m), 2J3 (3H, s), 2.94 (2H, m), 3.05 (2H, m), 4.28 (2H, m),
4.45 (2H, s), 4.69 ( I H, m), 6.77 (2H, m), 6.89 (2H, m), 7.24 (I H, d, J = 9 FIz), 7.56
(2H, m), 8.43 ( I H. d, J = 9 Hz).
Example 136 6-(4-(l-(2-(5-(2-Methyl)quinazolinyloxy)ethyl)piperidinyl)methyl)-4H-benzo[l,4]- oxazin-3-one (E136)
Figure imgf000082_0001
A mixture of 6-(4-piperidinylmethyl)-4H-benzo[l,4]oxazin-3-one hydrochloride (0.019 g, 0.067 mmol), 2-(5-(2-methyl)quinazolinyl)oxyethyl bromide (0.018 g, 0.067 mmol), diisopropylamine (0.3 mL) and isopropanol (5 mL) was heated at reflux for 64 h, cooled, then evaporated in vacuo. The residue was partitioned between 10% aqueous NaOΗ (2 mL) and dichloromethane (3 x 2 mL). The combined organic extracts were applied directly to a 5 g sep-pak silica cartridge. Gradient elution with 0 - 20% methanol in ethyl acetate gave the title compound (0.022 g, 76%) as an oil. Mass spectrum (API+): Found 433 (MΗ+). C25H28N4O3 requires 432. Ϊ H NMR DC^) δ: 1.32 (2H, m), 1.50 (IH, m), 1.65 (2H, m), 2.18 (2H, m), 2.46 (2H, d, J = 7 Hz), 2.90 (3H, s), 2.97 (2H, t, J = 6 Hz), 3.04 (2H, m), 4.33 (2H, ti J = 6 Hz), 4.59 (2H, s), 6.57 (IH, d, J = 2 Hz), 6.74 (IH, dd, J = 9, 2 Hz), 6.86 (2H, m), 7.50 (IH, d, J = 9 Hz). 7.75 (I H, t, J = 9 Hz), 8.49 (IH, br s), 9.64 (I H, s).
Example 137
6-(4-(l-(2-(5-(7-Fluoro-2-methyl)quinolinyloxy)ethyl)piperidinyl)methyl)-4H- benzo[l,4]oxazin-3-one (E137)
Figure imgf000082_0002
A solution of 2-(5-(7-fluoro-2-methyl)quinolinyl)oxyethyl bromide (0.10 g, 0.35 mmol), 6-(4-piperidinylmethyl)-4H-benzo[1.4]-oxazin-3-one hydrochloride (0.10 g, 0.35 mmol) and diisopropylamine (0.25 mL, 1.44 mmol) in isopropyl alcohol (10 mL) was heated at reflux for 48 h. cooled and evaporated in vacua. The residue was partitioned between dichloromethane (5 mL) and water (5 mL). The organic layer was added onto a pre-packed silica column (10 g) which was eluted with 0 - 20% methanol in ethyl acetate to give the title compound (0.068 g, 43%) as a colourless oil. Mass spectrum (API4"): Found 450 (MΗ4"). C2 Η28FN3θ3 requires 449. ^ H NMR ^DC^) δ: 1.32 (2H. m), 1.48 (I H, m), 1.63 (2H. m), 2.13 (2H, m), 2.45 (2H. m), 2.70 (3H, s). 2.92 (2H, m), 3.03 (2H, m). 4.24 (2H. m), 4.57 (2H, s), 6.57 (2H. m), 6.72 (IH, dd, J = 8, 2 Hz), 6.86 (IH. d, J = 8 Hz), 7.18 (2H, m), 8.33 (IH, d, J = 9 Hz), 9.17 (IH. br s).
Example 147 6-{ l-[2-(6-Fluoro-2-methyl-quinolin-5-yloxy)-ethyl]-piperidin-4-ylmethyI}-4H- benzo[l,4]oxazin-3-one (E147)
The title compound was prepared in a similar manner to Example 3. Mass spectrum (API): Found 450 (MH+). C2 H2 FN3θ3 requires 449. 1 H NMR (CDC13) δ: 1.33 (2H, m), 1.49 (IH, m), 1.62 (2H, m), 2.04 (2H, m), 2.46 (2H, m), 2.72 (3H, s), 2.81 (2H, m), 3.00 (2H, m), 4.37 (2H, m), 4.60 (2H, s), 6.58 (IH, d, J = 2H), 6.74 (IH, dd, J = 8 Hz, 2 Hz), 6.88 (IH, d, J = 8 Hz), 7.28 (IH, d, J = 9 Hz), 7.44 (IH, m), 7.70 (IH, m), 8.42 (IH, d, J = 9 Hz), 8.51 (IH, bs).
Example 148 6-{4-[2-(6-Fluoro-2-methyl-quinolin-5-yloxy)-ethyl]-piperazin-l-ylmethyl}-4H- benzo[l,4]oxazin-3-one (E148)
The title compound was prepared in a similar manner to Example 3 Mass spectrum (API): Found 451 (MFI4"). C25H27FN4O3 requires 450. 1 H NMR (CDCI3) δ: 2.48 (4H, bs), 2.60 (4H, bs), 2.73 (3H, s), 2.84 (2H. m), 3.43 (2H, s), 4.38 (2H, m), 4.60 (2H, s), 6.79 (IH, s), 6.91 (2FI, s), 7.28 (I H, d, J = 9 Hz), 7.44 ( 1 H. m), 7.70 ( 1 H, m), 7.87 ( 1 H, bs). 8.48 (1 H, d, J = 9 Hz).
Example 149
6-(l-[2-(7,8-Difluoro-2-methyl-quinolin-5-yloxy)-ethyl]-piperidin-4-ylmethyl}-4H- benzo[l,4]oxazin-3-one (E149)
The title compound was prepared in a similar manner to Example 3 Mass spectrum (API); Found 468 (MH+). C2gH27F2N3θ3 requires 467. ^ MR tCDC^ δ: 1.33 (2H, m), 1.47 (IH. m), 1.63 (2H, m). 2.12 (2H, m), 2.46 (2H. m), 2.77 (3H, s), 2.88 (2H, m), 3.02 (2H, m), 4.34 (2H, m), 4.59 (2H, s), 6.56 (I H, d, J = 2 Hz), 6.74 (IH, dd, J = 8 Hz, 2 Hz), 6.88 (IH, d, J = 8 Hz), 7.00 (I H, m), 7.26 (I H, d. J = 9 Hz), 8.19 (2H, m).
Example 150
6-{4-[2-(7,8-Difluoro-2-methyl-quinoIin-5-yloxy)-ethyl]-piperazin-l-yImethyl}-4H- benzo[l,4]oxazin-3-one (E150)
The title compound was prepared in a similar manner to Example 3
Mass spectrum (API): Found 469 (MH4"). C25H2 F2N4θ3 requires 468. iH NMR (CDCI3) δ: 2.48 (4H, bs), 2.64 (4H, bs), 2.77 (3H, s), 2.87 (2H, m), 3.42 (2H, s), 4.34 (2H, m), 4.60 (2H, s), 6.81 (IH, s), 6.90 (2H, m), 6.99 (IH, m), 7.26 (IH, d, J =
9 Hz), 8.19 (IH, dd, J = 9 Hz, 1Hz), 8.51 (lH, bs).
Example 151 6-{l-[2-(7-Iodo-2-methyl-quinoIin-5-yloxy)-ethyl]-piperidin-4-ylmethyl}-4H- benzo[l,4Joxazin-3-one (E151)
The title compound was prepared in a similar manner to Example 3 Mass spectrum (API): Found 558 (MH+). C2 H28lN3θ3 requires 557.
Example 152 2-Methyl-5-(2-[4-(3-oxo-3,4-dihydro-2H-benzo[l,4]oxazin-6-ylmethyl)-piperidin-l- yl]-ethoxy}-quinoline-7-carbonitriIe (E152)
A mixture of 6- [ l-[2-(7-Iodo-2-methyl-quinolin-5-yloxy)-ethyl]-piperidin-4-ylmethyl}- 4H-benzo[l ,4]oxazin-3-one ( 155mg, 0.28mmol) and copper (I) cyanide (50mg, 0.56mmol) in N-methylpyrrolidinone (2mL) was stirred at 90oC for 18hrs. Upon cooling to room temperature the reaction mixture was partitioned between dichloromethane (5mL) and ammonia (0.880, 5mL). The organic layer was separated and applied directly to a l Og pre-packed silica column eluting with 0-20% methanol in ethyl acetate to afford the title compound as a yellow oil (30mg, 23%>). Mass spectrum (API): Found 457 (MH4"). C25H2 F2N4θ3 requires 456.
The following compounds were prepared from 6-(4-( l -(2-(5-(2-methyl)quinolinyloxy) ethyl)piperazinyl)methyl)-4H-benzo[l,4]oxazin-3-one (El 15) and a suitable alkylating agent using a procedure similar to that described in Description 7.
Table 7
Figure imgf000085_0001
Figure imgf000085_0002
Figure imgf000086_0001
Example 159
4-Ethyl-6-{l-[2-(2-methyl-quinoIin-5-yloxy)-ethyl]-piperidin-4-ylmethyl}-4H- benzo[l,4]oxazin-3-one (E159) The title compound was prepared using a similar procedure to that described in Description 7
Mass spectrum (API): Found 460 (MH+). C2 FI33 3O3 requires 459. lH NMR (CDC1:>) : 1.28 (3H, t J 7.1), 1.35-1.40 (3H, m), 1.59-1.66 (2H, m). 2.19 (2H, br t J 1 1 ). 2.52 (2H, d J 6.6), 2.73 (3H. s), 2.97 (2H, t J 5.7), 3.07-3.1 1 (2H. m), 3.97 (2H, q J 7.2). 4.30 (2H, t y 5.7), 4.56 (2H, s). 6.56-6.81 (3FI, m), 6.86-6.91 (I H, m), 7.22-7.26 (IH, m), 7.51-7.62 (2H, m), 8.41 (IH, d 8.5).
Example 160
7,8-Difluoro-6-(4-(l-(2-(5-(2-methyl)quinolinyloxy)ethyl)piperazinyl)methyl)-4H- benzo[l,4]oxazin-3-one (E160)
The title compound was prepared using a similar procedure to that described in Description 16. The starting compound was 2,3-difluoro-4-hydroxy-benzoic acid methyl ester which was converted to D51 (see D51) and then underwent the sequential reactions described under D52-56. Mass spectrum (APl+): Found 469 (MH+). C25H26F2N4O3 requires 468.
! H NMR (CDCI3) δ: 1.59 (4H, m), 2.50-2.70 (4H. m), 2.73 (3H, m), 3.51 (2H, m), 4.29 (2H, m), 4.66 (2H, s), 6.60 ( I H. m), 6.80 ( I H, m), 6.92 (2H. s), 7.24 (I H, m). 7.50-7.65 (2H. m). 7.87 (I H, br s), 8.43 (I H, m). Example 161
8-Fluoro-6-(4-(l-(2-(5-(2-methyl)quinoIinyloxy)ethyl)piperidinyl)methyI)-4H- benzo[l,4]oxazin-3-one (E161)
The title compound was prepared in a similar manner to Example 3. Mass spectrum (API4"): Found 450 (MΗ4"). C2 Η2 FN3θ3 requires 449.
J H NMR ^DCh δ: 1.25 - 1.38 (2H, m), 1.45-1.55 (I H, m), 1.65-1.75 2H, m), 2.16 (2H. m). 2.44 (2H, d, J = 7 Hz). 2.73 (3H, s), 2.95 (2H, t, J = 6 Hz), 3.06 (2H, m), 4.28 (2H. t, J = 6 Hz), 4.65 (2H, s), 6.34 (IH, s), 6.60 (I H, dd, J = 7. 2 Hz). 6.79 (IH. d, j = 7 Hz), 7.24 ( I H, d. J = 8 Hz), 7.50 - 7.64 (2H, m). 7J4 (IH, br s), 8.42 (IH, d, j = 8 Hz).
Example 162
8-Fluoro-4-methyl-6-(4-(l-(2-(5-(2- methyl)quinolinyloxy)ethyl)piperidinyl)methyl)-4H-benzo[l,4]oxazin-3-one (E162) The title compound was prepared in a similar manner to Example 3.
Mass spectrum (API4"): Found 464 (MΗ4"). C27Η30FN3O3 requires 463. lH NMR (CDCI3) δ: 1.40 (2H, m), 1.50-1.65 (I H, m), 1.65-1 JO (2H, m), 2.20 (2H, m), 2.50 (2H, d, j = 7 Hz), 2J4 (3H, s), 2.90-3.20 (4H, m), 3.34 (3H, s), 4.30 (2H, s),
4.65 (2H, m), 6.51 (I H*, s), 6.65 (IH, d, J = 8 Hz), 6.80 (IH, d, J = 8 Hz), 7.24 (IH, d, j = 8 Hz), 7.50-7.60 (2H, m), 8.42 (IH, d, j = 8 Hz).
Example 163
7-Fluoro-6-(4-(l-(2-(5-(2-methyl)quinolinyloxy)ethyl)piperidinyl)methyl)-4H- benzo[l,4]oxazin-3-one (E163) The title compound was prepared in a similar manner to Example 3.
Mass spectrum (API"): Found 448 ([M-Η]"). C gΗ28FN3θ3 requires 449. l H NMR (CDCI3) δ: 1.25-1.38 (2H, m), 1.50-1.60 (IH, m), 1.60-1.70 (2H, m). 2.14 (2H. m), 2.49 (2H, d, j = 7 Hz), 2.73 (3H, s), 2.93 (2H, t, J = 6 Hz), 3.04 (2H, m), 4.27 (2H, t, J = 6 Hz), 4.58 (2H, s), 6.52 ( I H, d, J = 7 Hz), 6.69 (I H, d, J = 10 Hz), 6.80 (I H, d, J = 7 Hz), 7.24 ( I H, d, J = 8 Hz), 7.50 - 7.60 (2H, m), 7.61 (I H, br s), 8.42 (IH, d, J = 8 FIz).
The following compounds (El 64- 167) were prepared in a similar manner to Example 3:
Example 164
8-Fluoro-6-(4-(l-(2-(5-(2-Methyl)quinazolinyloxy)ethyl)piperidinyl)methyl)-4H- benzo[l,4]-oxazin-3-one (E164)
Example 165
7-Fluoro-6-(4-(l-(2-(5-(2-MethyI)quinazolinyloxy)ethyl)piperidinyl)methyl)-4H- benzo[l,4]-oxazin-3-one (E165)
Example 166 8-Fluoro-6-(4-(l-(2-(5-(7-Chloro-2- methyl)quinolinyloxy)ethyl)piperidinyl)methyl)-4H-benzo[l,4]oxazin-3-one (El 66)
Example 167
7-Fluoro-6-(4-(l-(2-(5-(7-Chloro-2- methyl)quinolinyloxy)ethyl)piperidinyl)methyl)-4H-benzo[l,4]oxazin-3-one (E167)

Claims

Claims
1. A compound of formula (I) or a pharmaceutically acceptable salt thereof:
Figure imgf000089_0001
(I) in which
Ar is phenyl, naphthyl, a monocyclic heteroaromatic group or a bicyclic heteroaromatic group, said Ar group being optionally substituted by 1 - 4 substituents, which may be the same or different, and which are selected from the group consisting of:
halogen, hydroxy, cyano, nitro, trifluoromethyl, trifluoromethoxy, C^.galkyl, trifluoromethanesulfonyloxy, pentafluoroethyl, Cj. alkoxy, arylCj. galkoxy, Ci .galkylthio, C ι_galkoxyCj. galkyl, C3_7cycloalkylCι _galkoxy,
Cι_galkanoyl, Cι_galkoxycarbonyl, C j.galkylsulfonyl, Cj.galkylsulfmyl, Cι_galkylsulfonyloxy, C^galkylsulfonylCj. galkyl, arylsulfonyl, arylsulfonyloxy, arylsulfonylC i .galkyl, C j .galkylsulfonamido, C \→ galky lamido, C ι .galkylsulfonamidoC [ .galkyl, C ι .galkylamidoC ι .galkyl, arylsulfonamido, arylcarboxamido, arylsulfonamidoC \ .galkyl, arylcarboxamidoC i. galkyl, aroyl, aroylC i. galkyl, arylC ι_galkanoyl, a group R OCO(CH )s, R3CON(R4)(CH2)s, R3R4NCO(CH2)s or R3 R4NS02(CH2)S where each of R3 and R4 independently represents a hydrogen atom or C ι _4alkyl or R3 and R4 form part of a C3_gazacyloalkane or C3_g(2- oxo)azacycloalkane ring and s represents zero or an integer from 1 to 4, and a group Arl - Z, wherein Z represents a single bond, 0, S or CH2 and Ar' represents a phenyl or a monocyclic heteroaromatic group, said Ar ' group being optionally substituted by 1 - 3 substituents, which may be the same or different, and which are selected from the group consisting of: a halogen, hydroxy, cyano, trifluoromethyl, C j .galkyl, C \ .galkoxy or C j.galkanoyl;
when Ar is a phenyl or a monocyclic heteroaromatic group, substituents positioned or/ho to one another may be linked to form a 5- or 6- membered ring;
R! is hydrogen, C \ _ galkyl, C3_galkenyl, C3_galkynyl or arylC j . alkyl;
R- is halogen. C \ -galkyl, cyano, CF3, C j.galkanoyl, C \ -galkoxy or hydroxy; X is CH or N;
Y is a single bond, O, or C=0; p is 0, 1 or 2; r is 0. 1 , 2 or 3; m is 2, 3 or 4; n and q are independently 1 or 2.
2. A compound according to claim 1 in which Ar is phenyl, naphthyl, indolyl, quinolinyl, quinazolinyl, indazolyl, isoquinolinyl, cinnolinyl or benzofuranyl, said groups being optionally substituted as defined in claim 1.
3. A compound according to claim 1 or 2, in which Ar is substituted by halogen (particularly fluoro or chloro), C[ -galkyl (particularly methyl, ethyl and propyl), cyano, CF3, C \ -galkoxy (particularly methoxy, ethoxy or isopropoxy), C i-galkanoyl or a group Ar' - Z as defined in claim 1.
4. A compound according to claim 3, in which Ar1 is a monocyclic heteroaromatic group (particularly isoxazolyl), optionally substituted as defined in claim 1 , and Z is a single bond.
5. A compound according to claim 1 in which Ar is 4-indolyl, 4-indolyl(2- CN), 5-quinolinyl, 5-quinolinyl(2-Me), 8-quinolinyl, 1-isoquinolinyl, naphthyl, phenyl(2-CN), phenyl(2,3-dichloro), phenyl(3-Br). phenyl(3-Me), phenyl(3-CF3), phenyl(2-propyl). phenyl(2-CN, 4-F). phenyl(2-(5-isoxazolyl), phenyl(3-ethyl-4-Cl), 2.2-dimethyl-2.3-dihydrobenzo[b]furan-7-yl. (5-F)-2,2-dimethyl-2,3- dihydiObenzo[b]furan-7-yl, (6-F)-3.4-dihydro-2H-benzo[b]pyranyl, (2,2-dimethyl)3,4- dihydro-2H-benzo[b]pyranyl, 5-oxo-5,6J,8-tetrahydronaphth-l-yl, 7-(2,3- dihydrobenzofuranyl), 7-(2-methyl)benzo[b]furanyl, 7-benzo[b]furanyl, 5-quinolinyl(2- Me, 8-Cl), 5-quinolinyl(2-Me, 8-F). 5-quinolinyl(2-Me, 7-Cl), 5-quinolinyl(2-Me, 7-F) or 5-quinazolinyl(2-Me).
6. A compound according to any of claims 1 to 5, wherein r is 0, 1 or 2.
")
7. A compound according to any of claims 1 to 6, wherein R- is halogen, particularly fluoro.
8. A compound according to any of claims 1 to 7, in which R* is hydrogen or methyl.
9. A compound according to any of claims 1 to 8, in which m is 2.
10. A compound according to claim 1 which is a compound selected from Example El - El 67 or a pharmaceutically acceptable salt thereof.
1 1. A compound according to claim 1 which is:
6-(4-( l -(2-(4-lH-Indolyloxy)ethyl)piperidinyl)oxy)-4H-benzo[l ,4]oxazin-3-one;
6-(4-( l-(2-(4-(2-Cyano)-l H-indolyloxy)ethyl)piperidinyl)oxy)-4H-benzo[l ,4]oxazin-3- one;
6-(4-( l-(3-(2-(5-Isoxazolyl)phenoxy)propyl)piperidinyl)oxy)-4H-benzo[l ,4]oxazin-3- one; 6-(4-(l-(2-(5-Quinolinyloxy)ethyl)piperidinyl)methyl)-4H-benzo[l,4]oxazin-3-one;
6-(4-(l-(3-(2-Cyanophenoxy)propyl)piperidinyl)oxy)-4H-benzo[l ,4]oxazin-3-one;
6-(4-(l-(3-(7-(2,2-Dimethyl-2,3-dihydro)benzo[b]furanyloxy)propyl)piperidinyl)-oxy)-
4H-benzo[ 1 ,4]oxazin-3-one; 6-(4-( l -(2-(7-(2J-Dimethyl-2,3-dihydro)benzo[b]furanyloxy)ethyl)piperidinyl)oxy)-4- methyl-4H-benzo[l ,4]oxazin-3-one;
6-(4-( 1 -(2-( l-naphthyloxy)ethyl)piperidinyl)oxy )-4-methyl-4H-benzo[ 1 ,4]oxazin-3- one;
(+)-6-(3-(l -(3-(2-Cyanophenoxy)propyl)piperidinyl)methoxy)-4H-benzo[l,4]oxazin-3- one;
(+)-6-(3-(l-(3-(2-Cyanophenoxy)propyl)pyrrolidinyl)methoxy)-4H-benzo[l,4]oxazin-
3-one;
6-(4-( 1 -(3-(2-(5-Isoxazoιyl)phenoxy)propyl)piperazinyl)methyl)-4H-benzo[l ,4]oxazin-
3-one; 6-(4-(l-(2-(5-(2-Methyl)quinolinyloxy)ethyl)piperidinyl)methyl)-4H-benzo[l,4]oxazin-
3-one;
6-(4-(l-(2-(5-(3-Methyl)quinolinyloxy)ethyl)piperidinyl)methyl)-4H-benzo[l,4]oxazin-
3 -one;
6-(4-(l-(2-(5-Cinnolinyloxy)ethyl)piperidinyl)methyl)-4H-benzo[l,4]oxazin-3-one; 6-(4-(l-(2-(4-(l ,2-Dihydro)benzo[b]furanyloxy)ethyl)piperidinyl)methyl)-4H- benzo[l ,4]oxazin-3-one;
6-(4-(l-(2-(4-(lH)-Indazolyloxy)ethyl)piperidinyl)methyl)-4H-benzo[l,4]oxazin-3-one;
6-(4-(l-(2-(5-(2-Methyl)quinolinyloxy)ethyl)piperidinyl)oxy)-4H-benzo[l ,4]oxazin-3- one; 4-Methyl-6-(4-(l-(2-(5-(2-methyl)quinolinyloxy)ethyl)piperidinyl)oxy)-4H- benzo[l,3]oxazin-3-one;
6-(4-( l-(2-(5-(2-Methyl)quinolinyloxy)ethyl)piperazinyl)methyl)-4H- benzo[l,4]oxazin-3-one;
6-(4-( l-(3-(5-(2-Methyl)quinolinyloxy)propyl)piperidinyl)methyl)-4H- benzo[l ,4]oxazin-3-one; 6-(4-(l-(3-(5-(2-Methyl)quinolinyloxy)propyl)piperazinyl)methyl)-4H- benzo[l,4]oxazin-3-one;
6-(4-( l-(3-(5-(2-Meιhyl)quinoIinyloxy)propyl)piperidinyl)oxy)-4H-benzo[l ,4]oxazin-
3 -one; 4-Methyl-6-(4-( 1 -(3-(5-(2-methyl)quinolinyloxy)propyl)piperidinyl)oxy)-4H- benzo[l ,4]oxazin-3-one;
4-Methyl-6-(4-(l-(2-(5-(2-methyl)quinolinyloxy)ethyl)piperidinyl)methyl)-4H- benzo[l,4]oxazin-3-one;
6-(4-(l -(2-(5-(8-Chloro-2-methyl)quinolinyloxy)ethyl)piperidinyl)methyl)-4H- benzo[l,4]oxazin-3-one;
4-Methyl-6-(4-(l-(3-(5-(2-methyl)quinolinyloxy)propyl)piperidinyl)-methyl)-4H- benzo[l ,4]oxazin-3-one;
6-(4-( l-(2-(5-(8-Chloro-2-methyl)quinolinyloxy)ethyl)piperidinyl)methyl)-4-methyl-
4H-benzo[l,4]oxazin-3-one; 6-(4-(l -(2-(5-(8-Fluoro-2-methyl)quinolinyloxy)ethyl)piperidinyl)methyl)-4H- benzo [ 1 ,4]oxazin-3 -one;
6-(4-(l-(2-(5-(8-Fluoro-2-methyl)quinolinyloxy)ethyl)piperidinyl)methyl)-4-methyl-
4H-benzo[l ,4]oxazin-3-one;
6-(4-(l-(2-(5-(8-Fluoro-2-methyl)quinolinyloxy)ethyl)piperidinyl)oxy)-4H- benzo[l,4]oxazin-3-one;
6-(4-(l-(2-(5-(8-Fluoro-2-methyl)quinolinyloxy)ethyl)piperidinyl)oxy)-4-methyl-4H- benzo[l ,4]oxazin-3-one;
6-(4-(l-(2-(5-(7-Chloro-2-methyl)quinolinyloxy)ethyl)piperidinyl)methyl)-4H- benzo[l,4]oxazin-3-one; 6-(4-(l -(2-(5-(7-Chloro-2-methyl)quinolinyloxy)ethyl)piperidinyl)methyl)-4-methyl-
4H-benzo[l ,4]oxazin-3-one;
6-(4-( l-(2-(5-(7-Chloro-2-methyl)quinolinyloxy)ethyl)piperidinyl)oxy)-4H- benzo[l ,4]oxazin-3-one;
6-(4-( l-(2-(5-(7-Chloro-2-methyl)quinolinyloxy)ethyl)piperidinyl)oxy)-4-methyl-4H- benzo[l ,4]oxazin-3-one; 6-(4-(l-(2-(5-(7-Chloro-2-methyl)quinolinyloxy)ethyl)piperazinyl)methyl)-4H- benzo[l ,4]oxazin-3-one;
6-(4-( l-(3-(5-(7-Chloro-2-methyl)quinolinyloxy)propyl)piperidinyl)oxy)-4H- benzo[1.4]oxazin-3-one: 6-(4-( l -(3-(5-(7-Chloro-2-methyl)quinolinyloxy)propyl)piperidinyl)oxy)-4-methyl-4H- benzo[l ,4]oxazine-3-one;
6-(4-(l-(2-(5-(2-Methyl)quinolinyloxy)ethyl)piperidinyl)methyl)-4-(2-propyl)-4H- benzo[l,4]oxazin-3-one;
6-(4-(l-(2-(5-(2-Methyl)quinazolinyloxy)ethyl)piperidinyl)methyl)-4H-benzo[l,4]- oxazin-3 -one;
6-(4-(l-(2-(5-(7-Fluoro-2-methyl)quinolinyloxy)ethyl)piperidinyl)methyl)-4H- benzo[l ,4]oxazin-3-one;
7-Fluoro-6-(4-(l-(2-(5-(2-methyl)quinolinyloxy)ethyl)piperidinyl)methyl)-4H- benzo[l,4]oxazin-3-one; 8-Fluoro-4-methyl-6-(4-(l -(2-(5-(2-methyl)quinolinyloxy)ethyl)piperidinyl) methyl)-
4H-benzo[l,4]oxazin-3-one;
8-Fluoro-6-(4-(l-(2-(5-(2-methyl)quinolinyloxy)ethyl)piperidinyl)methyl)-4H- benzo[l,4]oxazin-3-one;
7,8-Difluoro-6-(4-(l-(2-(5-(2-methyl)quinolinyloxy)ethyl)piperazinyl)methyl)-4H- benzo[l,4]oxazin-3-one;
4-Ethyl-6-{ l-[2-(2-methyl-quinolin-5-yloxy)-ethyl]-piperidin-4-ylmethyl}-4Η- benzo [ 1 ,4] oxazin-3 -one or a pharmaceutically acceptable salt thereof.
12. A process for the preparation of a compound of formula (I) or a pharmaceutically acceptable salt thereof, which process comprises:
(a) the coupling of a compound of formula (II):
Figure imgf000095_0001
(II)
in which R1, R-. Y, n. p. q and r are defined in formula (I). with a compound of formula (III):
Figure imgf000095_0002
(III) in which Ar and m are as defined for formula (I) and L is a leaving group; or
(b) reacting a compound of formula (II) as defined above with a compound of formula (IV)
Figure imgf000095_0003
(IV) in which Ar and m are defined in formula (I), in the presence of a reducing agent; or
(c) for a compound of formula (I) wherein X is N, reacting a compound of formula (V):
R1
Figure imgf000095_0004
(R
(V) in which p, R~, r and R1 are as defined in formula (I), with a compound of formula (NI):
Figure imgf000096_0001
(VI) in which Ar, m, q and n are as defined in formula (I), in the presence of a reducing agent; and optionally thereafter for each of process (a), (b) or (c):
• removing any protecting groups, and/or
• converting a compound of formula (I) into another compound of formula (I), and/or » forming a pharmaceutically acceptable salt.
13. A pharmaceutical composition which comprises a compound according to any one of claims 1 to 11 and a pharmaceutically acceptable carrier or excipient.
14. A process for preparing a pharmaceutical composition according to claim 13, the process comprising mixing a compound according to any one of claims 1 to 1 1 and a pharmaceutically acceptable carrier or excipient.
15. A compound according to any one of claims 1 to 1 1 or a composition according to claim 13 for use in therapy.
16. A compound according to any one of claims 1 to 11 or a composition according to claim 13 for use in the treatment or prophylaxis of CNS and other disorders.
17. A compound according to any one of claims 1 to 1 1 or a composition according to claim 13 for use in the treatment or prophylaxis of depression and/or anxietv.
18. A method of treating CNS and other disorders which comprises administering a safe and therapeutically effective amount to a patient in need thereof of a compound according to any one of claims 1 to 1 1 or a pharmaceutically acceptable
"1 salt thereof, or a composition according to claim 13.
19. A method according to claim 18, wherein the disorder is depression and/or anxietv.
0 20. The use of a compound according to any one of claims 1 to 1 1 or a pharmaceutically acceptable salt thereof, or a composition according to claim 13, in the manufacture of a medicament for the treatment or prophylaxis of CNS and other disorders.
21. The use as claimed in claim 20, wherein the medicament is for the treatment or prophylaxis of depression and/or anxiety.
PCT/EP2001/012344 2000-10-26 2001-10-22 Benzoxazinone derivatives, their preparation and use WO2002034754A2 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
IL15552001A IL155520A0 (en) 2000-10-26 2001-10-22 Benzoxazinone derivatives, their preparation and use
BR0114881-8A BR0114881A (en) 2000-10-26 2001-10-22 Benzoxazinone derivatives, their preparation and use
EP01988720A EP1330460B1 (en) 2000-10-26 2001-10-22 Benzoxazinone derivatives, their preparation and use
HU0301458A HUP0301458A2 (en) 2000-10-26 2001-10-22 Benzoxazinone derivatives, their preparation and use
US10/415,119 US6939871B2 (en) 2000-10-26 2001-10-22 Benzoxazinone derivatives, their preparation and use
DE60127434T DE60127434T2 (en) 2000-10-26 2001-10-22 BENZOXAZINE DERIVATIVES, THEIR PREPARATION AND USE
AU2002224791A AU2002224791A1 (en) 2000-10-26 2001-10-22 Benzoxazinone derivatives, their preparation and use
JP2002537744A JP4242643B2 (en) 2000-10-26 2001-10-22 Benzoxazinone derivatives, their manufacture and use
KR10-2003-7005789A KR20030051747A (en) 2000-10-26 2001-10-22 Benzoxazinone Derivatives, Their Preparation and Use
MXPA03003820A MXPA03003820A (en) 2000-10-26 2001-10-22 Benzoxazinone derivatives, their preparation and use.
CA002426706A CA2426706A1 (en) 2000-10-26 2001-10-22 Benzoxazinone derivatives, their preparation and use
NO20031838A NO20031838L (en) 2000-10-26 2003-04-24 Benzoxazinone derivatives, their preparation of use

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0026224.6 2000-10-26
GB0026224A GB0026224D0 (en) 2000-10-26 2000-10-26 Novel compounds
GB0111858.7 2001-05-15
GB0111858A GB0111858D0 (en) 2001-05-15 2001-05-15 Novel compounds

Publications (2)

Publication Number Publication Date
WO2002034754A2 true WO2002034754A2 (en) 2002-05-02
WO2002034754A3 WO2002034754A3 (en) 2002-07-11

Family

ID=26245199

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/012344 WO2002034754A2 (en) 2000-10-26 2001-10-22 Benzoxazinone derivatives, their preparation and use

Country Status (20)

Country Link
US (1) US6939871B2 (en)
EP (1) EP1330460B1 (en)
JP (1) JP4242643B2 (en)
KR (1) KR20030051747A (en)
CN (1) CN1478092A (en)
AR (1) AR034174A1 (en)
AT (1) ATE357448T1 (en)
AU (1) AU2002224791A1 (en)
BR (1) BR0114881A (en)
CA (1) CA2426706A1 (en)
CZ (1) CZ20031163A3 (en)
DE (1) DE60127434T2 (en)
ES (1) ES2280417T3 (en)
HU (1) HUP0301458A2 (en)
IL (1) IL155520A0 (en)
MX (1) MXPA03003820A (en)
NO (1) NO20031838L (en)
PL (1) PL366378A1 (en)
TW (1) TWI237023B (en)
WO (1) WO2002034754A2 (en)

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003068771A1 (en) * 2002-02-18 2003-08-21 Glaxo Group Limited Heterocyclymethylpiperidines and -piperazines possessing affinity at 5ht-1 type receptors
WO2003068772A1 (en) * 2002-02-18 2003-08-21 Glaxo Group Limited Heterocyclic compounds possessing affinity at 5ht1-type receptors and use thereof in therapy
WO2003068236A1 (en) * 2002-02-18 2003-08-21 Glaxo Group Limited Piperidine and piperazine derivatives possessing affinity at 5ht-1 type receptors
WO2003091248A1 (en) * 2002-04-23 2003-11-06 Glaxo Group Limited Benzoxazinone derivative
WO2004029048A1 (en) * 2002-09-26 2004-04-08 Warner-Lambert Company Llc Heterocyclic substituted piperazines for the treatment of schizophrenia
WO2004041792A1 (en) * 2002-11-08 2004-05-21 F. Hoffmann-La Roche Ag Substituted benzoxazinones and uses thereof
WO2004046124A1 (en) * 2002-11-21 2004-06-03 Glaxo Group Limited Benzoxazinone derivatives, preparation thereof and uses in the treatment of cns and other disorders
WO2004099196A1 (en) * 2003-05-12 2004-11-18 Glaxo Group Limited Benzoxazinone derivatives, their preparation and use
WO2004099198A1 (en) * 2003-05-12 2004-11-18 Glaxo Group Limited Benzoxazinone derivatives having affinity for 5- ht receptors, their preparation and use
WO2005014552A1 (en) 2003-07-18 2005-02-17 Glaxo Group Limited Quinoline and quinazoline derivatives having affinity for 5ht1-type receptors
JP2006525336A (en) * 2003-04-30 2006-11-09 エフ　エム　シー　コーポレーション Phenyl-substituted cyclic derivatives
WO2007042325A1 (en) * 2005-10-13 2007-04-19 Morphochem Aktiengesellschaft für kombinatorische Chemie Antibacterial active 5-chinolin derivative
WO2006015259A3 (en) * 2004-07-28 2008-10-16 Irm Llc Compounds and compositions as modulators of steroid hormone nuclear receptors
WO2010084152A1 (en) 2009-01-21 2010-07-29 Basilea Pharmaceutica Ag Novel bicyclic antibiotics
EP2239260A1 (en) 2002-10-10 2010-10-13 Morphochem Aktiengesellschaft Für Kombinatorische Chemie Novel compounds with antibacterial activity
WO2011073378A1 (en) 2009-12-18 2011-06-23 Basilea Pharmaceutica Ag Tricyclic antibiotics
WO2012171860A1 (en) 2011-06-17 2012-12-20 Basilea Pharmaceutica Ag Tricyclic antibiotics
US10675274B2 (en) 2018-09-19 2020-06-09 Forma Therapeutics, Inc. Activating pyruvate kinase R
US10836771B2 (en) 2017-03-20 2020-11-17 Forma Therapeutics, Inc. Compositions for activating pyruvate kinase
US11001588B2 (en) 2018-09-19 2021-05-11 Forma Therapeutics, Inc. Activating pyruvate kinase R and mutants thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997045419A1 (en) * 1996-05-29 1997-12-04 Warner-Lambert Company Benzoxazinone dopamine d4 receptor antagonists
EP0900792A1 (en) * 1997-09-02 1999-03-10 Duphar International Research B.V Piperazine and piperidine derivatives as 5-HT1 receptor agonists
WO2000040581A1 (en) * 1999-01-07 2000-07-13 American Home Products Corporation 3,4-dihydro-2h-benzo[1,4]oxazine derivatives
WO2000040580A1 (en) * 1999-01-07 2000-07-13 American Home Products Corporation 3,4-dihydro-2h-benzo[1,4]oxazinyl-methyl[3-(1h-indol-3-yl)-alkyl]-amines

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997045419A1 (en) * 1996-05-29 1997-12-04 Warner-Lambert Company Benzoxazinone dopamine d4 receptor antagonists
EP0900792A1 (en) * 1997-09-02 1999-03-10 Duphar International Research B.V Piperazine and piperidine derivatives as 5-HT1 receptor agonists
WO2000040581A1 (en) * 1999-01-07 2000-07-13 American Home Products Corporation 3,4-dihydro-2h-benzo[1,4]oxazine derivatives
WO2000040580A1 (en) * 1999-01-07 2000-07-13 American Home Products Corporation 3,4-dihydro-2h-benzo[1,4]oxazinyl-methyl[3-(1h-indol-3-yl)-alkyl]-amines

Cited By (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003068772A1 (en) * 2002-02-18 2003-08-21 Glaxo Group Limited Heterocyclic compounds possessing affinity at 5ht1-type receptors and use thereof in therapy
WO2003068236A1 (en) * 2002-02-18 2003-08-21 Glaxo Group Limited Piperidine and piperazine derivatives possessing affinity at 5ht-1 type receptors
WO2003068771A1 (en) * 2002-02-18 2003-08-21 Glaxo Group Limited Heterocyclymethylpiperidines and -piperazines possessing affinity at 5ht-1 type receptors
US7244726B2 (en) 2002-02-18 2007-07-17 Glaxo Group Limited Heterocyclic compounds possessing affinity at 5HT1 -type receptors and use thereof in therapy
US7214674B2 (en) 2002-02-18 2007-05-08 Glaxo Group Limited Heterocyclymethylpiperidines and -piperazines possessing affinity at 5ht-1 type receptors
WO2003091248A1 (en) * 2002-04-23 2003-11-06 Glaxo Group Limited Benzoxazinone derivative
WO2004029048A1 (en) * 2002-09-26 2004-04-08 Warner-Lambert Company Llc Heterocyclic substituted piperazines for the treatment of schizophrenia
EP2239260A1 (en) 2002-10-10 2010-10-13 Morphochem Aktiengesellschaft Für Kombinatorische Chemie Novel compounds with antibacterial activity
US7141562B2 (en) 2002-11-08 2006-11-28 Roche Palo Alto Llc Substituted benzoxazinones and uses thereof
WO2004041792A1 (en) * 2002-11-08 2004-05-21 F. Hoffmann-La Roche Ag Substituted benzoxazinones and uses thereof
JP2006513167A (en) * 2002-11-21 2006-04-20 グラクソ　グループ　リミテッド Benzoxazinone derivatives, their preparation and their use in the treatment of CNS and other disorders
WO2004046124A1 (en) * 2002-11-21 2004-06-03 Glaxo Group Limited Benzoxazinone derivatives, preparation thereof and uses in the treatment of cns and other disorders
JP2006525336A (en) * 2003-04-30 2006-11-09 エフ　エム　シー　コーポレーション Phenyl-substituted cyclic derivatives
WO2004099198A1 (en) * 2003-05-12 2004-11-18 Glaxo Group Limited Benzoxazinone derivatives having affinity for 5- ht receptors, their preparation and use
WO2004099196A1 (en) * 2003-05-12 2004-11-18 Glaxo Group Limited Benzoxazinone derivatives, their preparation and use
WO2005014552A1 (en) 2003-07-18 2005-02-17 Glaxo Group Limited Quinoline and quinazoline derivatives having affinity for 5ht1-type receptors
EP2145622A1 (en) 2003-07-18 2010-01-20 Glaxo Group Limited Quinoline and quinazoline derivatives having affinity for 5HT1-type receptors
WO2006015259A3 (en) * 2004-07-28 2008-10-16 Irm Llc Compounds and compositions as modulators of steroid hormone nuclear receptors
WO2007042325A1 (en) * 2005-10-13 2007-04-19 Morphochem Aktiengesellschaft für kombinatorische Chemie Antibacterial active 5-chinolin derivative
WO2010084152A1 (en) 2009-01-21 2010-07-29 Basilea Pharmaceutica Ag Novel bicyclic antibiotics
US8716280B2 (en) 2009-01-21 2014-05-06 Basilea Pharmaceutica Ag Bicyclic antibiotics
US8927542B2 (en) 2009-01-21 2015-01-06 Basilea Pharmaceutica Ag Bicyclic antibiotics
US9133219B2 (en) 2009-01-21 2015-09-15 Basilea Pharmaceutica Ag Bicyclic antibiotics
WO2011073378A1 (en) 2009-12-18 2011-06-23 Basilea Pharmaceutica Ag Tricyclic antibiotics
WO2012171860A1 (en) 2011-06-17 2012-12-20 Basilea Pharmaceutica Ag Tricyclic antibiotics
US10836771B2 (en) 2017-03-20 2020-11-17 Forma Therapeutics, Inc. Compositions for activating pyruvate kinase
US11014927B2 (en) 2017-03-20 2021-05-25 Forma Therapeutics, Inc. Pyrrolopyrrole compositions as pyruvate kinase (PKR) activators
US11396513B2 (en) 2017-03-20 2022-07-26 Forma Therapeutics, Inc. Compositions for activating pyruvate kinase
US11649242B2 (en) 2017-03-20 2023-05-16 Forma Therapeutics, Inc. Pyrrolopyrrole compositions as pyruvate kinase (PKR) activators
US10675274B2 (en) 2018-09-19 2020-06-09 Forma Therapeutics, Inc. Activating pyruvate kinase R
US11001588B2 (en) 2018-09-19 2021-05-11 Forma Therapeutics, Inc. Activating pyruvate kinase R and mutants thereof
US11071725B2 (en) 2018-09-19 2021-07-27 Forma Therapeutics, Inc. Activating pyruvate kinase R
US11844787B2 (en) 2018-09-19 2023-12-19 Novo Nordisk Health Care Ag Activating pyruvate kinase R
US11980611B2 (en) 2018-09-19 2024-05-14 Novo Nordisk Health Care Ag Treating sickle cell disease with a pyruvate kinase R activating compound

Also Published As

Publication number Publication date
NO20031838L (en) 2003-06-24
EP1330460A2 (en) 2003-07-30
TWI237023B (en) 2005-08-01
EP1330460B1 (en) 2007-03-21
PL366378A1 (en) 2005-01-24
IL155520A0 (en) 2003-11-23
ATE357448T1 (en) 2007-04-15
BR0114881A (en) 2003-09-30
ES2280417T3 (en) 2007-09-16
JP4242643B2 (en) 2009-03-25
CZ20031163A3 (en) 2004-04-14
CN1478092A (en) 2004-02-25
WO2002034754A3 (en) 2002-07-11
HUP0301458A2 (en) 2003-10-28
KR20030051747A (en) 2003-06-25
US6939871B2 (en) 2005-09-06
DE60127434T2 (en) 2007-11-29
NO20031838D0 (en) 2003-04-24
CA2426706A1 (en) 2002-05-02
AR034174A1 (en) 2004-02-04
MXPA03003820A (en) 2003-07-28
US20040063704A1 (en) 2004-04-01
JP2004516250A (en) 2004-06-03
AU2002224791A1 (en) 2002-05-06
DE60127434D1 (en) 2007-05-03

Similar Documents

Publication Publication Date Title
US6939871B2 (en) Benzoxazinone derivatives, their preparation and use
US20090076274A1 (en) Benzoxazinone derivatives, preparation thereof and uses in the treatment of cns and other disorders
KR100799134B1 (en) Phenoxypropylamine compounds
JP2009256363A (en) Oxazolidines as 5-ht2a antagonist
US20040132720A1 (en) Piperazine derivatives, their preparation and uses in therapy (5ht1b receptor activity)
US7244726B2 (en) Heterocyclic compounds possessing affinity at 5HT1 -type receptors and use thereof in therapy
US20040267010A1 (en) Sulfonamide compounds, their preparation and use
CA2184052A1 (en) Piperidinylmethyloxazolidinones
US7205326B2 (en) Aniline derivatives, their manufacture and use as pharmaceutical agents
EP1480972B1 (en) Compounds possessing affinity at 5ht1-type receptors and use thereof in therapy of cns disorders
US7214674B2 (en) Heterocyclymethylpiperidines and -piperazines possessing affinity at 5ht-1 type receptors
WO2003091248A1 (en) Benzoxazinone derivative
WO2004099198A1 (en) Benzoxazinone derivatives having affinity for 5- ht receptors, their preparation and use
WO2004099196A1 (en) Benzoxazinone derivatives, their preparation and use

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2001988720

Country of ref document: EP

Ref document number: 2002224791

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 155520

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2003/03118

Country of ref document: ZA

Ref document number: 200303118

Country of ref document: ZA

Ref document number: 525444

Country of ref document: NZ

Ref document number: 2426706

Country of ref document: CA

Ref document number: 622/DELNP/2003

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 1-2003-500291

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: PV2003-1163

Country of ref document: CZ

Ref document number: 1020037005789

Country of ref document: KR

Ref document number: 2002537744

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/003820

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 018197663

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 1020037005789

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2001988720

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10415119

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: PV2003-1163

Country of ref document: CZ

WWG Wipo information: grant in national office

Ref document number: 2001988720

Country of ref document: EP